Document:

STOCK PURCHASE AGREEMENT BETWEEN THE REGISTRANT AND PFIZER INC

 Exhibit 10.29 
  
 STOCK PURCHASE AGREEMENT 
  
 THIS AGREEMENT, dated as of March 16, 2005, is between PFIZER INC., a Delaware corporation having a place of business at 235 East 42nd Street, New York,
New York 10017-5755 (the “Purchaser”), and COLEY PHARMACEUTICAL GROUP, INC. (the “Company”), a Delaware corporation having a place of business at 93 Worcester Street, Wellesley, Massachusetts 02481. 
  
 WITNESSETH: 
  
 WHEREAS, concurrently with the execution and delivery of this Agreement, the Purchaser and the Company are entering into a
License Agreement (the “License Agreement”) and a Screening and Evaluation Agreement (the “S & E Agreement”); 
  
 WHEREAS, the Company has agreed to sell and Purchaser has agreed to purchase up to $10,000,000 of the Company’s common stock upon the Company’s
initial public offering in accordance with the terms and conditions of this Agreement; and 
  
 WHEREAS the License Agreement contemplates that the parties hereto shall enter into this Stock Purchase Agreement; 
  
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in the License Agreement and this Stock Purchase Agreement, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows: 
  
 ARTICLE I 
  
 Definitions 
  
 Section 1.1 Definitions. Capitalized terms used herein, unless otherwise defined herein, shall have the meanings given to them in the License
Agreement. 
  
 Section 1.2 As used in this Agreement: 

 
 (a) “Acquisition Proposal” shall mean any
tender offer or exchange offer, whether or not accepted by the Board of Directors of the Company, to the stockholders of the 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 
Company (including any publicly announced proposal thereof at a price per share in excess of the most recent closing trading price of Common Stock on the
applicable national securities exchange or NASDAQ on the trading day immediately preceding such public announcement to the stockholders of the Company), or an offer accepted by the Board of Directors of the Company, with respect to a Business
Combination or involving the purchase or other acquisition of forty percent (40%) or more of the outstanding voting securities of the Company, or newly issued securities, which after the issuance thereof, represent beneficial ownership of forty
percent (40%) or more of the outstanding voting securities of the Company. 
  
 (b) “Affiliate” means any entity directly or indirectly controlled by, controlling, or under common control with, a party to this Agreement, but only for so long as such control shall continue. For purposes
of this Agreement, “control” (including, with correlative meanings, “controlled by”, “controlling” and “under common control with”) of an entity means possession, direct or indirect, of (i) the power to direct
or cause direction of the management and policies of such entity (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (ii) at least fifty percent (50%) of the voting securities (whether
directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of such entity. 
  
 (c) “beneficial ownership” (including “beneficial owner” and other correlative terms) shall mean beneficial ownership
as defined in Rule 13d-3 under the United States Securities and Exchange Act of 1934, as amended (the “Exchange Act”); it being understood and agreed that, for purposes of determining whether a “Change of Control” has occurred,
“beneficial ownership” shall also include any securities which any person or any of such person’s Affiliates has the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to any
agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, rights, warrants or options, or otherwise. 
  
 (d) “Business Combination” shall mean (i) merger, consolidation, reorganization, acquisition, liquidation, scheme or other
similar arrangement with a Third Party in which the Company is a constituent corporation or party and pursuant to which 40% or more of the voting securities of the Company are or may be issued, acquired or exchanged for cash, 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 2 

 
securities or other property, or (ii) a sale of a material portion of the assets of the Company representing not less than forty percent (40%) of the fair
market value of the Company. 
  
 (e) “Change
of Control” means an event where: 
  
 (i)
any person or group becomes the beneficial owner, directly or indirectly, of at least fifty percent (50%) or more of the outstanding Voting Stock or voting power over Voting Stock of (x) the Company or (y) any one or more persons or entities which
are a direct or indirect parent holding company of the Company or Affiliates controlling the Company (the Company, together with the persons and entities described in this clause (y), each, individually, a “COLEY GROUP COMPANY” and,
collectively, the “COLEY GROUP COMPANIES”); or 
  
 (ii) occupation of a majority of the seats (other than vacant seats) on the board of directors or other governing body of any COLEY GROUP COMPANY (the “Board”) by any person or group who were neither
(x) members of the Board on the date hereof or members nominated by the Board or (y) appointed by members of the Board on the date hereof or members so nominated; or 
  
 (iii) any COLEY GROUP COMPANY enters into an agreement with any person or entity providing for a merger,
consolidation, reorganization or other similar transaction (or series of transactions) of any COLEY GROUP COMPANY with another person or other entity (other than with any of the COLEY GROUP COMPANY’s wholly-owned subsidiaries) as a result of
which, immediately following such transaction (or series of transactions) less than a majority of the outstanding Voting Stock or voting power over Voting Stock, as calculated on a fully-diluted basis, of the surviving or newly-created entity in
such transaction (or series of related transactions) is beneficially owned by the shareholders of the applicable COLEY GROUP COMPANY immediately prior to such transaction (or series of transactions); or 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 3 

 (iv) any COLEY GROUP COMPANY sells or otherwise transfers to any person(s) or entity that
is not a wholly-owned subsidiary of a COLEY GROUP COMPANY, in one or more related transactions not involving a merger, consolidation, reorganization or other similar transaction (or series of transactions) included in clause (iii) above, properties
or assets representing more than fifty percent (50%) of (x) all COLEY GROUP COMPANIES’ consolidated total assets (exclusive of goodwill) as reflected on the consolidated balance sheet for the most recently-completed fiscal year (or, if
applicable, the most recent Annual Report on Form 10-K), or (y) all COLEY GROUP COMPANIES’ consolidated operating income for the most recent fiscal year as reflected on the consolidated income statement for the most recently-completed fiscal
year (or, if applicable, the Annual Report on Form 10-K), or (z) all COLEY GROUP COMPANIES’ consolidated revenue for the most recent fiscal year as reflected on the consolidated income statement for the most recently-completed fiscal year (or,
if applicable, the Annual Report on Form 10-K). 
  
 For purposes of this
definition of “Change of Control”, references to any COLEY GROUP COMPANY shall be deemed to include all successors in any merger, consolidation, reorganization or similar transaction (or series of transactions) preceding any transaction
(or series of transactions) described above. 
  
 (f) “group” shall have the meaning with which such term is used in Section 13(d)(3) of the Exchange Act; 
  
 (g) “Indebtedness” shall mean all obligations, contingent and otherwise, which should, in accordance with generally accepted
accounting principles, be classified upon the obligor’s balance sheet (or notes thereto) as liabilities, but in any event including liabilities secured by any mortgage on property owned or acquired subject to such mortgage, whether or not the
liability secured thereby shall have been assumed, and also including (i) all guaranties, endorsements and other contingent obligations, in respect of Indebtedness (as defined herein) of others, whether or not the same are or should be so reflected
in said balance sheet (or the notes 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 4 

 
thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business and
(ii) the present value of any lease payments due under leases required to be capitalized in accordance with applicable Statements of Financial Accounting Standards, determined by discounting all such payments at the interest rate determined in
accordance with applicable Statements of Financial Accounting Standards. 
  
 (h) “Initial Public Offering” shall mean the initial firm commitment underwritten public offering by the Company of its common stock, $.01 par value (the “Common Stock”), resulting in gross
proceeds to the Company of not less than twenty-five million dollars ($25,000,000) pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”), and following which, the Company’s
Common Stock shall be listed on a national securities exchange (as defined in the Exchange Act) or the NASDAQ National Market. 
  
 (i) “Key Employee” means and includes (x) the President, chief executive officer, chief financial officer, chief technology
officer, vice president of operations, research, development, sales or marketing, or (y) any other individual who performs a significant role in the operations of the Company or a subsidiary as may be reasonably designated by the Board of Directors
of the Company. 
  
 (j) “Lien” shall
mean any mortgage, pledge, assessment, security interest, encumbrance, lien, levy, claim or charge of any kind, including, without limitation, any conditional sale or other title retention agreement, any lease in the nature thereof and the filing of
or agreement to give any financing statement under the Uniform Commercial Code of any jurisdiction and including any lien or charge arising by statute or other law, except such encumbrances for taxes not yet due and payable or such encumbrances
which arise in the ordinary course of business and which are not material and which do not materially impair the Company’s ownership or use of its property or assets. 
  
 (k) “person” shall have the meaning with which such term is used in Section 13(d)(3) under the
Exchange Act and under Section 2(2) of the Securities Act. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 5 

 (l) “Proxy Solicitation” means any solicitation of proxies or stockholder
consents (as such terms are defined under Regulation 14A and Regulation 14C of the Exchange Act) to vote or seek to advise or influence in any manner whatsoever any Third Party with respect to the Common Stock of the Company. 
  
 (m) “Standstill Period” shall mean the period
commencing on the execution date of this Agreement and terminating on the [*****] anniversary of the date hereof. 
  
 (n) “subsidiary” shall mean any company, partnership, trust, corporation or other non-corporate business enterprise (x) which is
controlled, directly or indirectly, by the first-mentioned company, partnership, trust, corporation or other non-corporate business enterprise; (y) more than 50% of the issued share capital of which is beneficially owned, directly or indirectly, by
the first-mentioned company, partnership, trust, corporation or other non-corporate business enterprise; or (z) which is a subsidiary of another subsidiary of the company, partnership, trust, corporation or other non-corporate business enterprise;
and, for these purposes, a company, partnership, trust, corporation or other non-corporate business enterprise shall be treated as being controlled by another if that other company, partnership, trust, corporation or other non-corporate business
enterprise is able to direct its affairs and/or to control the composition of its board of directors or equivalent body. 
  
 (o) “Third Party” shall mean a person or entity other than (i) the Purchaser, (ii) the Company or (iii) an Affiliate of either
the Purchaser or the Company. 
  
 (p)
“Voting Stock” means securities of any class or series of a corporation or other person, the holders of which are ordinarily, in the absence of contingencies, entitled to vote generally in matters put before the shareholders or members of
such corporation or other person. 
  
 ARTICLE II

  
 Purchase of Common Stock 
  
 Section 2.1 Agreement to Sell and Purchase Common Stock. Subject to
the terms and conditions set forth herein, upon the closing of the Company’s Initial Public Offering, the 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 6 

 
Purchaser shall purchase, and the Company shall sell and issue to the Purchaser, shares of Common Stock (each, a “Share” and, collectively, the
“Shares) having an aggregate purchase price equal to ten million dollars ($10,000,000) at a purchase price equal to the initial offering price to the public in the Initial Public Offering (as contained in the final prospectus for such Initial
Public Offering filed with the Securities and Exchange Commission); provided that (a) the Purchaser will have no right or obligation to purchase any Shares at the time of the Initial Public Offering if, and to the extent that, the purchase of Shares
would result in the Purchaser’s beneficial ownership of a number of shares of Common Stock which represent a percentage of the outstanding shares of Common Stock immediately following such purchase equal to or in excess of the lower, as
applicable, of (X) 10% and (Y) 5% if, but only if, the Company shall notify Purchaser in writing at any time within 30 days prior to the closing of the Initial Public Offering that the Company desires that Purchaser acquire a number of Shares equal
to the percentage just below the lesser percentage contained in this subclause (Y) (such lower percentage, as applicable contained in subclause (X) and subclause (Y), the “Capped Percentage”), and (b) in the event the purchase under this
Section 2.1 would result in ownership of a percentage of the outstanding shares of Common Stock immediately following such purchase equal to or in excess of the Capped Percentage but for this clause (b), the Purchaser shall only be obligated and
entitled to purchase the maximum number of Shares that will result in the Purchaser beneficially owning less than an aggregate of a percentage of the outstanding shares of Common Stock immediately following such purchase equal to the Capped
Percentage, and the above aggregate purchase price shall be adjusted downward accordingly, and (c) for the avoidance of doubt, the Purchaser shall only be obligated and entitled to purchase Shares under this Section 2.1 once. 
  
 Section 2.2 Termination of Purchase Obligation. Notwithstanding
anything to the contrary contained herein, the Purchaser’s obligations under Section 2.1 hereof prior to an Initial Public Offering shall terminate immediately following the earliest to occur of (i) a Change of Control, or (ii) the termination
of the License Agreement, in accordance with the provisions thereof, or (iii) the occurrence of a Material Default (as defined in the License Agreement) as a result of any breach of Section 10 of the License Agreement by the Company or any of its
Affiliates. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

  
 ARTICLE III

  
 Delivery of the Shares at the Closing

  
 Section 3.1 The completion of the purchase and sale of
the Shares of Common Stock pursuant to Section 2.1 of this Agreement (the “Closing”) shall occur on the business day of the closing of the Company’s Initial Public Offering, immediately following the closing of such Initial Public
Offering (provided the Company shall have provided Purchaser at least 3 business days advance notice of such closing). At the Closing, the Company shall deliver to Purchaser one or more stock certificates, in accordance with the Purchaser’s
reasonable request. Each such certificate shall be registered in the name of the Purchaser or one of its Affiliates, as the Purchaser shall instruct. 
  
 Section 3.2 The Company’s obligation to issue and deliver the Shares shall be subject to the following conditions, any of which may be waived by the
Company: 
  
 (a) receipt by the Company of a
certified or official bank check or checks or wire transfer of funds in the full amount of the purchase price for the Shares; 
  
 (b) the accuracy in all respects of the representations and warranties made by the Purchaser herein as though such representations and
warranties had been made on and as of Closing; 
  
 (c) no judgment, decree, injunction, order or ruling of any federal, state, local or foreign court or governmental or regulatory body or authority that is binding on any person or its property under applicable law (each a “Court
Order”) shall have been issued or entered into that would be violated by consummation of any of the transactions contemplated hereby and no lawsuit, action, arbitration, administrative or other proceeding, criminal prosecution or governmental
investigation or inquiry shall have been instituted or threatened which questions the validity or legality of the transactions contemplated hereby; and 
  
 (d) all authorizations, approvals, or permits, if any, of any governmental authority or regulatory body of the United States of America or
of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be duly obtained and effective as of the Closing. The Company shall have obtained all necessary 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 8 

 
blue sky permits and qualifications, or have the availability of exemptions therefrom, required by any state for the offer and sale of the Shares.

  
 Section 3.3 The Purchaser’s obligation to purchase the
Shares shall be subject to the fulfillment of the following conditions, any of which may be waived by the Purchaser: 
  
 (a) the Purchaser’s receipt of one or more stock certificates representing the Shares; 
  
 (b) the Purchaser’s receipt of a certificate issued by
the Secretary of State of the State of Delaware with respect to the Company as of a recent date before the Closing showing the Company to be validly existing and in good standing in Delaware; 
  
 (c) the accuracy in all respects of the representations and
warranties made by the Company herein as of the Closing as though such representations and warranties had been made on and as of Closing, provided, however, that for this purpose, the representations and warranties of the Company included herein
shall be deemed to be updated and modified by the information included in the final prospectus relating to the Company’s Initial Public Offering, a copy of which shall have been furnished to the Purchaser and on which Purchaser shall be
entitled to rely; 
  
 (d) no Court Order shall
have been issued or entered into that would be violated by consummation of any of the transactions contemplated hereby and no lawsuit, action, arbitration, administrative or other proceeding, criminal prosecution or governmental investigation or
inquiry shall have been instituted or threatened which questions the validity or legality of the transactions contemplated hereby; 
  
 (e) the fulfillment in all respects of those undertakings of the Company set forth herein to be fulfilled prior to Closing; 
  
 (f) the Purchaser’s receipt of a certificate,
reasonably satisfactory in form and content to the Purchaser and executed by an officer of the Company, certifying that the conditions specified in clauses (c) and (e) hereof have been fulfilled and that the closing of the Initial Public Offering
has occurred; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 9 

 (g) all authorizations, approvals, or permits, if any, of any governmental authority or
regulatory body of the United States of America or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be duly obtained and effective as of the Closing. The Company shall have
obtained all necessary blue sky permits and qualifications, or have the availability of exemptions therefrom, required by any state for the offer and sale of the Shares; and 
  
 (h) the Purchaser’s receipt of good standing certificates for the Company and certification by the
Company’s Secretary regarding the Board of Director and, if applicable, stockholder resolutions relating to this transaction. 
  
 ARTICLE IV 
  
 Representations and Warranties of the Company 
  
 The Company hereby represents and warrants to the Purchaser as follows on the date hereof and, subject to Article 2, as of Closing: 
  
 Section 4.1 Organization and Standing; Subsidiaries. 
  
 (a) The Company is a duly organized and validly existing
corporation in good standing under the laws of the State of Delaware and has all requisite corporate power and authority for the ownership and operation of its properties and for the carrying on of its business as now conducted and as now proposed
to be conducted. The Company is duly licensed or qualified and in good standing as a foreign corporation authorized to do business in all jurisdictions wherein the character of the property owned or leased, or the nature of the activities conducted,
by it makes such licensing or qualification necessary, except for those jurisdictions in which the failure to be so licensed or qualified, individually or in the aggregate, would not reasonably be expected to have a material adverse effect on the
business, operations, affairs or condition (financial or otherwise) of the Company or its properties or assets taken as a whole (a “Material Adverse Effect”). 
  
 (b) The attached Disclosure Letter contains a list of all of subsidiaries of the Company. Except for such
subsidiaries, the Company does not (i) own of record or beneficially, directly or indirectly, (A) any shares of capital stock or securities convertible into capital stock of 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 10 

 
any other corporation or (B) any participating interest in any partnership, limited liability company, joint venture or other non-corporate business
enterprise, or (C) any assets comprising the business or obligations of any other corporation, partnership, joint venture or other non-corporate business enterprise or (ii) control, directly or indirectly, any other entity. 
  
 (c) Each of the subsidiaries is a corporation or limited
liability company duly incorporated or organized, validly existing and in good standing (where such a concept exists) under the laws of its respective jurisdiction of incorporation or organization and is duly licensed or qualified to transact
business as a foreign corporation or foreign limited liability company and is in good standing (where such a concept exists) in each jurisdiction in which the nature of the business transacted by it or the character of the properties owned or leased
by it requires such licensing or qualification, except for those jurisdictions in which the failure to be so licensed or qualified, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. Each of the
subsidiaries has the corporate power and authority to own and hold its properties and to carry on its business as now conducted and as proposed to be conducted. All of the outstanding shares of capital stock of each of the subsidiaries are owned
beneficially and of record by the Company, one of its other wholly owned subsidiaries, or any combination of the Company and/or one or more of its other wholly owned subsidiaries, all as specified in the Disclosure Letter, in each case free and
clear of any liens, charges, restrictions, claims or encumbrances of any nature whatsoever, except for those set forth in the Disclosure Letter; and, except as set forth in the Disclosure Letter, there are no outstanding subscriptions, warrants,
options, convertible securities, or other rights (contingent or other) pursuant to which any of the subsidiaries is or may become obligated to issue any shares of its capital stock to any person other than the Company or one of the other
subsidiaries. 
  
 Section 4.2 Corporate Action. The Company
has all necessary corporate power and has taken all corporate action required to enter into and perform this Agreement. This Agreement is a valid and binding obligation of the Company, enforceable in accordance with its respective terms. The
issuance, sale and delivery of the Shares of Common Stock in accordance with this Agreement has been duly authorized by all necessary corporate action on the part of the Company. The Shares of Common Stock, when issued, sold and delivered against
payment therefor in accordance with the terms of this Agreement, will be duly and validly issued, fully 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 11 

 
paid and non-assessable. The Shares of Common Stock will not be subject to any Lien, and will not conflict with any provision of any material agreement or
material instrument to which the Company is a party or by which it or its property is bound. 
  
 Section 4.3 Governmental Approvals. Except for the filing of any notice subsequent to the Closing that may be required under applicable state and/or federal securities laws (which, if required, shall be filed
on a timely basis), no authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, is or will be necessary
for the execution and delivery by the Company of this Agreement, for the offer, issue, sale and delivery of the Shares of Common Stock or for the performance by the Company of its obligations under this Agreement. 
  
 Section 4.4 Litigation. There is no litigation or governmental
proceeding or investigation pending or, to the Company’s knowledge, threatened against the Company or any of its subsidiaries affecting any of its respective properties or assets, or to the Company’s knowledge, pending or threatened
against any officer or Key Employee of the Company or any subsidiary or holder of more than five percent (5%) of the capital stock of the Company relating to such person’s performance of duties for the Company or relating to his stock ownership
in the Company or otherwise relating to the business of the Company or any subsidiary, nor to the knowledge of the Company has there occurred any event or does there exist any condition on the basis of which any such litigation, proceeding or
investigation might reasonably be expected to be properly instituted. Neither the Company or any subsidiary nor, to the Company’s knowledge, any officer or Key Employee of the Company or any subsidiary or holder of more than five percent (5%)
of the capital stock of the Company is in default with respect to any order, writ, injunction, decree, ruling or decision of any court, commission, board or other governmental agency. There are no actions, suits, claims, investigations or
proceedings pending against or, to the knowledge of the Company, threatened against or affecting the Company or any subsidiary (or any basis therefor) which could reasonably be expected to result, either in any case or in the aggregate, in any
Material Adverse Effect, or which directly or indirectly challenge the validity of this Agreement, any of the Shares of Common Stock or any action taken or to be taken pursuant hereto or thereto. The foregoing sentences include, without limiting
their 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 12 

 
generality, actions pending against the Company or any subsidiary or, to the knowledge of the Company, threatened against or with the Company or any
subsidiary (or any basis therefor) involving the prior employment of any of the Company’s or any subsidiary’s officers or employees or their use in connection with the Company’s or any subsidiary’s business of any information or
techniques allegedly proprietary to any of their former employers. 
  
 Section 4.5 Certain Agreements of Officers and Key Employees. 
  
 (a) Except as set forth in the Disclosure Letter, neither the Company nor any subsidiary is a party to or obligated in connection with its business with respect to (i) outstanding contracts with employees, agents,
consultants, advisers, sales representatives, distributors, sales agents or dealers or (ii) collective bargaining agreements or contracts with any labor union or other representative of employees or any employee benefits provided for by any such
agreement. 
  
 (b) To the knowledge of the
Company (i) no officer or Key Employee of the Company or any subsidiary is in violation of any term of any employment contract, patent disclosure agreement, proprietary information agreement, noncompetition agreement, or any other contract or
agreement or any restrictive covenant relating to the right of any such officer or Key Employee to be employed by the Company or any subsidiary because of the nature of the business conducted or to be conducted by the Company or any subsidiary or
relating to the use of trade secrets or proprietary information of others, and (ii) the continued employment of the Company’s or any subsidiary’s officers and Key Employees does not subject the Company, any of its subsidiaries or any
Purchaser to any liability to third parties. 
  
 (c) To the knowledge of the Company, no officer of the Company or any subsidiary nor any Key Employee of the Company or any subsidiary whose termination, either individually or in the aggregate, would reasonably be expected to have a
Material Adverse Effect, has expressed any present intention of terminating his employment with the Company or any subsidiary. 
  
 Section 4.6 Compliance with Other Instruments. The Company and each subsidiary is in compliance with all of the terms and provisions of this
Agreement and of its certificate of incorporation and bylaws or other constitutive documents, and with all mortgages, indentures, 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 13 

 
leases, agreements and other instruments, if any, by which it is bound or to which it or any of its respective properties or assets are subject, except any
noncompliance which, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. The Company and each subsidiary is in compliance with all judgments, decrees, governmental orders, statutes, rules or
regulations by which it is bound or to which any of its properties or assets are subject. Neither the execution and delivery of this Agreement, the issuance of the Shares of Common Stock nor the consummation of any transaction contemplated by this
Agreement, has constituted or resulted in or will constitute or result in a default or violation of any term or provision of any of the foregoing documents, instruments, judgments, agreements, decrees, orders, statutes, rules and regulations, except
for such defaults or violations which, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 
  
 Section 4.7 Financial Information. The Disclosure Letter contains: (i) the audited consolidated balance sheet (the “Balance Sheet”) of
the Company and its subsidiaries as at December 31, 2003 (the “Balance Sheet Date”) and the related audited statements of income, stockholders’ equity and cash flows for the year then ended, and (ii) the unaudited consolidated balance
sheet of the Company and its subsidiaries as at September 30, 2004 and the related unaudited statements of income, stockholders’ equity and cash flows for the nine-month period then ended (collectively, the “Financial Statements”).
The Financial Statements present fairly the financial position of the Company and its subsidiaries as of the dates thereof and the results of operations for the period covered thereby and have been prepared in accordance with generally accepted
accounting principles consistently applied, except for the absence of footnotes not customarily included in such statements. The Company does not have reasonable grounds to know of, any material liability, contingent or otherwise, not adequately
reflected in or reserved against in the aforesaid financial statements or in the notes thereto. Except as set forth in the Disclosure Letter, since the Balance Sheet Date, (i) there has been no Material Adverse Effect, (ii) neither the business,
condition, or operations of the Company or any subsidiary nor any of the properties or assets of the Company or any subsidiary have been adversely affected as the result of any legislative or regulatory change, any revocation or change in any
franchise, permit, license or right to do business, or any other event or occurrence, whether or not insured against; and (iii) neither the Company nor any subsidiary has entered into any material transaction other 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 14 

 
than in the ordinary course of business, made any dividend or distribution on its capital stock, or redeemed or repurchased any of its capital stock, other
than repurchases of Common Stock from employees, directors or consultants of the Company and its subsidiaries upon termination pursuant to terms of agreements previously entered into with such persons. 
  
 Section 4.8 No Insolvency. No insolvency proceeding of any character,
including, without limitation, bankruptcy, receivership, reorganization, composition or arrangement with creditors, voluntary or involuntary, affecting the Company or any subsidiary or any of its assets or properties, is pending or, to the knowledge
of the Company, threatened. Neither the Company nor any subsidiary has taken any action in contemplation of, or that would constitute the basis for, the institution of any such insolvency proceedings. 
  
 Section 4.9 ERISA. Except as set forth in the Disclosure Letter,
neither the Company nor any ERISA Affiliate (as defined below) has ever maintained, sponsored, contributed to or incurred any liability under any employment, consulting, equity incentive and severance agreements, any cash incentive, equity
incentive, profit-sharing, savings, pension, medical, dental, life insurance, disability insurance, cafeteria or flexible benefits plans and any other employee benefit plan, program or arrangement, whether written or oral, including but not limited
to any “employee benefit plan” within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) (collectively, the “Benefit Plans”) subject to Section 412 of
the Internal Revenue Code of 1986 (the “Code”) or Title IV of ERISA. Neither the Company nor any ERISA Affiliate has ever incurred any obligation to contribute to or any liability under any “multiemployer plan” within the
meaning of Section 4001(a)(3) of ERISA or ever participated in any “multiple employer plan” within the meaning of Section 413(c) of the Code. The written terms of each Benefit Plan of the Company and of each ERISA Affiliate are, and the
Benefit Plans have been administered, in compliance with the requirements of ERISA, and, where applicable, Section 401 of the Code. There are not now, nor have there been, any transactions involving any of the Company’s Benefit Plans which are
prohibited under ERISA or the Code. There are no threatened or pending claims by or on behalf of any of the Company’s Benefit Plans or by any employee of the Company alleging a breach or breaches of fiduciary duties or violations of other
applicable state or federal law which could 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 15 

 
result in liability on the part of the Company or any of the Company’s Benefit Plan under ERISA or any other law, nor to the Company’s knowledge is
there any basis for such a claim. All returns, reports, disclosure statements and premium payments required to be made under ERISA and the Code with respect to the Company’s Benefit Plans have been timely filed or delivered. Each Benefit Plan
of the Company or any ERISA Affiliate that is intended to be qualified under Section 401(a) of the Code has received a determination letter from the Internal Revenue Service covering all amendments required to be adopted to date and, to the
knowledge of the Company, there are no circumstances which exist that are reasonably likely to adversely affect the tax-qualified status of such Benefit Plan or result in the revocation of such letter. The Company and each ERISA Affiliate has made
all contributions and payments required to be made to each of its Benefit Plans within the time prescribed by law or, if earlier, the terms of the Benefit Plan. The term “ERISA Affiliate” means any entity that, together with the
Company, is treated as a single-employer within the meaning of Sections 414(b), (c), (m) or (o) of the Code or Section 4001(b) of ERISA. 
  
 Section 4.10 Transactions with Affiliates. Except as set forth in the Disclosure Letter, and except as contemplated hereby, there are no loans,
leases, royalty agreements or other continuing transactions between the Company or any subsidiary and (a) any officer, employee or director of the Company or any subsidiary, or (b) any person owning five percent (5%) or more of any class of capital
stock of the Company, or (c) any member of the immediate family of such officer, employee, director or stockholder, or (d) any corporation or other entity controlled by such officer, employee, director or stockholder or a member of the immediate
family of such officer, employee, director or stockholder. 
  
 Section 4.11 Assumptions or Guaranties of Indebtedness of Other Persons. Except as contemplated hereby, neither the Company nor any subsidiary has assumed, guaranteed, endorsed or otherwise become directly or contingently liable on
(including, without limitation, liability by way of agreement, contingent or otherwise, to purchase, to provide funds for payment, to supply funds to or otherwise invest in the debtor or otherwise to assure the creditor against loss), any
Indebtedness of any other person. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 16 

 Section 4.12 Investments in Other Persons. Except as set forth in the Disclosure Letter, neither
the Company nor any subsidiary has made any loan or advance to any person, other than in the normal course of business and on an arm’s length basis on commercially reasonable terms and as reflected in the Financial Statements, which, after
giving effect to the transactions contemplated hereby, is outstanding on the date of this Agreement, nor is it committed or obligated to make any such loan or advance. 
  
 Section 4.13 Securities Act of 1933. The Company has complied and will comply with all applicable federal and state
securities laws in connection with the offer, issuance and sale of the Shares of Common Stock. Neither the Company nor anyone acting on its behalf has or will sell, offer to sell or solicit offers to buy the Shares of Common Stock, or solicit offers
with respect thereto from, or enter into any preliminary conversations or negotiations relating thereto with, any person, so as to bring the issuance and sale of the Shares of Common Stock under the registration provisions of the Securities Act and
applicable state securities laws. 
  
 Section 4.14 Brokers or
Finders. No person has or will have, as a result of the transactions contemplated by this Agreement, any right, interest or valid claim against or upon the Company or any subsidiary for any commission, fee or other compensation as a finder or
broker because of any act or omission by the Company or any of their respective agents. 
  
 Section 4.15 Capitalization; Status of Capital Stock. 
  
 (a) As of the date of this Agreement, the Company has a total authorized capitalization consisting of (i) 125,000,000 shares of Common
Stock, of which (a) 4,765,328 shares are issued and outstanding as of the date of this Agreement, and (b) 16,239,375 shares have been reserved for issuance upon exercise of options issuable under the Company’s 1997 Employee, Director and
Consultant Stock Option Plan, as amended (the “Stock Plan”), of which options to purchase 11,342,561 shares have been granted to employees, consultants or directors and are outstanding as of the date of this Agreement and 1,675,328
shares have been issued pursuant to stock option exercises, which shares are included in the Common Stock outstanding; and (ii) 67,946,524 shares of Preferred Stock, of which 1,530,000 are designated as Series A Preferred Stock, 591,000 are
designated as Series B Preferred Stock, 5,029,000 are 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 17 

 
designated as Series C Preferred Stock, 3,759,088 are designated as Series D Preferred Stock, 1,815,992 are designated as Series E Preferred Stock,
34,502,875 are designated as Series F Preferred Stock and 20,718,569 are designated as Series G Preferred Stock. As of the date of this Agreement, 1,530,000 shares of Series A Preferred Stock, 591,000 shares of Series B Preferred Stock, 4,355,000
shares of Series C Preferred Stock, 3,759,088 shares of Series D Preferred Stock, 1,813,485 shares of Series E Preferred Stock, 26,322,107 shares of Series F Preferred Stock, and 20,476,068 shares of Series G Preferred Stock are validly issued and
outstanding. 
  
 (b) A complete list of the
capital stock of the Company that has been previously issued and the names in which such capital stock is registered on the stock transfer books of the Company is set forth in the Disclosure Letter. All the outstanding shares of capital stock of the
Company have been duly authorized, and are validly issued, fully paid and non-assessable. The designations, powers, preferences, rights, qualifications, limitations and restrictions in respect of each class and series of authorized capital stock of
the Company are as set forth in the Fourth Amended and Restated Certificate of Incorporation of the Company (the “Charter”), and all such designations, powers, preferences, rights, qualifications, limitations and restrictions are valid,
binding and enforceable and in accordance with all applicable laws, except as such enforceability may be limited by any applicable bankruptcy, insolvency, moratorium or similar laws affecting creditors’ rights generally. Except as otherwise set
forth in the Disclosure Letter, no preemptive, conversion or other rights, options, warrants, subscriptions or purchase rights of any nature to acquire from the Company shares of capital stock or other securities are authorized, issued or
outstanding, nor is the Company obligated in any other manner to issue shares of its capital stock or other securities except as contemplated by this Agreement. Except as set forth in the Disclosure Letter, there are no restrictions on the transfer
of shares of capital stock of the Company other than those imposed by relevant federal and state securities laws and as otherwise contemplated by this Agreement. Other than as set forth in the Second Amended and Restated Stockholders Agreement dated
August 30, 2004, there are no agreements, understandings, trusts or other collaborative arrangements or understandings concerning the voting of the capital stock of the Company. The offer and sale of all capital stock and other securities of the
Company issued before the date of this Agreement complied with or were 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 18 

 
exempt from all applicable federal and state securities laws and no stockholder has a right of rescission with respect thereto. 
  
 Section 4.16 Registration Rights. Except as set forth in the
Disclosure Letter, and except as contemplated hereby, no person has demand or other rights to cause the Company to file any registration statement under the Securities Act relating to any securities of the Company or any right to participate in any
such registration statement. 
  
 Section 4.17 Insurance.
The Company and each of its subsidiaries carries insurance covering its properties and businesses customary for the type and scope of its properties and businesses, but in any event in amounts sufficient to prevent the Company or any subsidiary from
becoming a co-insurer. 
  
 Section 4.18 Books and Records.
The books of account, ledgers, order books, records and documents of the Company and each of its subsidiaries accurately and completely reflect all material information relating to the business of the Company and each of its subsidiaries, the
location and collection of its assets, and the nature of all transactions giving rise to the obligations or accounts receivable of the Company and each of its subsidiaries. 
  
 Section 4.19 Title to Assets. The Company and each of its subsidiaries has good and marketable title in fee to such
of its fixed assets, if any, as are real property, and good and marketable title to all of its other assets and properties, free of any Liens, except for those set forth in the Disclosure Letter. The Company and each of its subsidiaries enjoys
peaceful and undisturbed possession under all leases under which it is operating, and all said leases are valid and subsisting and in full force and effect. 
  
 Section 4.20 Computer Programs. Except as set forth in the Disclosure Letter and other than commercially available, off-the-shelf computer
software, neither the Company nor any subsidiary owns, licenses or otherwise uses any computer software in connection with the operation of its business as currently conducted. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 19 

 Section 4.21 Real Property Holding Corporation. Since its date of incorporation, the Company has
not been, and as of the date of this Agreement shall not be, a “United States real property holding corporation,” as defined in Section 897(c)(2) of the Code, and in Section 1.897-2(b) of the Treasury Regulations issued thereunder. The
Company has no current plans or intentions which would cause the Company to become a “United States real property holding corporation,” and the Company has filed with the IRS all statements, if any, with its United States income tax
returns which are required under Section 1.897-2(h) of the Treasury Regulations. 
  
 Section 4.22 Taxes. The Company and each of its subsidiaries has filed all tax returns, federal, state, county and local, domestic and foreign, required to be filed by it, and the Company and each of its
subsidiaries has paid all taxes shown to be due by such returns as well as all other taxes, assessments and governmental charges which have become due or payable, including without limitation all taxes which the Company or each of its subsidiaries
is obligated to withhold from amounts owing to employees, creditors and third parties. The Company has established adequate reserves for all taxes accrued but not yet payable to the extent required by generally accepted accounting principles. All
material tax elections of any type which the Company and each of its subsidiaries has made as of the date hereof are set forth in the Financial Statements. No deficiency assessment with respect to or, proposed adjustment of the Company’s or any
subsidiary’s federal, state, county or local taxes, domestic and foreign, is pending or, to the knowledge of the Company, threatened. There is no tax lien (other than for current taxes not yet due and payable), whether imposed by any federal,
state, county or local taxing authority, domestic or foreign, outstanding against the assets, properties or business of the Company or any subsidiary. Neither the Company (including any subsidiary) nor any of its present or former stockholders has
ever filed an election pursuant to Section 1362 of the Code, that the Company or any subsidiary be taxed as an S corporation. 
  
 Section 4.23 Other Agreements. Except as set forth in the Disclosure Letter, neither the Company nor any subsidiary is a party to or otherwise
bound by any written or oral agreement, instrument, commitment or restriction which individually or in the aggregate could have a Material Adverse Effect or any other written or oral: 
  
 (a) distributor, dealer or manufacturer’s representative contract or agreement which is not terminable
on less than ninety (90) days’ notice without cost or other liability to the Company or any subsidiary (except for contracts which, in the aggregate, are not material to the business of the Company or any subsidiary); 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 20 

 (b) sales agreement which entitles any customer to a rebate or right of set-off, to
return any product to the Company or any subsidiary after acceptance thereof or to delay the acceptance thereof, or which varies in any material respect from the Company’s or any subsidiary’s standard form contracts (except for contracts
which, in the aggregate, are not material to the business of the Company or any subsidiary); 
  
 (c) agreement with any labor union in the United States or any foreign jurisdiction (and, to the Company’s knowledge, no
organizational effort is being made with respect to any of its employees); 
  
 (d) agreement with any supplier containing any provision permitting any party other than the Company or any subsidiary to renegotiate the price or other terms, or containing any pay-back or other similar provision,
upon the occurrence of a failure by the Company or any subsidiary to meet its obligations under the agreement when due or the occurrence of any other event (except for contracts which, in the aggregate, are not material to the business of the
Company or any subsidiary); 
  
 (e) agreement for
the future purchase of fixed assets or for the future purchase of materials, supplies or equipment in excess of its normal operating requirements; 
  
 (f) agreement for the employment of any officer, individual, employee or other person (whether of a legally binding nature or in the
nature of informal understandings) on a full-time or consulting basis which is not terminable on notice without cost or other liability to the Company or any subsidiary, except accrued vacation pay; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 21 

 (g) bonus, pension, profit-sharing, retirement, hospitalization, insurance, stock
purchase, stock option or similar plan, agreement or understanding pursuant to which benefits are provided to any employee of the Company or any subsidiary (other than group insurance plans applicable to employees generally or as otherwise required
by law); 
  
 (h) agreement or indenture relating
to the borrowing of money or to the mortgaging or pledging of, or otherwise placing a lien or security interest on, any material asset of the Company or any subsidiary; 
  
 (i) agreement, or group of related agreements with the same party or any group of affiliated parties, under
which the Company or any subsidiary has advanced or agreed to advance money, has agreed to lease any real property as lessee or lessor, or has agreed to lease any personal property as lessee or lessor if such lease for personal property was not
entered into in the ordinary course of business; 
  
 (j) agreement or obligation (contingent or otherwise) to issue, sell or otherwise distribute or to repurchase or otherwise acquire or retire any shares of its capital stock or any of its other equity securities (other than in connection
with the transaction contemplated by this Agreement); 
  
 (k) assignment, license or other agreement with respect to any form of intangible property, which assignment, license or other agreement was entered into other than in the ordinary course of business; 
  
 (l) agreement under which it has granted any person
registration rights with respect to its capital stock; 
  
 (m) agreement under which it has limited or restricted its right to compete with any person in any respect; 
  
 (n) except as set forth above, any other agreement or group of related contracts with the same party involving more than $100,000 or
continuing over a period of more than six months from the date or dates thereof (including renewals or extensions of options with 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 22 

 
another party), which agreement or group of agreements is not terminable by the Company or any subsidiary without penalty upon notice of thirty (30) days or
less, but excluding any agreement or group of agreements with a customer of the Company or any subsidiary for the sale, lease or rental of the Company’s or any subsidiary’s products or services if such agreement or group of agreements was
entered into by the Company or such subsidiary in the ordinary course of business; or 
  
 (o) other contract, instrument, commitment, plan or arrangement, a copy of which would be required to be filed with the Commission as an
exhibit to a registration statement on Form S-1 if the Company were registering securities under the Securities Act. 
  
 Except as set forth in the Disclosure Letter, the Company and each of its subsidiaries and, to the Company’s knowledge after due inquiry, each other party thereto
have in all material respects performed all the actions required to be performed by them to date and neither the Company nor any subsidiary has received any notice of default and is, and to the Company’s knowledge, each other party thereto is
not, in default under any lease, agreement or contract now in effect to which the Company or any subsidiary is a party or by which it or its property may be bound. Neither the Company nor any subsidiary has any present expectation or intention of
not fully performing all its respective material obligations under each such lease, contract or other agreement, and neither the Company nor any subsidiary has any knowledge of any material breach or anticipated breach by the other party to any
contract or commitment to which the Company or such subsidiary is a party. 
  
 Section 4.24 Foreign Corrupt Practices Act. Neither the Company nor any subsidiary has taken any action which would cause it to be in violation of the Foreign Corrupt Practices Act of 1977, as amended, or any
rules and regulations thereunder. To the Company’s knowledge, there is not now, and there has never been, any employment by the Company or any subsidiary of, or beneficial ownership in the Company or any subsidiary by, any governmental or
political official in any country in the world. 
  
 Section 4.25
Federal Reserve Regulations. Neither the Company nor any subsidiary is engaged in the business of extending credit for the purpose of purchasing or carrying margin 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 23 

 
securities (within the meaning of Regulation G of the Board of Governors of the Federal Reserve System), and no part of the proceeds of the sale of the
Shares of Common Stock will be used to purchase or carry any margin security or to extend credit to others for the purpose of purchasing or carrying any margin security or in any other manner which would involve a violation of any of the regulations
of the Board of Governors of the Federal Reserve System. 
  
 Section 4.26 Significant Customer or Supplier. The Disclosure Letter lists all of the Company’s and of its subsidiary’s significant customers, suppliers and vendors (the “Significant Parties”), and none of the
Significant Parties has terminated, materially reduced or threatened to terminate or materially reduce its purchases from or provision of products or services to the Company or any of its subsidiaries, as the case may be. 
  
 Section 4.27 Environmental Liabilities. Neither the Company nor any
subsidiary has caused or allowed, or contracted with any party for the generation, use, transportation, treatment, storage or disposal of any Hazardous Substances (as defined below) in connection with the operation of its business or otherwise. The
Company and each of its subsidiaries, the operation of its business, and any real property that the Company and each of its subsidiaries owns, leases or otherwise occupies or uses (the “Premises”) are in compliance in all material
respects with all applicable Environmental Laws (as defined below) and orders or directives of any governmental authorities having jurisdiction under such Environmental Laws, including, without limitation, any Environmental Laws or orders or
directives with respect to any cleanup or remediation of any release or threat of release of Hazardous Substances. Neither the Company nor any subsidiary has received any citation, directive, letter or other communication, written or oral, or any
notice of any proceeding, claim or lawsuit, from any person arising out of the ownership or occupation of the Premises, or the conduct of its operations, and neither the Company nor any subsidiary is aware of any basis therefor. The Company and each
of its subsidiaries has obtained and is maintaining in full force and effect all necessary permits, licenses and approvals required by all Environmental Laws applicable to the Premises and the business operations conducted thereon (including
operations conducted by tenants on the Premises), and is in compliance with all such permits, licenses and approvals. Neither the Company nor any subsidiary has caused or allowed a release, or a threat of release, of any Hazardous Substance unto, at
or near the 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 24 

 
Premises, and, to the best of the Company’s knowledge, neither the Premises nor any property at or near the Premises has ever been subject to a release,
or a threat of release, of any Hazardous Substance. For the purposes of this Agreement, the term “Environmental Laws” shall mean any federal, foreign (as applicable), state or local law or ordinance or regulation pertaining to the
protection of human health or the environment, including, without limitation, the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Sections 9601, et seq., the Emergency Planning and Community Right-to-Know Act, 42
U.S.C. Sections 11001, et. seq., and the Resource Conservation and Recovery Act, 42 U.S.C. Sections 6901, et. seq. For purposes of this Agreement, the term “Hazardous Substances” shall include oil and petroleum products, asbestos,
polychlorinated biphenyls, urea formaldehyde and any other materials classified as hazardous or toxic under any Environmental Laws. 
  
 Section 4.28 Disclosure. Neither this Agreement nor any other document, certificate or written statement furnished to the Purchaser or its counsel
by or on behalf of the Company in connection with the transaction contemplated hereby, including, at the time of Closing, the final Prospectus relating to the Initial Public Offering, a copy of which has been furnished to the Purchaser, contains any
untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein, in view of the circumstances under which they were made, not misleading. 
  
 ARTICLE V 
 Representations and Warranties of the Purchaser 
  
 Section 5.1 Securities Act Exemption. The Purchaser hereby represents and warrants to the Company, on the date hereof and, subject to Article 2, as
of Closing, as follows: (i) the Purchaser is an “accredited investor” as defined in Regulation D under the Securities Act and also is knowledgeable and experienced in making investments in private placement transactions such as the
purchase of the Shares; (ii) effective as of Closing, the Purchaser is acquiring the Shares for its own account for investment and with no present intention of distributing any of such Shares, and no arrangement or understanding exists with any
other person regarding the distribution of any of such Shares (this representation and warranty not limiting the Purchaser’s right to sell pursuant to an effective registration statement registering the Shares for resale or 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 25 

 
pursuant to any other means of sale legally available); and (iii) effective as of Closing and subject to the cooperation of the Company, the Purchaser has
had an opportunity to ask questions of and receive answers from the management of the Company regarding the Company, its business and the offering of the Shares. 
  
 Section 5.2 Due Authorization. (a) The Purchaser further represents and warrants to the Company that, on the date
hereof and, subject to Article 2, as of Closing, the Purchaser has all requisite right, power and authority to enter into and perform this Agreement. The execution and delivery of this Agreement by the Purchaser and the consummation by it of the
transactions contemplated hereby have been duly authorized by all necessary corporate action on behalf of such Purchaser. This Agreement constitutes a valid and binding obligation of the Purchaser enforceable against the Purchaser in accordance with
its terms, (i) except as rights to indemnity and contribution may be limited by state, federal or foreign laws or the public policy underlying such laws, (ii) except as enforceability may be limited by applicable bankruptcy, fraudulent conveyance,
insolvency, reorganization, moratorium or similar laws now or hereafter in effect affecting creditors’ and contracting parties’ rights generally and (iii) except as enforceability may be subject to general principles of equity (regardless
of whether such enforceability is considered in a proceeding in equity or at law). 
  
 (b) The Purchaser further represents and warrants to the Company that, on the date hereof and, subject to Article 2, as of Closing,
neither the execution and delivery of this Agreement by the Purchaser nor the consummation by it of the transactions contemplated hereby conflicts with or constitutes a violation of or default under the charter, by-laws or other organizational
documents of the Purchaser, any statute, law, regulation, order or decree applicable to the Purchaser, or any contract, commitment, agreement, arrangement or restriction of any kind to which the Purchaser is a party or by which it is bound.

  
 Section 5.3 Restrictions on Transfer. The Purchaser
acknowledges and understands that the Purchaser must bear the economic risk of its investment in the Shares for an indefinite period of time because the Shares will not have been registered under the Securities Act and, therefore, cannot voluntarily
be offered, sold, pledged or otherwise disposed of unless registered under the Securities Act or an exemption from such registration is available and in compliance 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 26 

 
with applicable state and foreign securities laws. The certificates representing the Shares issued to the Purchaser will bear a legend in substantially the
following form: 
  
 THE SECURITIES EVIDENCED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). SUCH SECURITIES MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED, OR A SALE PURSUANT TO RULE 144 OF THE SECURITIES ACT. THE SECURITIES EVIDENCED BY THIS
CERTIFICATE ARE ALSO SUBJECT TO THE PROVISIONS OF A STOCK PURCHASE AGREEMENT DATED AS OF MARCH 11, 2005. 
  
 The Purchaser agrees that any sale, transfer, pledge, hypothecation or other disposition of the Shares shall be made in compliance with such legends.

  
 Section 5.4 Lock-up. During the period commencing on
the Initial Public Offering and ending on the earliest to occur of (x) the fifth anniversary thereof or (y) such date as the Purchaser waives all of its rights (but in no event earlier than the first anniversary of the closing of the Initial Public
Offering) to register Shares pursuant to Article VIII or (z) such date as the Purchaser no longer owns at least 1% of the outstanding shares of Common Stock of the Company, the Purchaser agrees that it shall, if so requested by the Company, enter
into an agreement providing that it shall not offer, sell or grant an option for the sale, or otherwise dispose of (collectively, “transfer”) any Shares of Common Stock or any securities convertible into or exercisable for Shares of Common
Stock (including, without limitation, the Shares and any options, warrants, stock appreciation rights, or similar rights with an exercise or conversion privilege at a price related to, or derived from, the market price of Shares of Common Stock),
during the 14-day period prior to, and during the 90-day period beginning on, the date of any firm commitment underwritten public offering of Common Stock (180-day period in the case of 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 27 

 
the Initial Public Offering), without the prior written consent of the managing underwriters of such public offering; provided, however, that this Section
5.4 shall not apply or be effective unless all executive officers and directors and all shareholders of the Company’s outstanding Common Stock having an ownership interest equal to or greater than that held by the Purchaser (calculated on a
fully-diluted basis) and having registration rights entitling them to participate in the public offering enter into similar agreements, and shall only take effect following notice to the Purchaser of the foregoing. 
  
 Section 5.5 Compliance. The Purchaser acknowledges that it is aware
that by receiving certain information under this Agreement, the License Agreement and/or the S & E Agreement (i) it may result in the Purchaser receiving material non-public information about the Company and (ii) there exist United States
federal and state securities laws that may restrict or eliminate the recipient’s ability to sell or purchase securities of the Company. The Purchaser agrees with the Company to comply in all material respects with all United States federal and
state securities laws. 
  
 ARTICLE VI 
 Survival of Representations, Warranties and Agreements 
  
 Section 6.1 Survival of Representations, Warranties and Agreements. Notwithstanding any investigation made by any
party to this Agreement, all covenants, agreements, representations and warranties made by the Company and the Purchaser herein shall survive the execution hereof, the delivery to the Purchaser of the Shares being purchased, and the payment
therefor. 
  
 ARTICLE VII 
 Limitations and Restrictions 
  
 Section 7.1 Restrictions on Certain Actions by the Purchaser. Except (i) with the written consent of the Company or (ii) by way of stock dividends
or other distributions or offerings made available to the Company’s shareholders generally, or (iii) pursuant to a merger, reclassification, recapitalization or other similar transaction approved by the Company’s Board of Directors, or
(iv) pursuant to a rights offering pursuant to which the Purchaser offers to 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 28 

 
purchase such number of shares of Voting Stock so that its percentage of owned Voting Stock after the rights offering is not more than its percentage of
ownership before the rights offering, assuming all shares of Voting Stock offered in the rights offering are in fact sold or (v) as provided in this Agreement, the Purchaser agrees that it will not, nor will any of its Affiliates: 
  
 (a) sell, exchange, transfer or otherwise dispose of the
Shares acquired pursuant to this Agreement until the first anniversary following the closing of the Initial Public Offering; 
  
 (b) during the Standstill Period: 
  
 (i) acquire or agree, offer, seek or propose to acquire ownership, or cause ownership to be acquired (including, but not limited to,
beneficial ownership as defined in Rule 13d-3 under the Exchange Act) of any Voting Stock of the Company or securities convertible or exchangeable into or exercisable for any Voting Stock of the Company if as a result of such acquisition, the
Purchaser and any Affiliates controlled by the Purchaser in the aggregate would own more than 10% of the Voting Stock of the Company at the time of such acquisition; 
  
 (ii) initiate or participate as the soliciting party in any Proxy Solicitation involving any election
contest subject to Regulation 14A under the Exchange Act with respect to the Company; 
  
 (iii) form or join, or permit any Affiliate controlled by the Purchaser to form or join, any partnership, limited partnership, syndicate
or other “group” (within the meaning of Section 13(d)(3) of the Exchange Act) with respect to the acquisition of any Voting Stock of the Company that would violate clause (i) above; 
  
 (iv) arrange, or in any way participate in, any financing
for the purchase of any Voting Stock or securities convertible or exchangeable into or exercisable for any Voting Stock or assets of the Company that would violate clause (i) above; or 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 29 

 (v) enter into any discussions, negotiations, arrangements or understandings with, or
advise, assist or encourage any other person with respect to, any of the foregoing prohibited matters in this Section 7.1(b). 
  
 (c) Nothing contained in this Section 7 shall preclude the Purchaser from (i) making proposals, on a confidential basis, to the Company or
its Board of Directors, or (ii) seeking a waiver from the Company of any of the foregoing provisions of this Section 7, or (iii) selling Common Stock of the Company in a tender offer or exchange offer initiated by a person other than the Purchaser
or its Affiliates, or (iv) in the case where the Purchaser’s percentage ownership of the outstanding shares of Common Stock has increased above the percentage ownership in effect as of the Closing (the “Closing Percentage”) for any
reason (other than a purchase of shares of Common Stock by the Purchaser from any person after the Closing), disposing of any number of shares in one or more transactions up to the amount that would result in the Purchaser owning a percentage of the
outstanding shares of the Company equal to or greater than the Closing Percentage. Nothing contained in this Section 7 shall preclude the Purchaser (and the Company agrees to facilitate), in the case where the Purchaser’s percentage ownership
of the outstanding shares of Common Stock has decreased below the Closing Percentage for any reason (other than a sale or other transfer by the Purchaser to any third party after the Closing), from acquiring shares of Common Stock in one or more
transactions from the Company up to an amount that would result in the Purchaser owning a percentage of the outstanding shares of the Company equal to or less than the Closing Percentage; it being understood that if, following 30 days prior written
notice to the Company that the Purchaser wishes to acquire shares of Common Stock pursuant to this sentence and no such requested sale has occurred, the Purchaser shall be entitled to purchase such requested shares of Common Stock from any person.

  
 (d) Notwithstanding anything to the contrary
contained herein, the prohibitions set forth in this Section 7.1 shall not apply to (i) any investment in any Voting Stock of the Company by or on behalf of any pension or employee benefit plan or trust, including without limitation (1) any direct
or indirect interests in portfolio securities held by an investment company registered under the Investment Company Act of 1940, as amended, or (2) interests in securities comprising part of a mutual fund or broad based, publicly traded market
basket or 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 30 

 
index of stocks approved for such a plan or trust in which such plan or trust invests; or (ii) Voting Stock of the Company held by a person acquired by the
Purchaser on the date such person first entered into an agreement to be acquired by the Purchaser or acquired after such person was acquired by the Purchaser pursuant to an agreement requiring (but only to the extent requiring) such person to sell
or acquire such Voting Stock, which agreement was in effect on the date such person first entered into an agreement to be acquired by the Purchaser, or (iii) any assets or securities of the Company, as debtor, that are acquired in a transaction
subject to the approval of the United States Bankruptcy Court pursuant to proceedings under the United States Bankruptcy Code (meaning 11 U.S.C §§ 101-1330, as amended), or (iv) any securities sold to any Third Party as part of an
Acquisition Proposal or Business Combination or voted for or against any such Acquisition Proposal or Business Combination. 
  
 (e) The provision of this Section 7.1 shall terminate and shall be of no further force and effect from and after the date that any of the
following is disclosed: (i) a Third Party independently or in concert with others commences or makes an Acquisition Proposal, or (ii) a Third Party shall have publicly announced an intention to seek a change of control of the board of directors of
the Company through the solicitation of proxies or otherwise, or (iii) the Company enters into a binding agreement with a Third Party with respect to an Acquisition Proposal or a Business Combination, or (iv) the Company publicly announces (by press
release or otherwise) that it is in discussions or negotiations with any Third Party with respect to a possible Acquisition Proposal or a Business Combination or that the Company is seeking any purchaser for a controlling interest in its business.
For the purposes of this Article VII, the term “controlling interest” shall mean the possession, through ownership of voting securities or otherwise, of the ability to direct the management and affairs of the Company and, without
limitation, shall be conclusively presumed to be present in the case of the direct or indirect ownership of a majority of the voting securities and/or equity interests of the Company, without precluding the existence of control in the case of the
ownership of a lesser amount of such securities. 
  
 Section 7.2
Agreement with Third Party. The provisions of Section 7.1 shall terminate and shall be of no further force and effect from and after the earliest to occur of any Acquisition Proposal, Business Combination or Change of Control. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 31 

 Section 7.3 Freedom to Vote. Nothing contained herein shall prevent the Purchaser or any of its
Affiliates from voting any equity securities owned by them in their sole discretion, and to that extent, seeking to influence the policies or affairs of the Company. 
  
 ARTICLE VIII 
  
 Registration of the Shares; Compliance with the Securities Act 
  
 Section 8.1 Demand Registration. (a) At any time after the Company becomes eligible to file a Registration Statement
on Form S-3 (or any successor form relating to secondary offerings), the Purchaser may request, in writing, the Company to effect the registration on Form S-3 (or such successor form) (“Demand Registration Statement”), of the Shares having
an aggregate value of at least three million dollars ($3,000,000) (based on the then current public market price). The rights granted by the Company under this Section 8.1 shall terminate on the fifth anniversary of the date of the Initial Public
Offering. 
  
 (b) Upon receipt of such request
for registration pursuant to this Section 8, the Company shall, as expeditiously as possible, cause to be filed with the Securities and Exchange Commission (the “SEC”) a Demand Registration Statement providing for the registration under
the Securities Act of the Shares which the Company has been requested to so register by the Purchaser, and shall use its best efforts to have such Demand Registration Statement declared effective by the SEC as soon as practicable thereafter and to
keep such Demand Registration Statement continuously effective for a period of time necessary following the date on which such Demand Registration Statement is declared effective to permit the sale of all the Shares covered by such Demand
Registration Statement or such shorter period which will terminate when all the Shares covered by such Demand Registration Statement have been sold pursuant thereto (including, if necessary, by filing with the SEC a post-effective amendment or a
supplement to the Demand Registration Statement or the related prospectus or any document incorporated therein by reference or by filing any other required document or otherwise supplementing or amending the Demand Registration Statement, if
required by the rules, regulations or instructions applicable to the registration form under the Securities Act used by the Company for such Demand Registration Statement or by the Securities Act, any state securities or “blue sky” laws,
or any other rules and regulations thereunder). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 32 

 (c) A Demand Registration Statement shall be deemed not have become effective unless it
has been declared effective by the SEC; provided, however, that if, after it has been declared effective, the offering of any Shares pursuant to such Demand Registration Statement is interfered with by any stop order, injunction or other order or
requirement of the SEC or any other governmental agency or court (other than such stop order or injunction issued as a result of (i) the inclusion in such Demand Registration Statement of any information supplied to the Company for inclusion therein
by the Purchaser or (ii) the conduct of the offering by the Purchaser of its agents), such Demand Registration Statement will be deemed not to have become effective. 
  
 (d) The Purchaser shall be entitled to two Demand Registration Statements pursuant to Section 8.1(a). For
purposes of this Section 8.1(d), a registration shall not be counted until such time as a Registration Statement covering the applicable Shares has been declared effective by the SEC (subject to Section 8.1(c)), except that a registration shall
count if prior to the Registration Statement being declared effective the Purchasers withdraw their request for such registration by providing written notice to the Company and elect not to pay the registration expenses therefor pursuant to Section
8.3. Notwithstanding the foregoing, in the event the withdrawal by the Purchaser is based upon material adverse information related to the Company that is different from the information known or available to the Purchaser at the time of its request
for registration, or a material change in the business, assets, liabilities, condition (financial or otherwise) or prospects of the Company after the time of such request, then such registration shall not be counted for purposes of this Section
8.1(d) even though the Purchaser does not bear the Registration Expenses therefor. 
  
 (e) If the Purchaser intends to distribute the Shares covered by its request by means of an underwriting, it shall so advise the Company
as a part of its request made pursuant to Section 8.1(a). If the Company desires that any officers or directors of the Company holding securities of the Company be included in any registration for an underwritten offering requested pursuant to
Section 8.1(e) or if other holders of securities of the Company who are entitled, by contract with the Company, to have securities included in such a registration (the “Other 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 33 

 
Holders”) request such inclusion, the Company shall offer to include the securities of such officers, directors and Other Holders in such
registration and underwriting. The Company shall (together with the Purchasers, officers, directors and Other Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form
(including, without limitation, customary indemnification and contribution provisions on the part of the Company) with the underwriter. The Company may include securities for its own account in such registration if the underwriter so agrees and if
the number of Shares and other securities that would otherwise have been included in such registration and underwriting will not thereby be limited. Notwithstanding any other provision of this Section 8.1, if the underwriter determines that the
inclusion of the number Shares requested to be registered would have a material adverse effect on the price, timing or distribution of the Common Stock to be registered, the Company shall limit the number of Shares to be included in the registration
and underwriting to such number of Shares that the Purchaser is so advised can be sold without having such a material adverse effect. The Company shall so advise all holders of Shares requesting registration, and the number of shares that are
entitled to be included in the registration and underwriting shall be allocated in the following manner: first, all securities initially proposed to be sold pursuant to the Demand Registration Statement by the Purchaser; and second,
the number of Shares requested to be included in such registration by the Other Holders that the Purchaser is so advised can be sold without having a material adverse effect on the price, timing or distribution of the Common Stock, allocated pro
rata among the Other Holders requesting such registration on the basis of the number of Shares requested to be included by all such Other Holders. 
  
 (f) If at the time of any request to register Shares by the Purchaser pursuant to Section 8.1(a), the Company is engaged or has plans to
engage in a registered public offering or is engaged in any other material activity which, in the good faith and reasonable determination of the Company’s Board of Directors, would be materially adversely affected by the requested registration,
then the Company may at its option direct that such request be delayed for a period not in excess of ninety (90) days from the date of such request, such right to delay a request to be exercised by the Company not more than once in any twelve-month
period. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 34 

 (g) The Purchaser shall have the right to select the underwriter for an underwritten
offering requested pursuant to a Demand Registration Statement, subject to the Company’s approval, which will not be unreasonably withheld. 
  
 Section 8.2 “Piggyback” Registration. (a) If at any time the Company shall initiate a registration under the Securities Act of any of its
Common Stock for its own account or for the account of any stockholder of the Company that holds registration rights other than securities to be issued (i) in connection with the Company’s Initial Public Offering, (ii) in connection with any
acquisition of any entity or business for which shares are being registered on a Form S-4 or its then equivalent or (iii) pursuant to employee benefit plans (including registrations on Form S-8 or Form S-4 or their then equivalents), it shall send
to the Purchaser at least thirty (30) days’ prior written notice of such determination and, if within fifteen (15) days after the giving of such notice, the Purchaser shall so request in a writing received by the Company, the Company shall
include in such registration statement any or all of the Shares that the Purchaser requests to be registered therein; except that, if in connection with any underwritten public offering of Common Stock, the managing underwriter shall recommend that
the number of Shares to be included in such registration statement be limited because, in the underwriter’s reasonable judgment, such limitation is necessary to permit the public distribution of the shares of Common Stock being sold by the
Company without materially adversely affecting the price, timing or distribution of such Common Stock, then the number of Shares to be included in such registration statement shall be limited to the extent so recommended (which may be the complete
exclusion of such Shares); provided, however, that such limitation shall be proportionate (based on the number of shares to be included) to the limitation applied to any other holders of Common Stock with registration rights who request the
inclusion of shares in the registration statement. The rights granted by the Company under this Section 8.2 shall terminate on the fifth anniversary of the date of the Initial Public Offering. 
  
 (b) The Company will use commercially reasonable efforts to
maintain the effectiveness of any registration statement under which any of the Shares are being offered pursuant to this Section 8.2 until the earlier to occur of (i) the completion of the distribution pursuant to such registration statement and
(ii) one hundred eighty (180) days after the effectiveness of such registration statement; provided, however, that such 180-day period will be 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 35 

 
deemed to be suspended for so long as the Purchaser is prohibited from using such registration statement pursuant to the third sentence of this Section
8.2(b). The Company will promptly notify the Purchaser and each underwriter under such registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event of
which the Company has knowledge as a result of which the prospectus contained in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in light of the circumstances then existing. The Purchaser agrees upon receipt of such notice forthwith to cease making offers and sales of Shares pursuant to such registration statement or
deliveries of the prospectus contained therein for any purpose until the Company has prepared and furnished such amendment or supplement to the prospectus as may be necessary so that, as thereafter delivered to a purchaser of Shares, such prospectus
shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company shall
prepare and furnish such amendment or supplement to the prospectus to the Purchaser within 10 days after it has given notice to the Purchaser. The Purchaser further agrees that, upon receipt of any notice from the Company of the happening of any
event of the kind described in this Section 8.2(b), the Purchaser will, if requested by the Company, deliver to the Company (at the Company’s expense) all copies, other than permanent file copies, then in the Purchaser’s possession of the
prospectus current at the time of receipt of such notice from the Company. 
  
 Section 8.3 Expenses of Registration. All costs and expenses incurred in connection with any registration pursuant to this Section 8, including, without limitation, all registration, filing and qualification
fees, printing expenses, fees and disbursements of counsel for the Company, and expenses of any special audits of the Company’s financial statements incidental to or required by such registration shall be paid by the Company; provided, however,
that the Company shall have no obligation to pay any stock transfer taxes, underwriters’ fees, discounts or commissions with respect to the sale of the Shares, or the fees and expenses of any counsel or advisor to the Purchaser. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 36 

 Section 8.4 Registration Procedures. Whenever the Purchaser has requested that any Shares be
included in a Company registration statement pursuant to this Section 8, the Company will use commercially reasonable efforts to effect the registration and sale of such Shares upon the terms and conditions hereof, and in connection with any such
request, the Company will: 
  
 (a) promptly
prepare and file with the SEC and furnish to the Purchaser copies of such registration statement as filed and each amendment and supplement thereto, as many copies of the prospectus included in such registration statement and any amendments or
supplements thereto as the Purchaser may reasonably request (including any preliminary prospectus contained therein and shall reflect in each such document such comments as the Purchaser may reasonably propose) and use its commercially reasonable
efforts to cause such registration statement to become effective and to keep the Purchaser advised in writing of the initiation and progress of proceedings regarding such registration; 
  
 (b) use its best efforts to ensure that (i) such registration statement and any amendment thereto and such
prospectus forming part thereof and any amendment or supplement thereto complies as to form in all material respects with the Securities Act, (ii) such registration statement and any amendment thereto does not, when it becomes effective, contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements contained therein not misleading and (iii) any prospectus forming part of such registration statement, and any
amendment or supplement to such prospectus, does not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements contained therein not misleading in light
of the circumstances in which they were made; provided, however, that the Company shall have no liability under clauses (ii) or (iii) of this paragraph (b) with respect to any such untrue statement or omission made therein in reliance upon and
conformity with information furnished to the Company by or on behalf of the Purchaser or any underwriter for inclusion therein; 
  
 (c) use its best efforts to register or qualify such Shares under the securities or blue sky laws of such jurisdictions as the managing
underwriter of such offering, if any, or the selling shareholders under such registration statement if there is no underwriter, may reasonably 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 37 

 
request and do any and all other acts and things which may be reasonably necessary or advisable to enable the Purchaser to consummate the disposition in such
jurisdictions of the Shares; provided, that the Company will not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this paragraph (c), or (ii) take any action that
would subject it to the service of process in suits other than relating to the sale of the Shares or any violation of state securities laws in any jurisdiction where it is not now so subject; 
  
 (d) use its best efforts to cause the Shares covered by such
registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the Purchaser or the underwriter or underwriters, if any, to consummate the disposition of such Shares subject
to the proviso contained in paragraph (c) above; 
  
 (e) promptly advise the Purchaser and, if requested by the Purchaser, promptly confirm such advice in writing: 
  
 (i) when such registration statement or prospectus and any amendment or supplement thereto has been filed with the SEC and when such
registration statement or any post-effective amendment thereto has become effective; 
  
 (ii) of the issuance by the SEC of any stop order suspending the effectiveness of such registration statement or the initiation or threat
of any actions or proceeding for that purpose; 
  
 (iii) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of the Shares included in such registration statement for sale in any jurisdiction or the initiation
or threatened initiation of any action nor proceeding for such purpose; and 
  
 (iv) of the happening of any event that requires the amendment or supplementation of such registration statement or prospectus (or documents incorporated or deemed to be incorporated therein) so as to ensure that such
registration statement or prospectus is not misleading and does not contain any untrue statement of material fact or omit to state a 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 38 

 
material fact required to be stated therein or necessary to make the statements contained therein (in the case of the prospectus, in light of the
circumstances under which they were made) not misleading; 
  
 (f) deliver to the Purchaser, without charge, as many copies of the prospectus included in such registration statement, and any amendment or supplement thereto, as the Purchaser shall reasonably request; and subject
to Sections 8.1(d) and 8.2(b) hereof, the Company consents to the use of the prospectus or any amendment or supplement thereto by the Purchaser in connection with the offering and sale of the Shares covered by the prospectus or any amendment or
supplement thereto; 
  
 (g) otherwise comply with
all applicable rules and regulations of the SEC, and make generally available to its security holders, as soon as reasonably practicable but no later than 90 days after the end of each 12-month period, an earnings statement covering a period of 12
months after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder; 
  
 (h) cause all such Shares to be listed on each securities exchange or quotation system on which similar
securities issued by the Company are then listed; and 
  
 (i) take such other reasonable steps that are necessary or advisable to permit the sale of such Shares. 
  
 The Company may require the Purchaser to furnish to the Company such “blood letter” information regarding the distribution of the Shares as the
Company may from time to time reasonably request in writing which is customarily provided by selling stockholders in a public offering of securities. 
  
 Section 8.5 Indemnification. 
  
 (a) Indemnification by the Company. In connection with any registration statement in which the Purchaser includes Shares pursuant
to this Section 8, the Company will indemnify and hold harmless the Purchaser, together with each of the Purchaser’s officers, 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 39 

 
directors, shareholders, employees, agents and affiliates, each person who controls the Purchaser, each underwriter of the Shares, if any, each person who
controls such underwriter and each other person who participates in the offering of such Shares against all claims, losses, expenses, damages, reasonable attorneys’ fees, costs, expenses, liabilities (or actions in respect thereof), joint or
several (the “Damages”), insofar as such Damages arise out of or are based on any untrue statement or alleged untrue statement of a material fact contained in any such registration statement or prospectus, or in any amendment or supplement
thereof, or arise out of or are based on any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each such person for any
reasonable legal and any other expenses incurred in connection with investigating, defending or settling any such claim, loss, damage, liability or action; provided that the Company will not be liable in any such case to the extent that any such
claim, loss, damage or liability (or actions in respect thereof) arise out of or is based on any untrue statement or alleged untrue statement or omission or alleged omission made therein based upon written information furnished to the Company by the
Purchaser or underwriter, specifically for use therein which is not corrected in the final registration statement or prospectus or in an amendment or supplement thereto. 
  
 (b) Indemnification by the Purchaser. The Purchaser will, if any of the Purchaser’s Shares are
included in a registration pursuant hereto, indemnify the Company, each of its directors and officers, each underwriter, if any, of the Shares covered by such registration statement, and each person who controls the Company and any underwriter
within the meaning of the Securities Act, and each other holder of securities registered under the registration statement, each of its officers, directors and partners and each person controlling such holder, against all Damages insofar as such
Damages arise out of or are based on any untrue statement or alleged untrue statement of a material fact contained in any such registration statement or prospectus, or based on any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each such person for any reasonable legal and any other expenses incurred in connection with investigating, defending or settling any such
claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement or omission or alleged untrue statement or omission is made in such registration statement or prospectus in 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 40 

 
reliance upon and in conformity with written information furnished to the Company by the Purchaser specifically for use therein which is not corrected in the
final registration statement or prospectus or in an amendment or supplement thereto. 
  
 (c) Contribution. In order to provide for just and equitable contribution in any case in which any person exercising rights under
this Section 8.5 makes a claim for indemnification, but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that
such indemnification may not be enforced in such case notwithstanding the fact that this Section 8.5 provides for indemnification in such case, then, the Company and the Purchaser will contribute to the aggregate Damages to which they may be subject
(after contribution from others) in such proportion as is appropriate to reflect the relative fault of the Company on the one hand and of the Purchaser on the other in connection with the statements or omissions which resulted in such Damages, as
well as any other relevant equitable considerations. The relative fault of the Company on the one hand and of the Purchaser on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or by the Purchaser on the other, and each party’s relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (i) the Purchaser will not be required to contribute for all Damages an aggregate of any amount in excess of the proceeds received from the
public offering of all Shares offered by it pursuant to such registration statement; and (ii) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution
from any person or entity who was not guilty of such fraudulent misrepresentation. 
  
 (d) Indemnification Procedures. Each party entitled to indemnification under this Section 8.5 (the “Indemnified Party”)
shall give written notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the
Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party who shall conduct the defense of such claim or 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 41 

 
litigation shall be approved by the Indemnified Party (which approval shall not be unreasonably withheld), and the Indemnified Party may participate in such
defense at such party’s expense; provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations hereunder, except to the extent such failure resulted in
actual detriment to the Indemnifying Party. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not
include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or litigation; provided, however, that the Indemnifying Party will not consent to the
entry of any judgment or enter into any settlement (other than for the payment of money only) without the consent of the Indemnified Party (which consent shall not be unreasonably withheld). An Indemnifying Party who is not entitled to, or elects
not to, assume the defense of the claim, will not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such Indemnifying Party with respect to such claim, unless in the reasonable judgment of any
Indemnified Party a conflict of interest may exist between such Indemnified Party and any other such Indemnified Parties with respect to such claim, in which event the Indemnifying Party shall be obligated to pay the fees and expenses of such
additional counsel or counsels. 
  
 Section 8.6 Conditions to
Registration Obligations. The Company shall not be obligated to effect the registration of the Purchaser’s Shares pursuant to this Section 8 unless the Purchaser consents to such reasonable conditions imposed by the Company as the Company
shall determine with the advice of counsel to be required by law, including, without limitation: 
  
 (a) conditions requiring the Purchaser to comply with all prospectus delivery requirements of the Securities Act and with all
anti-stabilization, anti-manipulation and similar provisions of Section 10 of the Exchange Act, and any rules issued thereunder by the SEC, and to furnish to the Company information about sales made in such public offering; 
  
 (b) conditions prohibiting the Purchaser upon receipt of
telegraphic or written notice required by law from the Company from effecting sales of Shares until further notice; and 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 42 

 (c) conditions requiring that at the end of the period during which the Company is
obligated to keep the registration statement effective under this Section 8, the Purchaser shall discontinue sales of Shares pursuant to such registration statement upon receipt of notice from the Company of its intention to remove from registration
the securities covered by such registration statement that remain unsold, and requiring the Purchaser to notify the Company of the number of Shares registered that remain unsold promptly upon receipt of notice from the Company. 
  
 In addition, the Company shall not be obligated to effect a registration of
the Purchaser’s Shares pursuant to this Section 8 unless the Purchaser consents to reasonable conditions requested by the Company requiring the Purchaser to enter into an underwriting agreement with customary terms and conditions and in form
and substance consistent with such agreement as entered into by all other applicable selling shareholders. 
  
 ARTICLE IX 
  
 Rule 144 Reporting 
  
 Section 9.1 Rule 144 Reporting. 
  
 With a
view to making available the benefits of certain rules and regulations of the SEC, which may at any time permit the sale of the Shares to the public without registration, the Company agrees to: 
  
 (a) make and keep public information available, as those
terms are understood and defined in Rule 144 under the Securities Act; 
  
 (b) use its best efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 
  
 (c) furnish to any holder of Shares forthwith upon request a
written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act, a copy of the most recent annual or quarterly report of the Company, and such other reports and
documents so filed by the Company as such holder may reasonably request in availing itself of any rule or regulation of the SEC allowing such holder to sell any Shares without registration. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 43 

  
 ARTICLE X

  
 Miscellaneous 
  
 Section 10.1 [Intentionally left blank.] 
  
 Section 10.2 Enforcement. (a) The Purchaser and the Company
acknowledge and agree that irreparable damage would occur if any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that monetary damages would be an inadequate remedy
therefor. Accordingly, either party will be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically its provisions in any court of the United States or any state having jurisdiction, this being
in addition to any other remedy to which the Company may be entitled at law or in equity. 
  
 (b) No failure or delay on the part of the Purchaser or the Company in the exercise of any power, right or privilege hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege. 
  
 Section 10.3 Entire Agreement. This Agreement, together with the
applicable provisions of the License Agreement and the S&E Agreement, constitute the entire understanding of the parties with respect to the transactions contemplated hereby. This Agreement may be amended only by an agreement in writing executed
by all the parties hereto and their respective successors. 
  
 Section 10.4 Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, the remaining provisions shall remain in full force and effect. It is
declared to be the intention of the parties that they would have executed the remaining provisions without including any that may be declared unenforceable. 
  
 Section 10.5 Headings. Descriptive headings are for convenience only and will not control or affect the meaning or construction of any provision of
this Agreement. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 44 

 Section 10.6 Counterparts. This Agreement may be executed in one or more counterparts, and each of
which shall constitute an original instrument, but all of which, when taken together, shall constitute one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties.

  
 Section 10.7 Notices. All notices, consents, requests,
instructions, approvals and other communications provided for in this Agreement will be validly given or made, if in writing and delivered personally, by telecopy or sent by registered mail postage paid: 
  

			
	if to the Company:	  	Coley Pharmaceutical Group, Inc.
	 	  	93 Worcester Road, Suite 101
	 	  	Wellesley, MA 02481
	 	  	Attention: President
		
	with copies to:	  	Coley Pharmaceutical Group, Inc.
	 	  	93 Worcester Road, Suite 101
	 	  	Wellesley, MA 02481
	 	  	Attention: Charles E. Yon
	 	  	Vice President and General Counsel
	 	  	Fax: (781) 431-6403
		
	 	  	William T. Whelan, Esq.
	 	  	Mintz, Levin, Cohn, Ferris,
	 	  	Glovsky and Popeo, PC.
	 	  	One Financial Center
	 	  	Boston, MA 02111
	 	  	Tel: (617) 542-6000
	 	  	Fax: (617) 542-2241
		
	if to the Purchaser:	  	Pfizer Inc.
	 	  	235 East 42nd Street
	 	  	New York, New York 10017-5755
	 	  	Attention: President, Pfizer Human Health
	 	  	Fax: (212) 808-8652
		
	with copies to:	  	Pfizer Inc.
	 	  	235 East 42nd Street
	 	  	New York, New York 10017-5755
	 	  	Attention: Executive Vice President and General Counsel
	 	  	Fax: (212) 808-8924

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 45 

 or to such other address or telecopy number as any party may, from time to time, designate in a written notice given in a
like manner. Notice by telecopy shall be deemed delivered on the day telephone confirmation of receipt is given. 
  
 Section 10.8 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the parties,
including affiliates of the Purchaser; provided, however that this Agreement shall not be binding upon any purchaser of the Shares from the Purchaser or an Affiliate of the Purchaser in a transaction effected on a public trading market or pursuant
to a public offering. The rights granted to the Purchaser or any Affiliate hereunder may be transferred by the Purchaser or any Affiliate (i) with the prior written consent of the Company, or (ii) without the prior written consent of the Company in
connection with the transfer of all or a portion of the Shares to Affiliates of the Purchaser; provided, however, that each transferee of rights shall be subject to the same obligations as the Purchaser, and provided, further, that if any such
transferees are Affiliates of the Purchaser, one entity (which may be the Purchaser) shall be designated by the Purchaser to act on behalf of the Purchaser and such Affiliates to give and receive all notices and other communications pursuant to this
Agreement. 
  
 Section 10.9 Term. The term of this
Agreement shall commence on the date first referred to above and shall terminate upon the earliest to occur of the following: (i) a Change of Control, or (ii) the termination of the License Agreement, in accordance with the provisions thereof, or
(iii) the occurrence of a Material Default (as defined in the License Agreement) as a result of any breach of Section 10 of the License Agreement by the Company or any of its Affiliates. 
  
 Section 10.10 Governing Law. This Agreement will be governed by and construed and enforced in accordance with the
laws of the State of Delaware, without giving effect to the conflict of laws principles thereof. 
  
 [Remainder of page intentionally blank] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 46 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first referred to
above. 
  

					
	PFIZER INC.
		
	By:	 	 /s/ Lisa Ricciardi

	 	 	 Name:
	 	 Lisa Ricciardi

	 	 	 Title:
	 	 Sr. Vice President

	
	COLEY PHARMACEUTICAL GROUP, INC
		
	By:	 	 /s/ Robert L. Bratzler

	 	 	 Name:
	 	 Robert L. Bratzler

	 	 	 Title:
	 	 President and CEO

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 47LICENSE AGREEMENT AMONG THE REGISTRANT AND PFIZER INC

 EXHIBIT 10.30 
  
 CONFIDENTIAL 
  
 LICENSE AGREEMENT 
  
 Among 
  
 COLEY PHARMACEUTICAL GROUP, INC. 
  
 COLEY PHARMACEUTICAL GROUP, LTD. 
  
 COLEY PHARMACEUTICAL GmbH 
  
 and

  
 PFIZER INC. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 TABLE OF CONTENTS 
  

					
	 SECTION 1.
	  	 DEFINITIONS.
	  	1
			
	 SECTION 2.
	  	 LICENSE GRANT.
	  	15
	 2.1
	  	 EXCLUSIVE LICENSES.
	  	15
	 2.2
	  	 NON-EXCLUSIVE LICENSE.
	  	16
	 2.3
	  	 CLINICAL DEVELOPMENT LICENSE
	  	16
	 2.4
	  	 RESEARCH LICENSE.
	  	16
	 2.5
	  	 LICENSE GRANT TO COLEY.
	  	16
			
	 SECTION 3.
	  	 HSR.
	  	18
	 3.1
	  	 HSR.
	  	18
			
	 SECTION 4.
	  	 DEVELOPMENT; MANUFACTURING; COMMERCIALIZATION.
	  	19
	 4.1
	  	 TRANSITION PLAN.
	  	19
	 4.2
	  	 PFIZER DEVELOPMENT ACTIVITIES.
	  	19
	 4.3
	  	 COLEY DEVELOPMENT ACTIVITIES.
	  	19
	 4.4
	  	 DILIGENCE.
	  	22
	 4.5
	  	 DEVELOPMENT COMMITTEE.
	  	22
	 4.6
	  	 DEVELOPMENT REPORTS
	  	23
	 4.7
	  	 MANUFACTURING.
	  	23
	 4.8
	  	 REGULATORY RESPONSIBILITIES.
	  	24
	 4.9
	  	 4.9 POST-DEVELOPMENT COMMITTEE
	  	25
	   4.10
	  	 COLEY COMMERCIALIZATION RIGHTS.
	  	26
			
	 SECTION 5.
	  	 MILESTONE PAYMENTS AND ROYALTIES.
	  	31
	 5.1
	  	 EVENT MILESTONE PAYMENTS
	  	31
	 5.2
	  	 COMMERCIAL MILESTONE PAYMENT
	  	36
	 5.3
	  	 ROYALTY PAYMENTS.
	  	36
	 5.4
	  	 DURATION OF ROYALTY PAYMENTS
	  	43
	 5.5
	  	 LIMITS ON ROYALTY PAYMENT REDUCTIONS
	  	43
			
	 SECTION 6.
	  	 ACCOUNTING AND PROCEDURES FOR PAYMENT.
	  	44
	 6.1
	  	 INTER-COMPANY SALES.
	  	44
	 6.2
	  	 CALCULATION OF NET SALES.
	  	44
	 6.3
	  	 ROYALTY PAYMENTS.
	  	44
	 6.4
	  	 METHOD OF PAYMENTS
	  	44
	 6.5
	  	 INSPECTION OF RECORDS.
	  	44
	 6.6
	  	 TAX MATTERS
	  	45
			
	 SECTION 7.
	  	 PATENTS AND INFRINGEMENT.
	  	46
	 7.1
	  	 FILING AND PROSECUTION OF PATENTS
	  	46
	 7.2
	  	 MAINTENANCE OF PATENTS
	  	46
	 7.3
	  	 PATENT TERM EXTENSIONS
	  	47
	 7.4
	  	 INTERPRETATION OF PATENT JUDGMENTS
	  	47
	 7.5
	  	 INFRINGEMENT ACTIONS.
	  	47
	 7.6
	  	 ASSIGNMENT OF [**** ****** ******]
	  	48
			
	 SECTION 8.
	  	 COVENANTS.
	  	48
	 8.1
	  	 TECHNICAL ASSISTANCE.
	  	48
	 8.2
	  	 NON-COMPETITION.
	  	48
	 8.3
	  	 TRADEMARK
	  	50
			
	 SECTION 9.
	  	 CONFIDENTIALITY; PUBLICATION.
	  	50
	 9.1
	  	 CONFIDENTIALITY.
	  	50
	 9.2
	  	 PUBLICATION.
	  	51
	 9.3
	  	 PUBLICITY.
	  	52
	 9.4
	  	 REGISTRATION AND FILING OF THIS
AGREEMENT.
	  	52

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

					
	SECTION 10.	  	REPRESENTATIONS.	  	53
	 10.1
	  	COLEY WARRANTIES	  	53
	 10.2
	  	PFIZER WARRANTIES.	  	56
	 10.3
	  	COVENANTS OF COLEY	  	57
			
	SECTION 11.	  	TERM	  	58
			
	SECTION 12.	  	TERMINATION.	  	58
	 12.1
	  	TERMINATION	  	58
	 12.2
	  	RIGHTS UPON TERMINATION.	  	60
	 12.3
	  	BANKRUPTCY.	  	62
	 12.4
	  	CHANGE OF CONTROL	  	63
			
	 SECTION 13.
	  	INDEMNIFICATION.	  	63
	 13.1
	  	INDEMNIFICATION.	  	63
	 13.2
	  	CO-INDEMNIFICATION	  	64
	 13.3
	  	LOSSES.	  	65
	 13.4
	  	DEFENSE PROCEDURES; PROCEDURES FOR THIRD PARTY CLAIMS	  	65
	 13.5
	  	EXCLUSIVE REMEDY.	  	67
	 13.6
	  	LIMITATION OF LIABILITY	  	67
			
	 SECTION 14
	  	GOVERNING LAW; ARBITRATION AND JURISDICTION	  	67
	 14.1
	  	GOVERNING LAW	  	67
	 14.2
	  	ARBITRATION.	  	67
	 14.3
	  	JURISDICTION.	  	70
			
	 SECTION 15.
	  	MISCELLANEOUS.	  	71
	 15.1
	  	FORCE MAJEURE	  	71
	 15.2
	  	SEVERABILITY	  	71
	 15.3
	  	ACCRUED OBLIGATION	  	71
	 15.4
	  	WAIVERS	  	71
	 15.5
	  	ENTIRE AGREEMENTS; AMENDMENTS	  	71
	 15.6
	  	SURVIVAL.	  	71
	 15.7
	  	ASSIGNMENT.	  	71
	 15.8
	  	INDEPENDENT CONTRACTOR	  	72
	 15.9
	  	NON-SOLICITATION OF EMPLOYEES	  	72
	   15.10
	  	JOINT AND SEVERAL LIABILITY	  	72
	   15.11
	  	DESIGNATION OF COLEY INC AS AGENT	  	72
	   15.12
	  	NOTICES	  	72
	   15.13
	  	THIRD PARTY BENEFICIARIES.	  	73
	   15.14
	  	BINDING EFFECT.	  	73
	   15.15
	  	COUNTERPARTS.	  	73
	   15.16
	  	HEADINGS.	  	73

  
 EXHIBIT A – COLEY PATENT
RIGHTS 
 EXHIBIT B – TRANSITION PLAN 
 EXHIBIT
C – COLEY INDICATION PLAN 
 EXHIBIT D – PRESS RELEASE 
  
 SCHEDULE 1.28 – THIRD PARTY LICENSEE AGREEMENT IN THE FIELD 
  
 SCHEDULE 4.7(c) – [******************] MANUFACTURING COSTS 
  
 SCHEDULE 4.10(e) – TRAINING PROGRAM DESCRIPTION 
  
 SCHEDULE 8.2(a) – THIRD PARTY LICENSEE OUTSIDE THE FIELD 
  
 SCHEDULE 8.2(a)-1 – MATERIAL TRANSFER AGREEMENTS 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 SCHEDULE 8.3 – TRADEMARKS 
  
 SCHEDULE 9.3 – PERMITTED DISCLOSURES 
  

SCHEDULE 10.1(a)(ii) – CHALLENGE TO COLEY PATENT 
  
 SCHEDULE 10.1(g)(i) – THIRD PARTY PATENT RIGHTS 
  
 SCHEDULE 10.1(j) – SUBSIDIARIES 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 406 of the Securities Act. 

 LICENSE AGREEMENT 
  
 License Agreement, dated as of March 16, 2005 (this “Agreement”), among COLEY PHARMACEUTICAL GROUP, INC., a
Delaware corporation, with offices located at 93 Worcester Street, Suite 101, Wellesley, Massachusetts 02481, USA (“Coley Inc.”); COLEY PHARMACEUTICAL GROUP, LTD, a Canadian corporation and wholly owned subsidiary of Coley Inc.,
with offices at 340 Terry Fox Drive, Kanata (Ottawa), Canada (“Coley Canada”), COLEY PHARMACEUTICAL, GmbH., a German corporation and wholly-owned subsidiary of Coley Inc., with offices located at Elisabeth-Selbert-Strasse 9,
Langenfeld, Germany (“Coley Germany”), and, together with Coley Inc. and Coley Canada, hereinafter collectively referred to as “COLEY” and hereinafter separately referred to as a “Coley Entity,” and
PFIZER INC., a Delaware corporation, with offices located at 235 East 42nd Street, New York, New York, 10017
(“PFIZER”). 
  
 WHEREAS, COLEY owns or controls
certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides; and 
  
 WHEREAS, PFIZER has extensive experience and expertise in the development and commercialization of pharmaceutical products, and desires to acquire an
exclusive license in the Territory (as defined below) and in the Field (as defined below) to such patents, patent applications, technology, know-how and technical information. 
  
 NOW, THEREFORE, in consideration of the covenants and agreements provided herein, COLEY and PFIZER hereby agree as follows:

  
 Section 1. DEFINITIONS. 
  
 For purposes of this Agreement, the following definitions shall be
applicable: 
  
 1.1 “Affiliate” means any entity
directly or indirectly controlled by, controlling, or under common control with, a party to this Agreement, but only for so long as such control shall continue. For purposes of this definition, “control” (including, with correlative
meanings, “controlled by”, “controlling” and “under common control with”) of an entity means possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of such entity
(whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other
comparable equity interests of such entity. 
  
 1.2
“Ancillary Agreements” means the Screening and Evaluation Agreement, the Stock Purchase Agreement, and the Pharmacovigilance Agreement. 
  
 1.3 “Antigen” means any ingredient that, either alone or as part of a vaccine, elicits an antigen-specific immune response to itself
and/or to a pathogenic micro-organism that expresses or contains the antigen such as, but not limited to, live attenuated micro-organisms, whole killed micro-organisms or subunit vaccine (including but not limited to, polysaccharides, polysaccharide
conjugates, peptides, recombinant proteins, glycolipids and fragments thereof). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 1 

 1.4 “Business Day” means any day, other than a Saturday, Sunday, bank or other public
holiday in New York, New York. 
  
 1.5 “Change of
Control” means an event where: 
  
 (a) any person or
group (other than a Biotech Company (as defined below)) becomes the beneficial owner, directly or indirectly, of at least fifty percent (50%) or more of the outstanding Voting Stock or voting power over Voting Stock of (i) Coley Inc. or (ii) any one
or more persons or entities which are direct or indirect parent holding companies of Coley Inc. or Affiliates controlling Coley Inc. (Coley Inc., together with the persons and entities described in this clause (ii), each, individually, a “Coley
Group Company” and, collectively, the “Coley Group Companies”); or 
  
 (b) a majority of the seats (other than vacant seats) on the board of directors or other governing body of any Coley Group Company (the “Board”) is occupied by any person or group (other than a
Biotech Company) who were neither (i) members of the Board on the date hereof or members nominated by the Board or (ii) appointed by members of the Board on the date hereof or members so nominated; or 
  
 (c) any Coley Group Company enters into an agreement with any person or
entity (other than a Biotech Company) providing for a merger, consolidation, reorganization or other similar transaction (or series of related transactions) of any Coley Group Company with another person or other entity (other than with any of the
Coley Group Company’s wholly-owned subsidiaries (or any Biotech Company) as a result of which, immediately following such transaction (or series of related transactions) less than a majority of the outstanding Voting Stock or voting power over
Voting Stock of the surviving or newly-created entity in such transaction (or series of related transactions) is beneficially owned by the shareholders of the applicable Coley Group Company immediately prior to such transaction (or series of related
transactions); or 
  
 (d) any Coley Group Company sells or
otherwise transfers to any person(s) or entity that is not a wholly-owned subsidiary of a Coley Group Company, in one or more related transactions not involving a merger, consolidation, reorganization or similar transaction (or series of related
transactions) included in clause (c) above, properties or assets representing more than fifty percent (50%) of (i) all Coley Group Companies’ consolidated total assets (exclusive of goodwill) as reflected on the consolidated balance sheet for
the most recently-completed fiscal year (or, if applicable, the most recent Annual Report on Form 10-K), or (ii) all Coley Group Companies’ consolidated operating income for the most recent fiscal year as reflected on the consolidated income
statement for the most recently-completed fiscal year (or, if applicable, the most recent Annual Report on Form 10-K), or (iii) all Coley Group Companies’ consolidated revenue for the most recent fiscal year as reflected on the consolidated
income statement for the most recently-completed fiscal year (or, if applicable, the most recent Annual Report on Form 10-K) it being understood and agreed that the licensing of intellectual property by any Coley Group Company solely for use in
making, having made, using, selling, offering for sale or importing 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 2 

 pharmaceutical products, other than in the field of oncology, shall not be deemed to be an event covered by this Section
1.5(d); or 
  
 (e) (x) any
[**************************************************] company that [*************] (i) [************* ***********************************************************************************************] (ii)
[************************************************************************] (based on data provided by IMS International, or, if such data is not available, such other reliable data source as reasonably determined by PFIZER and agreed to by COLEY,
with such agreement not to be unreasonably withheld, conditioned or delayed), [*******************************], for its most recently-completed fiscal year (of at least 12 months or more), or (y) any one or more persons or entities that are direct
or indirect parent holding companies or subsidiaries of the [**************************************************] company described in clause (x) above, or (z) any Affiliate of [******************************************************] company
described in clause (x) above (collectively, any of the persons or entities described in clauses (x), (y) or (z), a “Large Pharmaceutical Company”) acquires beneficial ownership of [**************************] or more of the
outstanding Voting Stock or voting power over Voting Stock of any Coley Group Company. 
  
 For purposes of this definition of “Change of Control”: (a) references to any Coley Group Company shall be deemed to include all successors in any merger, consolidation, reorganization or similar transaction (or series of related
transactions) preceding any transaction (or series of related transactions) described above; (b) “beneficial ownership” (and other correlative terms) shall mean beneficial ownership as defined in Rule 13d-3 under the United States
Securities and Exchange Act of 1934, as amended; it being understood and agreed that “beneficial ownership” shall also include any securities which any person or any of such person’s Affiliates has the right to acquire (whether such
right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, rights, warrants or options, or otherwise; (c)
[**********************] means [*******************************************] or [****************** ********************************************************************************************************] or
[******************************************************************************************************] and [****************************************************************] or [************************************** **********] (d)
“Voting Stock” means securities of any class or series of a corporation or other person, the holders of which are ordinarily, in the absence of contingencies, entitled to vote generally in matters put before the
shareholders or members of such corporation or person; (e) “control” (including, with correlative meanings, “controlled by”, “controlling” and “under common control with”) of an entity means possession, direct
or indirect, of (I) the power to direct or cause direction of the management and policies of such entity (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (II) at least 50% of the
voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of such entity. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 3 

 1.6 “Coley Confidential Information” means all information about any element of Coley
Technology or any other information that is disclosed (whether orally or in writing) by COLEY to PFIZER in connection with this Agreement, including but not limited to all information disclosed by COLEY to PFIZER in the course of COLEY’s
performance of this Agreement and (x) in the case of oral information, is outlined in a summary prepared by COLEY and delivered to PFIZER promptly after such disclosure and (y) in the case of written information, is designated
“Confidential” in writing by COLEY at the time of disclosure to PFIZER, in each case, only to the extent that such information is not (i) as of the date of disclosure to PFIZER, known to PFIZER other than by virtue of a prior confidential
disclosure to PFIZER by COLEY, as demonstrated by PFIZER’s written records, or (ii) disclosed in published literature, or otherwise generally known to the public through no fault or omission of PFIZER; or (iii) obtained from a third party free
from any obligation of confidentiality to COLEY; or (iv) independently developed by PFIZER without access to the Coley Confidential Information, as demonstrated by PFIZER’s written records. All information about the existence and terms of this
Agreement shall be considered Coley Confidential Information and Pfizer Confidential Information. 
  
 1.7 “Coley Indication” means the treatment, Control (as defined in Section 1.25) or prevention of cutaneous T cell lymphoma, including,
without limitation, [*****************]. 
  
 1.8 “Coley
Patent Rights” means: (i) all patents and patent applications listed on Exhibit A attached hereto and any patents which may issue from the applications listed on Exhibit A; (ii) all other patents and patent applications in the
Territory, now or hereafter during the term of this Agreement owned or controlled by COLEY or any of its Affiliates and which COLEY or any of its Affiliates has the right to license to PFIZER, which relate to the Compound, any Research Compound or
any Licensed Product or methods of use or manufacturing processes for the Compound, any Research Compound or any Licensed Product or pharmaceutical compositions or dosage forms thereof; (iii) any [*******************************************]; and
(iv) all provisionals, divisionals, continuations, renewals, continuations-in-part, re-examinations, patents of addition, supplementary protection certificates (“SPC”), extensions, letters of patent, registration or confirmation
patents and reissues with respect to any patents described in the foregoing clauses (i), (ii) or (iii) hereof. 
  
 1.9 “Coley Substance” means (i) any independently therapeutically active substance or other substance that enhances the therapeutic
effect of the Compound or any Research Compound, as applicable, or (ii) any Tumor Antigen, that, in the case of each clauses (i) and (ii), is owned or controlled by COLEY or any of its Affiliates. 
  
 1.10 “Coley Technology” means all scientific and technical
information and data, including, without limitation, know-how, trade secrets and technology related thereto, now or hereafter during the term of this Agreement owned or controlled by COLEY or any of its Affiliates that relate to the Compound, any
Research Compound or any Licensed Product, including but not limited to: (a) medical, clinical, toxicological or other scientific data, and (b) processes and analytical methodology useful in the development, formulation, testing, analysis,
manufacture or packaging of the Compound, any Research Compound or any Licensed Product. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 4 

 1.11 “Coley Work Plan” means the Coley Work Plan to be discussed and approved by the
Development Committee, as the same may be amended from time to time. 
  
 1.12 “Combination Ingredient” means a substance (other than the Compound, a Research Compound or a Coley Substance) that either (i) is independently therapeutically active or (ii) enhances the therapeutic effect of the
Compound or a Research Compound, as applicable. 
  
 1.13
“Combination Product” means any Covered Product in all dosage strengths and formulations (other than a Vaccine Product) in which a Combination Ingredient is either (a) physically, chemically, or otherwise combined or mixed with the
Compound (including without limitation any Combination Ingredient that is covalently linked to the Compound) to produce a single entity for commercial distribution; or (b) packaged together with the Compound or any Licensed Product that contains the
Compound (other than a Vaccine Product) in a single package or unit for commercial distribution. 
  
 1.14 “Commercially Reasonable Efforts” means those efforts and resources that PFIZER would use were it developing or commercializing its
own pharmaceutical products that are of similar market potential as the Licensed Products, taking into account product labeling or anticipated labeling, present and future market potential, past performance, financial return, medical and clinical
considerations, present and future regulatory environment and competitive market conditions in the Field, all as measured by the facts and circumstances at the time such efforts are due. 
  
 1.15 “Compound” means (i) a [**************************************************************************
*****], referred to by COLEY as CpG 7909 or ProMuneTM and (ii) any salts of the molecule referred to in clause (i). 
  
 1.16 “Confidential Information” means the Coley Confidential Information and the Pfizer Confidential Information. 
  
 1.17 “Covered Product” means any pharmaceutical product, the manufacture, use, sale, offer for sale or
importation of which (i) in the absence of the licenses granted to PFIZER under this Agreement, would infringe any of the Coley Patent Rights, or (ii) utilizes any Coley Technology. 
  
 1.18 “DARPA” means the Defense Advanced Research Projects Agency of the United States Department of
Defense. 
  
 1.19 “Dermatologic Disease” means
basal cell carcinoma in the skin and squamous cell carcinoma in the skin. 
  
 1.20 “Detail” means a face-to-face contact of a COLEY sales representative with a Specialty Dermatologist in the United States during which scientific and/or medical information about the Product for
the Coley Indication is discussed. Details shall be measured by COLEY’s internal recording of such activity; provided that such measurement shall be on the same basis as COLEY’s measurement for its sales representatives detailing
other COLEY products, consistently applied throughout the term of this Agreement. The parties understand and agree that (i) multiple interactions of any COLEY sales representative during a single day with any 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 5 

 Specialty Dermatologist will be recorded as a single Detail, (ii) any presentation by a COLEY sales representative to a
group of Specialty Dermatologists will be recorded as a single Detail, unless attendance at such presentation is auditable (e.g., by signature sheets signed by all attendees), in which case (x) one Detail will be recorded for each Specialty
Dermatologist who attended such presentation and (y) PFIZER shall have the right to audit such attendance and (iii) a Detail does not include a reminder call. When used as a verb, the term “Detailing” means to engage in the activity of a
Detail. 
  
 1.21 “Effective Date” means the date
upon which the applicable waiting period under the HSR Act shall have expired or been terminated with respect to this Agreement. 
  
 1.22 “EMEA” means the European Agency for the Evaluation of Medicinal Products or any successor entity. 
  
 1.23 “FDA” means the United States Food and Drug
Administration and any successor agency thereto. 
  
 1.24
“FDCA” means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder. 
  
 1.25 “Field” means (A) on a country-by-country basis, [*************************************************
**************************************************************] the treatment, Control or prevention of cancer in humans; or (B) for any country, any and all [******************************************************] or the [*****] for the treatment,
control or prevention of cancer in humans. Notwithstanding the foregoing, (i) the “Field” includes the treatment, Control and prevention of: [**************************************************************************** ***] and (ii) the
“Field” excludes the [************************************************************************** **** ****************************]; and [*********************************************************************
*******************************]. For purposes of this definition of “Field” and Sections 2.3 and 8.2(d) only, “Control” means the prevention of recurrence of a disease or condition in humans who have previously been
diagnosed with such disease or condition. For purposes of this definition of “Field” and Section 8.2(d) only [**********************] means the [**********************] of a [**************] for [**************] that [*****************] or
the [*****] or [***************************************] that [*****************************]. 
  
 1.26 “Generic Competition” means competition that exists during a given calendar quarter with respect to any specific Licensed Product in any country in the Territory if, during such calendar quarter,
one or more Generic Products shall be commercially available in such country and shall have, in the aggregate, [********************] or more share of total sales of the aggregate of such Licensed Product and Generic Products (based on data provided
by IMS International, or if such data is not available, such other reliable data source as reasonably determined by PFIZER and reasonably agreed to by COLEY) as measured by unit sales. In the event IMS International data (or such other agreed data
source) is not sufficient to determine the percentage market share for each country in the European Union (“EU”), the average percent market share of the EU countries for which data is not available will be deemed to be the percent
market share for those countries in which the data is available. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 6 

 1.27 “Generic Market Share” means a fraction (expressed as a percentage), the numerator
of which shall be the total unit sales of a Generic Product in a country in the Territory, and the denominator of which shall be the aggregate total unit sales of such Generic Product and the relevant Licensed Product in that country, based on data
provided by IMS International, or if such data is not available from IMS International, such other reliable data source as reasonably determined by PFIZER and reasonably agreed to by COLEY. 
  
 1.28 “Generic Product” means any pharmaceutical product sold
in a country in the Territory by a Third Party (other than any Licensed Product, a product sold under license of PFIZER, or a product sold by the Third Party Licensee pursuant to the license listed in Schedule 1.28 attached hereto) that (i)
with respect to a Product or a Research Product, contains the same Compound or Research Compound as the sole active ingredient and is administered via the same route of administration as such Product or Research Product; (ii) with respect to a
Combination Product or a Research Combination Product, contains both the same Combination Ingredient(s) and the same Compound or Research Compound and is administered via the same route of administration as such Combination Product or Research
Combination Product; or (iii) with respect to a Vaccine Product or a Research Vaccine Product, contains both the same Tumor Antigen(s) and the same Compound or Research Compound as such Vaccine Product or Research Vaccine Product. For purposes of
this definition of “Generic Product” only, (a) the definitions of “Compound” and “Research Compound” shall each include all esters thereof; and (b) the definitions of “Combination Ingredient” and “Tumor
Antigen” shall each include all salts and esters thereof. 
  
 1.29 “Governmental Authority” means any court, agency, department, authority or other instrumentality of any foreign, federal, state, county, city or other political subdivision. 
  
 1.30 “HSR Act” means the Hart-Scott-Rodino Act, as amended

  
 1.31 “IND” means an Investigational New Drug
Application submitted under the FDCA or any comparable application required by a Regulatory Authority in any other country in the Territory. 
  
 1.32 “Indication” means any Major Indication, Intermediate Indication or Minor Indication. 
  
 1.33 “Intermediate Indication” means (i) except with respect
to [******] all treatment of [******************* *************************] (ii) all treatment of [**************] (iii) [*******] Line Treatment of [*********************] (iv) [*****] Line Treatment of [****] or [****] treatment of [****] and (v)
[********] Line Treatment of [*************] or [*****] Line Treatment of [****************]. For purposes of this definition of “Intermediate Indication” only, the following terms shall have the following meanings: (a) [*******] Line
Treatment of [******************] means the [******] regimen of anti-cancer drug therapy administered for [***************************************************] (b) [*******] Line Treatment of [********] means the [******] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 7 

 regimen of anti-cancer drug therapy administered for [*************************************] (c) [********] Line
Treatment of [***********] means the [******] regimen of anti-cancer drug therapy administered for [******************************** **********] and (d) [*******] Line Treatment of [*****************] means the [******] regimen of anti-cancer drug
therapy administered for [********************* ****************************]. 
  
 1.34 “Launch” means, on a country-by-country and a Licensed Product-by-Licensed Product basis, the first shipment of a Licensed Product in Commercial Quantities (as defined below) for commercial sale
by PFIZER, its Affiliates or its sublicensees to an unaffiliated third party after receipt by PFIZER of the first Regulatory Approval and Price Approval for such Licensed Product in the applicable country in the Territory. For purposes of this
definition of “Launch” only, “Commercial Quantities” means such quantities of a Licensed Product as are normally shipped by PFIZER or its Affiliates in such country at the time of first sale, taking into account similar products,
reasonably necessary to stock normal and customary channels of trade. 
  
 1.35 “Law” or “Laws” means all laws, statutes, rules, regulations, orders, judgments and/or ordinances of any Governmental Authority. 
  
 1.36 “Licensed Product” means any Product, Combination Product, Vaccine Product, Research Product, Research
Combination Product or Research Vaccine Product. 
  
 1.37
“Main EU Countries” means the United Kingdom, Spain, Italy, France and Germany. 
  
 1.38 “Major Indication” means (i) [*****] Line Treatment of [*************], (ii) [******] Line Treatment of [*************] (iii)
[*******] Line Treatment of [******] (iv) [*******] Line Treatment of [********************] and (v) with respect to [**********] all treatment of each of [************************************************************]. For purposes of this
definition of “Major Indication” only, the following terms shall have the following meanings: (a) [********] Line Treatment of [***************************] means the [******] regimen of anti-cancer drug therapy administered for
[*****************************] including adjuvant therapy for [********************] (b) [*****] Line Treatment of [*************************] means the [*****] regimen of anti-cancer drug therapy administered for [******************
**************************************] (c) [*******] Line Treatment of [******] means the [******] regimen of anti-cancer drug therapy administered for [************************************] and (d) [********] Line Treatment of [***************]
means the [******] regimen of anti-cancer drug therapy administered for [************************** ******************]. 
  
 1.39 “Market Price(s)” means, for any pharmaceutical product that contains as its sole active ingredient any of the Compound, a Pfizer
Substance or a Third Party Substance, for all countries in the Territory, the [****************************************] of such pharmaceutical product in the United States reasonably calculable for such pharmaceutical product for the applicable
calendar year. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 8 

 1.40 “Material Default” means: 
  
 (a) any default by any party hereto of its representations,
warranties, covenants, agreements or other performance obligations under this Agreement (other than a payment obligation) that is (a) material to this Agreement, taken as a whole, and (b) shall have continued for ninety (90) days after notice
thereof was provided to the alleged defaulting party by the non-defaulting party (or, if such default cannot be cured within such ninety (90)-day period, if the alleged defaulting party does not promptly commence and diligently continue all
reasonable actions to cure such defaults during such ninety (90)-day period, or does not materially cure such default within one hundred eighty (180) days after notice thereof was provided to the alleged defaulting party); or 
  
 (b) any default by any party hereto of its payment
obligations hereunder that shall have continued for thirty (30) days after notice thereof was provided to the alleged defaulting party by the non-defaulting party; provided that, in the event of a good faith payment dispute, such thirty
(30)-day cure period shall be extended through the thirtieth (30th) day following the date on which such dispute is
resolved if the alleged defaulting party paid all undisputed amounts when due and provided the non-defaulting party with a reasonably detailed written explanation of the alleged defaulting party’s basis for disputing the payment obligation
within the thirty (30)-day period following the notice of the default by the non-defaulting party. 
  
 Notwithstanding anything to the contrary contained herein, for purposes of determining the existence of any “Material Default,” no party shall
be deemed to be in material breach or material default if its actions or omissions resulted from (x) compliance with any decision of a committee or subcommittee under this Agreement that is mutually agreed to in writing by the parties, or (y)
compliance with any Law or the express terms of this Agreement. 
  
 1.41 “Minor Indication” means all treatment of [*********************************************************** ****************************************************************************************************
******************************] and any other cancers within the Field, other than any Major Indications or Intermediate Indications. 
  
 1.42 “NDA” means a new drug application or a supplemental new drug application filed under the FDCA filed with the FDA with respect to a
pharmaceutical product. 
  
 1.43 “Net Sales”
means with respect to a Licensed Product, the amount invoiced by PFIZER or its Affiliate or a Third Party sublicensee for sales of such Licensed Product, to Third Parties, less (i) actual bad debts related to such Licensed Product and (ii) sales
returns and allowances actually paid, granted or accrued, including, without limitation, trade, quantity and cash discounts and any other adjustments, including, but not limited to, granted on account of price adjustments, billing errors, rejected
goods, damaged or defective goods, recalls, rebates, chargeback rebates, reimbursements or similar payments granted or given to wholesalers or other distributors, buying groups, health care insurance carriers or other institutions or arising in
connection with any Pfizer Discount or Savings Program (as defined below), customs or excise 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 9 

 duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes) or duties relating to sales
and any payment in respect of sales to the United States government, any State government or any foreign government, or to any Governmental Authority or Regulatory Authority, or with respect to any government-subsidized program or managed care
organization, and freight and insurance (to the extent that PFIZER bears the cost of freight and insurance for a Licensed Product). Net Sales shall be determined from books and records maintained in accordance with generally acceptable accounting
principles in the United States, consistently applied. For purposes of this definition of “Net Sales” only, “Pfizer Discount or Savings Program” means any discount, rebate or reimbursement program applicable to a Licensed Product
under which PFIZER or its Affiliates provides to low income, uninsured or other patients the opportunity to purchase PFIZER pharmaceutical products at discounted prices. 
  
 1.44 “NIAID” means the National Institute of Allergy and Infectious Diseases, a division of the United
States National Institutes of Health 
  
 1.45
“NSCLC” means non-small cell lung cancer. 
  
 1.46 “OHRI License Agreement” means the License Agreement, effective as of September 1, 1998, between The Ottawa Health Research Institute at the Ottawa Hospital (successor in interest to The Loeb Health Research Institute
at Ottawa Hospital) (“OHRI”) and Coley Inc. (formerly known as CpG ImmunoPharmaceuticals, Inc.), as amended on September 25, 2001. 
  
 1.47 “Oligodeoxynucleotide” means an oligomer or polymer of nucleotides or nucleoside monomers, i.e., molecules comprising a sugar (e.g.
ribose or deoxyribose) and an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)) or a modified base, optionally including a
linker moiety between each monomer, such as but not limited to, one or more phosphodiester bonds, phosphorothioate bonds, or mixed phosphodiester/phosphorothioate bonds, which [**************] to at least [*************************] in the
[********] using the [********] in the [*************************************] to the [********************* **********]. As used 
 herein,
“Oligodeoxynucleotide” may include one or more [************************************************************ 
 *******************************************]. The term “Oligedeoxynucleotide” shall also include [***************] comprising a [*********************************]. For example and without limitation, the definition of
“Oligedeoxynucleotide” includes [*******************************] that [******************************* ***********] other than a [*****************************] and other than a [*********************]. Thus, [**************] may include
[****************************]. In addition, [********************] may include [*******]such as [************] instead of [*********]. Thus the [*******] may be [************************************************]. The [*************] and
[*****************] of the [**********] include [************************] such as [****] as well as 
 [*************************************************]
and [***********] include but are not limited to [*************** 
 **************************************************************************************************] and other [****************************************************************] and [**********************] The term
“Oligodeosynucleotide” shall include [**********] of any of the foregoing. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 10 

 1.48 “Pfizer Confidential Information” means all information about any element of Pfizer
Technology or any other information that is disclosed by PFIZER to COLEY (whether orally or in writing) in connection with this Agreement, including but not limited to all information disclosed by PFIZER to COLEY in the course of PFIZER’s
performance of this Agreement and (x) in the case of oral information, is outlined in a summary prepared by PFIZER and delivered to COLEY promptly after such disclosure and (y) in the case of written information, is designated
“Confidential” in writing by PFIZER at the time of disclosure to COLEY, in each case, only to the extent that such information is not (i) as of the date of disclosure to COLEY, known to COLEY other than by virtue of a prior confidential
disclosure to COLEY by PFIZER, as demonstrated by COLEY’s written records, or (ii) disclosed in published literature, or otherwise generally known to the public through no fault or omission of COLEY; or (iii) obtained from a third party free
from any obligation of confidentiality to PFIZER; or (iv) independently developed by COLEY without access to the Pfizer Confidential Information, as demonstrated by COLEY’s written records. All information about the existence and terms of this
Agreement shall be considered Coley Confidential Information and Pfizer Confidential Information. 
  
 1.49 “Pfizer Quarter” means (i) in the United States, each of the four (4) thirteen (13) week periods as used by PFIZER in its audited
financial reports, the first commencing on January 1 of any year, and (ii) in any country in the Territory other than the United States, each of the four (4) thirteen (13) week periods as used by PFIZER in its audited financial reports, the first
commencing on December 1 of any year. 
  
 1.50 “Pfizer
Substance” means any independently therapeutically active substance that is owned by PFIZER or any of its Affiliates, other than any substance (x) the rights to which were acquired by license by PFIZER or any of its Affiliate from any Third
Party or (y) that involves the payment of a royalty by PFIZER or any of its Affiliates to a Third Party, in each case, primarily for the purpose of developing, making and selling any Licensed Product. 
  
 1.51 “Pfizer Technology” means all scientific and technical
information and data, including, without limitation, know-how, trade secrets and technology related thereto, hereafter during the term of this Agreement owned or controlled by PFIZER or any of its Affiliates that relate to the Compound, any Research
Compound or any Licensed Product, including but not limited to: (a) medical, clinical, toxicological or other scientific data, and (b) processes and analytical methodology used in the development, formulation, testing, analysis, manufacture or
packaging of any Compound, Research Compound or Licensed Product. 
  
 1.52 “Pfizer Year” means (i) in the United States, each of the twelve (12) month periods as used by PFIZER in its audited financial reports, the first commencing on January 1 of any year and ending on December 31 of such
year and (ii) in any country in the Territory other than the United States, each of the twelve (12) month periods as used by PFIZER in its audited financial reports, the first commencing on December 1 of any year and ending on November 30 of the
following year. 
  
 1.53 “Pharmacovigilance
Agreement” means the Pharmacovigilance Agreement entered into by Coley Inc. and PFIZER on the date hereof, as the same may be amended from time to time. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 11 

 1.54 “Phase II Clinical Study” means a clinical study, other than a Phase III Clinical
Study, designed to evaluate the efficacy of a drug. A Phase II Clinical Study is deemed to commence upon enrollment of the first human subject. 
  
 1.55 “Phase III Clinical Study” means one or more clinical studies that are intended to form the primary basis of an efficacy claim for
purposes of a Regulatory Approval. A Phase III Clinical Study is deemed to commence upon enrollment of the first human subject in the first such study for a given Indication. 
  
 1.56 “Price Approval” means, in countries where Governmental Authorities or Regulatory Authorities
authorize for reimbursement, or approve or determine pricing for pharmaceutical products for reimbursement or otherwise, such authorization, approval or determination. 
  
 1.57 “Product” means any Covered Product in all dosage strengths and formulations that contains the
Compound as its sole therapeutically active substance, other than any Combination Product or Vaccine Product. 
  
 1.58 “Product Liability” means any and all Losses (as defined in Section 13.3) resulting from claims of Third Parties relating to any
death or bodily injury caused by the use of the Licensed Products manufactured or sold by PFIZER or its Affiliates. 
  
 1.59 “ProMune Product” means any Product, Combination Product or Vaccine Product. 
  
 1.60 “Regulatory Authority” means any Governmental Authority
with responsibility for granting any licenses or approvals (with the exception of Price Approvals) necessary for the marketing and sale of pharmaceutical products, including, without limitation, any drug regulatory authority of countries of the
European Union, Japan and the FDA, and where the context admits, any ethics committee or any equivalent review board. 
  
 1.61 “Regulatory Approval” means authorization granted by a Regulatory Authority to market and sell a Licensed Product in a country in
the Territory that is required before the Licensed Product may be commercially marketed and sold in such country. 
  
 1.62 “Research Combination Product” means any Covered Product in all dosage strengths and formulations (other than a Research Vaccine
Product) in which a Combination Ingredient is either (a) physically, chemically or otherwise combined or mixed with a Research Compound (including without limitation any Combination Ingredient that is covalently linked to a Research Compound) to
produce a single entity for commercial distribution or (b) packaged together with a Research Compound or any Licensed Product that contains a Research Compound (other than a Vaccine Product) in a single package or unit for commercial distribution.

  
 1.63 “Research Compound” means (i) any
compound that is designed and screened by COLEY specifically for PFIZER, and that is delivered to, and selected by, PFIZER pursuant to Section 2.2 of the Screening and Evaluation Agreement and (ii) any salts, esters, ethers, amides, and amines of
any compound referred to in clause (i). In connection with clause (ii) of this definition of Research Compound, the parties agree that PFIZER shall be permitted to make any of the changes recited in (ii) to any portion of a Research Compound
molecule, including, 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 12 

 without limitation, to a base, DNA sugar, backbone moiety, or combinations thereof, provided that
[**********************************************] in the [***********************] and [************************* *] of the [***************************] or [*************]. 
  
 1.64 “Research Compound Patent Rights” shall have the meaning assigned thereto in the Screening and
Evaluation Agreement. 
  
 1.65 “Research Product”
means any Covered Product in all dosage strengths and formulations that contains a Research Compound as its sole therapeutically active substance, other than any Research Combination Product or Research Vaccine Product. 
  
 1.66 “Research Vaccine Product” means any Covered Product in
all dosage strengths and formulations that contains at least one Research Compound and at least one Tumor Antigen (other than a Coley Substance) and in which the Research Compound induces, augments or enhances a Tumor Antigen-specific immune
response. 
  
 1.67 “Royalty Term” means on a
country-by-country and Licensed Product-by-Licensed Product basis, the period beginning on the date of the Launch of a Licensed Product and ending on the last day on which royalty payments are payable by PFIZER to COLEY pursuant to Section 5.4.

  
 1.68 “Screening and Evaluation Agreement”
means the Screening and Evaluation Agreement entered into by Coley Inc. and PFIZER on the date hereof, as the same may be amended from time to time. 
  
 1.69 “Special Protocol Assessment Meeting” means a meeting conducted pursuant to FDCA Section 505(b)(4) for the purpose of reaching
agreement on the design and size of a Phase III Clinical Study. 
  
 1.70 “Specialty Dermatologist” means any board certified dermatologist or other dermatology specialist approved by PFIZER in accordance with the procedures outlined in Section 4.10(g). 
  
 1.71 “Stock Purchase Agreement” means the Stock Purchase
Agreement entered into by Coley Inc. and PFIZER on the date hereof, as the same may be amended from time to time. 
  
 1.72 “Term” means the period beginning on the Effective Date and ending on the earlier of (i) the date of expiration of the last Royalty
Term and (ii) the effective date of any termination pursuant to Section 8.2(e) or Section 12.1. 
  
 1.73 “Territory” means the entire world. 
  
 1.74 “Third Party” means a person or entity other than (a) PFIZER, (b) COLEY or (c) an Affiliate of either PFIZER or COLEY. 

 
 1.75 “[*********************]” shall have the meaning
assigned to it in Section 5.3(b)(ii)(A). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 13 

 1.76 “Third Party Licensees” means the individuals and entities with certain license
rights pursuant to agreements as set forth on Schedule 8.2(a) attached hereto. 
  
 1.77 “Third Party Substance” shall have the meaning defined in Section 5.3(b)(ii). 
  
 1.78 “Transition Plan” means the Transition Plan attached as Exhibit B hereto, as the same may be amended from time to time.

  
 1.79 “Tumor Antigen” means any ingredient
that is associated with a tumor cell, or is an antigenic mimic of a component of a tumor cell, and that, either alone or as part of a Vaccine Product, elicits a tumor antigen-specific immune response to but not limited to, such tumor antigen and/or
live tumor cells, killed tumor cells, tumor cell membranes, subunits of tumor cells or components, fragments or extracts thereof (including, but not limited to, polysaccharides, polysaccharide subconjugates, peptides, proteins, recombinant proteins,
glycoproteins, glycolipids and fragments thereof). 
  
 1.80
“Tumor Type” means each of the following separate tumor disease areas: (i) breast cancer; (ii) NSCLC; (iii) colorectal cancer; (iv) non-Hodgkin’s lymphoma; (v) prostate cancer; (vi) gastric cancer; and (vii) ovarian cancer.

  
 1.81 “UIRF License Agreement” means the
License Agreement, entered into as of March 31, 1997, between the University of Iowa Research Foundation (“UIRF”) and COLEY. (formerly known as CpG ImmunoPharmaceuticals, Inc.), as amended on March 7, 2001. 
  
 1.82 “Vaccine Adjuvant” means a compound or composition used
to induce, augment or enhance the Antigen-specific response of an Antigen. 
  
 1.83 “Vaccine Product” means any Covered Product in all dosage strengths and formulations that contains the Compound and at least one Tumor Antigen (other than a Coley Substance) and in which the
Compound induces, augments or enhances a Tumor Antigen-specific immune response. 
  
 1.84 “Valid Claim” means any claim [************************************************************************ **********] from an issued and unexpired patent included within patents under the Coley
Patent Rights which has not been revoked or held unenforceable or invalid by a final, nonappealable decision of a court or other Governmental Authority of competent jurisdiction or unappealed within the time allowable for appeal, and which has not
been explicitly disclaimed, or admitted by COLEY to be invalid or unenforceable or of a scope not covering Licensed Products through reissue, disclaimer or otherwise. If a claim [**************************] as a claim of an issued patent
[******************************************************* *********************************************************************************************************** **********] for purposes of this Agreement [*****] and [*****************] claim of
an issued patent. 
  
 1.85 “Variant” means any
change to the Compound or Research Compound, excluding changes to the nucleotide sequence, which resulting molecule [***********************] to at least [*****************************************************
*********************************************************************************************************** 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 14 

 ***************] and which may optionally include modifications to the sugar or linker moieties or a combination of the
two. For example and without limitation, a Variant may include a linker moiety between each monomer, such as but not limited to, one or more phosphodiester bonds, phosphorothioate bonds, or mixed phosphodiester/phosphorothioate bonds. Further, a
Variant may include one or more nucleotides or nucleosides comprising ribose sugars, as well as one or more oligomers comprising oligoribonucleotides. A Variant may include a 2’-O-alkylated ribose group or an arabinose instead of ribose. Thus,
a Variant may be heterogeneous or homogeneous in backbone composition. 
  
 Section 2. LICENSE GRANT. 
  
 2.1
Exclusive Licenses. Subject to the terms of this Agreement and subject to the rights as of the date hereof granted to a Third Party pursuant to the license agreement identified in Schedule 1.28, with respect to the rights owned or
controlled by each of them, each of the Coley Entities hereby grants to PFIZER, and PFIZER hereby accepts: (i) an exclusive license (even as to each of the Coley Entities), including the right to sublicense, under the Coley Patent Rights to make,
have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product in the Field in the Territory, (ii) an exclusive license (even as to each of the Coley Entities), including the right to sublicense, to use
Coley Technology and Coley Confidential Information to the extent reasonably useful for the manufacture, use, sale, offer for sale and importation of the Compound, any Research Compound and any Licensed Product in the Field in the Territory;
provided that with respect to any Coley Patent Rights and Coley Technology that any Coley Entity or any of their respective Affiliates hereafter acquires from a Third Party (whether by purchase, license, assignment or other means), such Coley
Entity shall only be required to grant PFIZER a license to such Coley Patent Rights or Coley Technology to the extent permitted under its agreement with such Third Party and if such Coley Patent Rights or Coley Technology is reasonably necessary for
the manufacture, use, sale, offer for sale or importation of the Compound, any Research Compound or any Licensed Product in the Field in the Territory; provided, further, that each Coley Entity or Affiliate thereof shall negotiate in
good faith with any such Third Party to obtain the right to grant PFIZER such license, and to the extent that such Coley Entity or Affiliate incurs any additional applicable milestone and royalty obligations to a Third Party as a direct result of
the license granted to PFIZER, PFIZER shall pay such Coley Entity such additional royalty obligation amounts, (iii) with respect to the OHRI License Agreement, an exclusive sublicense (even as to each of the Coley Entities), including the right to
sublicense, under the Coley Patent Rights and Coley Technology licensed to COLEY thereunder to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product in the Field in the Territory and (iv)
with respect to the UIRF License Agreement, an exclusive sublicense (even as to each of the Coley Entities), including the right to sublicense, under the Coley Patent Rights and Coley Technology licensed to COLEY thereunder to make, have made, use,
sell, offer for sale and import the Compound, any Research Compound and any Licensed Product in the Field in the Territory. PFIZER will promptly notify COLEY of any sublicense under this Section 2.1 and provide copies of any such sublicenses granted
by PFIZER to a Third Party in final, executed form. PFIZER shall require any such Third Party sublicensee to confirm in writing to COLEY that it will comply with all of the covenants, agreements and obligations of PFIZER 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 15 

 hereunder and shall guarantee that any sublicensee fulfills all of PFIZER’s obligations under this Agreement. PFIZER
shall not be relieved of its obligations pursuant to this Agreement by virtue of any such sublicense. Except as expressly provided by the licenses granted in this Section 2 and any license granted in the Screening and Evaluation Agreement, PFIZER
shall have no rights to use the Coley Patent Rights, Coley Technology, Compound, Research Compounds and Licensed Products for any other purpose. 
  
 2.2 Non-Exclusive License. Subject to the terms of this Agreement, with respect to the rights owned or controlled by each of them, each of the
Coley Entities hereby grants to PFIZER, and PFIZER hereby accepts a nonexclusive, worldwide, royalty-free license, including the right to sublicense, under the Coley Patent Rights in the Field, the Coley Technology in the Field, and the Coley
Confidential Information, to make, have made, use, sell, offer for sale and import any molecule that is incidental to the manufacture and use of the Compound, any Research Compound, any Licensed Product or any Generic Product. 
  
 2.3 Clinical Development License. With respect to the rights owned or
controlled by each of them, each of the Coley Entities hereby grants to PFIZER, and PFIZER hereby accepts an exclusive license (even as to each of the Coley Entities), including the right to sublicense, under the Coley Patent Rights, the Coley
Technology, and the Coley Confidential Information, to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product, for any clinical study in the Territory (i)
[********************************************] or [************************] or (ii) [***************** *****************************************] provided that, [***********************************************] may include (x)
[**********************] that is [*******************************************] or (y) [****************** ********************] for the [*********************] of [*************] that [************************************ *********]. For purposes of
this Section 2.3 [***********************] means [*************************************** ****] or [*********] that [******************] a [********************] in [***********************] from [*********** *******************************].

  
 2.4 Research Licenses. Without limiting any of the
licenses granted in this Section 2, each of the Coley Entities hereby grants to PFIZER a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the
Coley Technology (excluding any patents relating thereto) disclosed to PFIZER during the Term; provided that PFIZER shall not have any right to use the Coley Technology for the sale or manufacture for sale of products or processes. PFIZER
hereby grants to COLEY, and COLEY hereby accepts a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Pfizer Technology (excluding any patents
relating thereto) disclosed to COLEY during the Term; provided that COLEY shall not have any rights to use the Pfizer Technology for the sale or manufacture for sale of products or processes. 
  
 2.5 License Grant to Coley. 
  
 (a) Subject to the provisions of this Section 2.5, PFIZER
hereby grants to COLEY a non-exclusive license, including the right to sublicense solely to Affiliates of 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 16 

 COLEY, in the Territory under Pfizer Use Patent Claims (as defined below) which are determined to include
Infringing Claims (as defined below) for use in connection with Covered ODNs (as defined below) outside the Field to the extent otherwise not prohibited by this Agreement. 
  
 (b) Subject to the provisions of this Section 2.5, PFIZER hereby grants to COLEY a non-exclusive license,
including the right to sublicense to Permitted Sublicensees (as defined below), in the Territory under Pfizer Process Patent Claims (as defined below) for use in connection with the manufacture of Covered ODNs. 
  
 (c) For purposes of this Section 2.5, (i) “Pfizer
Use Patent Claims” shall mean any claims contained in any issued patent hereafter during the Term of this Agreement owned or controlled by PFIZER or its Affiliates, which claims are directed to the therapeutic use of any Covered ODN (in
each case as the sole therapeutically active ingredient) and where the inventive work Derived from the Collaboration (as defined below); (ii) “Infringing Claims” means any Pfizer Use Patent Claims which are found, as specified
below, as of the Date of Determination (as defined below), to literally infringe any issued claim of a patent owned or controlled by COLEY or any of its Affiliates; (iii) “Permitted Sublicensees” shall mean any Affiliate of COLEY or
any Third Party that manufactures Covered ODNs for COLEY or any sublicensee of COLEY having rights thereto; (iv) “Pfizer Process Patent Claims” shall mean any claims contained in any issued patent hereafter during the Term of this
Agreement owned or controlled by PFIZER or its Affiliates, which claims are directed to any manufacturing process (including, without limitation, synthesis, purification or analytical methods) that have been used by PFIZER or its Affiliates in the
manufacturing or processing of bulk active substance for the Compound or a Research Compound; (v) “Covered ODNs” means [************
**************************************************************************************************** ******** ****** *******************************************]; (vi) “Derived from the Collaboration” means those circumstances under
which the conception or reduction to practice of an invention is materially related to performance of activities of PFIZER employees under the Screening and Evaluation Agreement or this Agreement. 
  
 (d) In determining whether any Pfizer Use Claims are
Infringing Claims, the following procedure will be used: 
  

	 	(i)	Promptly upon the issuance to PFIZER or any Affiliate of PFIZER of any Pfizer Use Patent Claims in each of USA, any Major EU Country (United Kingdom, France, Germany, Spain and
Italy), and Japan, PFIZER will determine and notify COLEY whether PFIZER believes, as of the date of issuance of each such Pfizer Use Patent Claims (the “Date of Determination”) in the respective country, whether such Pfizer Use Patent
Claim literally infringes for each such country any issued patents for Covered ODNs owned or controlled by COLEY as of the Determination Date. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 17 

	 	(ii)	If after discussing the foregoing with COLEY, PFIZER and COLEY do not agree as to whether any Pfizer Use Patent Claims is an Infringing Claim regarding such country, then COLEY and
PFIZER shall agree upon and appoint an independent outside patent counsel, licensed in the relevant country, who shall render a legal opinion regarding such infringement, which opinion shall be binding on the parties for the purposes of this Section
2.5. 

  
 (e) Each license granted
under Section 2.5(a) shall terminate, on a country-by-country basis, on the date the relevant Coley patent which formed the basis for the infringement determination expires or is found invalid or unenforceable by a court of competent jurisdiction.
In addition, all licenses granted to COLEY under Sections 2.5(a) and 2.5(b) shall terminate upon a Change of Control of COLEY and upon expiration or termination of this Agreement. 
  
 (f) Notwithstanding the foregoing, with respect to any Pfizer Use Patent Claims or Pfizer Process Patent
Claims that PFIZER hereafter acquires from a Third Party (whether by purchase, license, assignment or other means), PFIZER shall only be required to grant COLEY a sublicense to such patent claims to the extent permitted under its agreement with such
Third Party; provided that PFIZER shall negotiate in good faith with any such Third Party to obtain the right to grant COLEY such sublicense and COLEY shall be responsible for any applicable milestone payments and royalty obligations to such
Third Party for such sublicense. 
  
 (g) In
consideration of the license granted to COLEY under this Section 2.5 COLEY shall pay to PFIZER, within 60 days after the end of each calendar quarter, [***************] of net sales (determined in a manner analogous to that provided in Section 1.43)
of COLEY products which are embraced within the claims of issued Pfizer Use Patent Claims licensed to COLEY under this Section 2.5. The amount of such royalties shall be deducted from royalties owed by PFIZER to COLEY under Section 5.3.

 
 Section 3. HSR. 
  
 3.1 HSR. Promptly following signing of this Agreement and, so long as
COLEY delivers to PFIZER all required information in a timely manner, in no event later than fifteen (15) Business Days after the signing of this Agreement, PFIZER and COLEY (or its Affiliate) shall take (i) all actions necessary to make the filing
required under the HSR Act, and (ii) promptly reply to any requests for information received from the United States Federal Trade Commission (“FTC”) or Antitrust Division of the United States Department of Justice
(“DoJ”) pursuant to the HSR Act. The parties shall, to the extent reasonably practicable, consult with one another prior to making any filings, responses to inquiries or other contacts with the FTC or DoJ concerning the transactions
contemplated hereby. PFIZER shall be responsible for the payment of all fees and costs associated with the HSR filing. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 18 

 Section 4. DEVELOPMENT; MANUFACTURING; COMMERCIALIZATION. 
  
 4.1 Transition Plan. In order to ensure the smooth transition of
ongoing development activities for the Compound that are subject to PFIZER’s licenses under this Agreement and to facilitate the transfer of the Coley Patent Rights in the Field and the Coley Technology in the Field to PFIZER, the parties are
entering into the Transition Plan attached as Exhibit B hereto on the date hereof to be effective on the Effective Date. 
  
 4.2 Pfizer Development Activities. Other than as expressly provided in Sections 4.3, 4.5 and 4.10 below and in the Screening and Evaluation
Agreement, PFIZER shall have the exclusive right and responsibility to plan and implement all research and development activities for the Compound and any and all Research Compounds and Licensed Products, and all decisions with respect to the
creation, modification and implementation of all such research and development activities shall be made by PFIZER in its sole discretion and at its sole cost. Nothing in this Section 4.2 shall modify PFIZER’s obligations under Sections 4.4,
4.6, 4.7 and 4.8. 
  
 4.3 Coley Development Activities.

  
 (a) Coley Indication. 
  
 (i) COLEY shall have the right to continue to develop the
Compound for the Coley Indication, as expressly provided in this Section 4.3 and the Transition Plan. COLEY shall have the right to (x) continue and complete its current Phase II trial for the Coley Indication as in effect on the date hereof under
the Transition Plan (the “Existing Phase II Coley Indication Plan”), (y) subject to PFIZER’s approval through the Coley Indication Committee (as defined below), modify and/or expand the trial design for the Existing Phase II
Coley Indication Plan (any and all such modifications or expansions, being hereinafter referred to as the “Expanded Phase II Coley Indication Plan”) and implement the Expanded Phase II Coley Indication Plan in accordance with such
plan and (z) subject to PFIZER’s approval of the Phase III Coley Indication Plan (as defined below) through the Coley Indication Committee, conduct the Phase III Clinical Study for the Coley Indication in accordance with the Phase III Coley
Indication Plan, beginning on the first anniversary of the commencement by PFIZER of the Phase III Clinical Study for NSCLC. By no later than December 31, 2005, COLEY shall deliver to PFIZER a detailed draft of its Phase III development plan for
Compound for the Coley Indication (such plan, as approved and amended from time to time by the Coley Indication Committee, the “Phase III Coley Indication Plan”). All of COLEY’s development plans and activities (including,
without limitation, all protocols, clinical study reports and budgets) for the Compound for the Coley Indication and any material modifications thereto or implementation thereof are subject to approval by PFIZER in its reasonable discretion through
the Coley Indication Committee. 
  
 (ii) Upon the
Effective Date, the parties shall establish a committee (the “Coley Indication Committee”) to discuss and approve the Expanded Phase II 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 19 

 Coley Indication Plan and the Phase III Coley Indication Plan, to request a Special Protocol Assessment
Meeting with the FDA for the Coley Indication and to discuss the commercialization of the Compound for the Coley Indication. The Coley Indication Committee will determine the frequency of its meetings and the timing for delivery of written reports
on the Coley Indication, as appropriate. All meetings of the Coley Indication Committee shall be chaired by a representative appointed by PFIZER, who shall be knowledgeable about the clinical development of the Compound for the Coley Indication,
and, in all cases, in the event of a deadlock between the PFIZER and COLEY representatives, the PFIZER chairperson shall have the deciding vote. 
  
 (iii) No later than ten (10) Business Days prior to the commencement of the first study under the final Expanded Phase II Coley Indication
Plan that has been approved by the Coley Indication Committee, PFIZER shall pay to COLEY [***] of the budgeted amount for such study, and COLEY shall promptly commence the implementation of the Expanded Phase II Coley Indication Plan in accordance
with the terms and provisions thereof. In accordance with the procedures set forth in this Section 4.3(a)(iii), [*******] shall be responsible for paying to [*******] the first [******************** *************] of costs incurred by COLEY in
implementing the Phase III Coley Indication Plan. Any further costs incurred in connection with the implementation of the Phase III Coley Indication Plan will be shared equally by the parties; provided that in no event will COLEY’s costs
for the implementation of the Coley Indication Phase III Plan exceed two million dollars ($2,000,000). COLEY’s total costs for implementing the Expanded Phase II Coley Indication Plan (all of which will be paid by PFIZER) and the Phase III
Coley Indication Plan (which shall be split between the parties as set forth in this Section 4.3(a)(iii)) will be calculated at a rate equal to two and one half (2.5) times the amount of payments made by COLEY to the clinical sites that are
conducting the clinical work for the Coley Indication, excluding any costs related to data management and specialized immunological assays for the Coley Indication (the “Non-Clinical Costs”). If, at PFIZER’s request, COLEY
undertakes any data management or conducts any specialized immunological assays in connection with the development of the Compound for the Coley Indication, the parties shall discuss and agree on appropriate compensation for COLEY for such work. No
later than ten (10) Business Days prior to the commencement of the first study under the final Phase III Coley Indication Plan that has been approved by the Coley Indication Committee, PFIZER shall pay to COLEY [***] of the budgeted amount for such
study, and COLEY shall promptly commence the implementation of the Phase III Coley Indication Plan in accordance with the terms and provisions thereof. Within thirty (30) days after the end of each six-month period ending June 30 or December 31,
COLEY shall provide PFIZER with a written report containing a reasonably detailed accounting of its payments to the clinical sites that are conducting the clinical work for the Coley Indication in connection with the implementation of the Expanded
Phase II Coley Indication Plan and the Phase III Coley Indication Plan during such six-month period. Within twenty (20) Business Days of its receipt of such report, PFIZER shall pay to COLEY the amount, if any, due to COLEY under this Section
4.3(a)(iii). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 20 

 (iv) PFIZER and COLEY hereby agree that (x) the Coley Indication Plan attached as
Exhibit C hereto (the “Coley Indication Plan”) is a reasonable and appropriate outline of a plan for the Expanded Phase II Coley Indication Plan and the Phase III Coley Indication Plan, (y) so long as the Phase II and Phase
III clinical work for the Coley Indication is carried out in a manner generally consistent with the Coley Indication Plan (including any changes to the Coley Indication Plan made in response to feedback received from the FDA), except as provided in
clause (z) below, PFIZER shall have no further obligation to COLEY to develop the Compound for the Coley Indication and (z) in no event (including as a result of feedback from the FDA in a Special Protocol Assessment Meeting or a Pre-NDA Meeting (as
defined below) for the Coley Indication) shall PFIZER and COLEY be required to spend more than [**********************************], in the aggregate, in connection with the Expanded Phase II Coley Indication Plan and the Phase III Coley Indication
Plan. Such [**********] includes any costs or expenses of Coley in performing data management or specialized immunological assays, but excludes charges for such activities if performed by PFIZER. 
  
 (v) Prior to finalizing the Phase III Coley Indication Plan,
PFIZER will request a Special Protocol Assessment Meeting with the FDA to discuss such studies. After or near the conclusion of the Phase III Clinical Studies for the Coley Indication, PFIZER and COLEY will meet with the FDA in a Pre-NDA Meeting to
discuss the results of such studies. Unless otherwise determined by the Coley Indication Committee, at each of the Special Protocol Assessment Meeting and the Pre-NDA Meeting for the Coley Indication, COLEY may have one representative present who
may attend only as an observer. If, as a result of the Pre-NDA Meeting, the FDA does not uncover any major unresolved problems, PFIZER will use diligent efforts to file an NDA and seek Regulatory Approval from the FDA for the Compound for the Coley
Indication. If the FDA does uncover a major unresolved problem, PFIZER’s obligations to COLEY to continue to develop the Compound for the Coley Indication shall be limited to those set forth in Section 4.3. “Pre-NDA Meeting”
shall have the meaning given to it in 21 C.F.R. § 312.47(b)(2). 
  
 (b) Other Development Activities. For the three (3)-year period of time beginning within the first calendar quarter of 2006 and ending three (3) years thereafter, PFIZER shall pay to COLEY no less than
[***********************************] per year for the development work to be specified in the Coley Work Plan; any amounts in excess of a total of [**********] for such development work must be mutually agreed to by the parties. The Coley Work Plan
could include, without limitation, preclinical, clinical, biomarker work or other similar activities with respect to the Compound and will include the budget and deliverables for the activities to be conducted by COLEY. The Coley Work Plan will be
updated, as appropriate, to reflect material changes and submitted to the Development Committee for approval as described in Section 4.5(a) 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 21 

 below. PFIZER shall pay to COLEY [*******************] of the budgeted amount for each project or work
activity prior to the commencement of such project or work activity and [*******************] of the budgeted amount upon the completion of the deliverable for each such project or work activity. If the scope or resources required for a deliverable
changes materially during the course of the development activities, COLEY will promptly notify the Development Committee, and the Development Committee will work, in good faith, to modify the Coley Work Plan or adjust the budget, as appropriate.

  
 4.4 Diligence. PFIZER shall use Commercially Reasonable
Efforts to (i) commence a Phase III Clinical Study for NSCLC that is intended to be included in a submission for Regulatory Approval in the United States and the European Union, (ii) commence a [********] Clinical Study for [********] that is
intended to be included in a submission [**************] in the United States and the European Union, (iii) commence a clinical trial with the aim of registration for one Major Indication in [*****] and (iv) develop, seek Regulatory Approval for and
commercialize Licensed Products in the Territory in the Field. 
  
 4.5 Development Committee. 
  
 (a) Development Committee. The parties shall establish a development committee (the “Development Committee”) to review and discuss current material clinical development activities and safety information relating to
Licensed Products, approve and update the Coley Work Plan, and review and discuss, as appropriate, future material clinical development and regulatory plans for the Licensed Products. PFIZER and COLEY shall each appoint four (4) members to the
Development Committee. PFIZER shall appoint one of its members to act as the committee chair and ensure that one of the four (4) PFIZER members of the Development Committee will be the person with primary responsibility and accountability for the
development of the Licensed Products (the “Program Leader”). Substitutes, replacements or alternates may be appointed at any time, so long as the Program Leader continues to be a PFIZER member of the Development Committee and so
long as the party proposing such substitution, replacement or alternate gives the other party reasonable prior notice thereof. The Development Committee shall not have any decision-making authority, except with respect to the Coley Work Plan, which
the parties will discuss in good faith, and as set forth in the last sentence of Section 4.5(b) below. The initial Coley Work Plan and any material amendments thereto must be approved by both parties in their reasonable discretion. 
  
 (b) Meetings. Beginning no later than ninety (90)
days after the Effective Date, the Development Committee shall meet quarterly until the first Launch of the first Licensed Product (the “Initial Period”). After the first Launch of the first Licensed Product, the Development
Committee will meet semi-annually until PFIZER pays to COLEY the Commercial Milestone in accordance with Section 5.2 (the “Interim Period”). Thereafter, the Development Committee shall meet annually. All meetings of the Development
Committee will be timed to follow the receipt of the Development Reports (as defined in Section 4.6 below) and will be held in person at a mutually agreeable time and a location to be designated by each party in turn in New York, Connecticut or

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 22 

 Massachusetts, or at another location agreed upon by the parties, unless the parties agree that any given
meeting is not necessary or can be held by videoconference or teleconference. In addition to the Development Committee members, representatives of PFIZER or COLEY or both may attend such meetings at the invitation of either party and with reasonable
prior notice thereof. The Development Committee will have the discretion to (i) form and charter additional sub-committees to discuss specific issues and make reports and recommendations to the full Development Committee and (ii) call additional
meetings, as appropriate. 
  
 (c)
Expenses. PFIZER and COLEY shall each bear all expenses of their respective members relating to their participation on the Development Committee. 
  
 4.6 Development Reports. (i) During the Initial Period, no later than sixty (60) days after the end of each calendar quarter, PFIZER shall provide
written reports to COLEY containing (w) a summary of the regulatory activities for the Licensed Products, including any material changes in such activities since the prior reporting period, (x) a summary of the clinical study results for the
Compound and the Research Compounds and Licensed Products, including any material changes in the clinical activities since the prior reporting period, (y) as deemed appropriate by PFIZER in its reasonable discretion, other development activities for
the Licensed Products (which may include material changes in the projected timelines) and (z) a summary of material planned regulatory and clinical activities for the four (4) calendar quarters following such reporting period; the relevant reporting
period shall be the three (3)-month period ending March 31, June 30, September 30 or December 31 of each calendar year preceding such report, as applicable; (ii) during the Interim Period, no later than sixty (60) days after the end of each six
(6)-month period ending June 30 and December 31 of each calendar year, PFIZER shall provide written reports to COLEY containing the information specified in clause (i) above for the six (6)-month reporting period ending June 30 or December 31 of
each calendar year preceding such report and a summary of material planned regulatory and clinical activities for the following two (2) six (6)-month periods ending December 31 and June 30; and (iii) thereafter, no later than sixty (60) days after
the end of each calendar year, PFIZER shall provide written reports to COLEY containing the information specified in clause (i) above for each calendar year preceding such report and a summary of material planned regulatory and clinical activities
for the following calendar year (each report referred to in clauses (i), (ii) and (iii), a “Development Report”). All Development Reports shall be deemed Pfizer Confidential Information; provided that, to the extent required
by the UIRF License Agreement and the OHRI License Agreement, Coley shall be permitted to disclose summaries of Development Reports provided by PFIZER to COLEY, subject to appropriate confidentiality agreements, to each of UIRF and OHRI. 

 
 4.7 Manufacturing. 
  
 (a) Other than as expressly provided in the Screening and
Evaluation Agreement, the Transition Plan, the Coley Work Plan and this Section 4.7, PFIZER shall have the exclusive right and responsibility for the manufacture (for the avoidance of doubt, either by manufacturing itself, through its Affiliates or
by an arrangement with a Third Party) of all pre-clinical, clinical and commercial quantities of Licensed Products and the Compound and Research Compounds required therefor. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 23 

 (b) PFIZER agrees not to request or take any action that would prevent COLEY from
entering into its own supply arrangement with either the same Third Party that has entered into a supply arrangement with PFIZER or any other Third Party for the purpose of allowing COLEY to exercise its retained rights to the Coley Patent Rights
and the Coley Technology to the extent permitted under this Agreement. 
  
 (c) PFIZER agrees, within twenty (20) Business Days after the Effective Date, [****************] for certain manufacturing [******************************] prior to the Effective Date and set forth on Schedule
4.7(c) attached hereto if COLEY has delivered to PFIZER a copy of the final report [********] as applicable, for the work set forth on Schedule 4.7(c) prior thereto. If COLEY has not delivered to PFIZER a copy of the final report
[********], as applicable, for the work set forth on Schedule 4.7(c) prior to the twentieth (20th) Business
Day after the Effective Date, then PFIZER shall [***************************] set forth on Schedule 4.7(c) within twenty (20) Business Days after the date of its receipt of such report [**********], as applicable. It is understood that COLEY
shall have no obligation to incur any costs relating to manufacturing prior to the Effective Date, and any decision to incur such costs shall be made in COLEY’s sole discretion. 
  
 (d) PFIZER agrees that any Licensed Product produced for sale in the United States and embraced by a Valid
Claim under a Coley Patent Right listed on Exhibit A with UIRF identified as an Assignee will be manufactured substantially in the United States, unless any waiver of such requirement is obtained. COLEY shall, at PFIZER’s request and
expense, assist, and cause UIRF to assist, PFIZER in attempting to obtain such a waiver, should PFIZER determine to do so. 
  
 4.8 Regulatory Responsibilities. 
  
 (a) PFIZER shall have the exclusive right and responsibility (i) for all filings and approvals with Governmental Authorities relating to
the Compound and any Research Compounds and Licensed Products in the Territory in the Field (including, for the avoidance of doubt, any filings or approvals for the Coley Indication) and (ii) except as expressly set forth in Section 4.10, for
planning and implementing all commercialization activities related thereto. PFIZER shall have the exclusive right and responsibility for all reimbursement matters relating to Medicare, formularies, managed care organizations or other similar groups
with respect to all Licensed Products. Except as expressly set forth in Section 4.10, PFIZER shall be solely responsible for all costs related to regulatory and commercialization matters. Nothing in this Section 4.8 shall modify PFIZER’s
obligations under Sections 4.3 and 4.4. 
  
 (b)
PFIZER further agrees (x) with respect to [********************** *********] or [*************] for any [*************************************] as [***********] for [****************] and to include [*************** *********] and (y) with respect
to [******************************************************************* ****************************************************************************] or [********************** *******************************] for [**************] to [**********] as
[*********] for [********************* ********************]. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 24 

 (c) The parties shall exchange adverse event reports and other safety information
relating to the Compound in accordance with the Pharmacovigilance Agreement. In addition, PFIZER shall provide to COLEY summary reports of safety information pertaining to each Licensed Product on an annual basis. This Section 4.8(c) shall survive
and continue for so long as PFIZER is subject to any Governmental Authority requirement to report safety information relating to any Licensed Product. 
  
 4.9 Post-Development Committee: 
  
 (a) Post-Development Committee. Within six (6) months of the Effective Date, the parties shall establish a committee (the
“Post-Development Committee”) to provide certain information to Coley and be a forum for discussion. The Post-Development Committee shall have no decision-making authority. The Post-Development Committee will review and discuss (i)
PFIZER’s [********************************] activities for the prior reporting period, (ii) summaries of [***************] and summary information about [********************************] with the Licensed Products, (iii) an overview of the
[*******************], if any, for such year, which overview shall include material deemed appropriate by PFIZER in its reasonable discretion, and (iv) as deemed appropriate by PFIZER in its reasonable discretion, other [**************] and
[*********] activities which may include [******************] as well as [*************] and [************] activities planned for the Licensed Products. PFIZER shall appoint no less than two (2) and COLEY shall appoint no more than five (5) members
to the Post-Development Committee. PFIZER shall appoint one of its members to act as the committee chair and ensure that its members are knowledgeable about the matters addressed by such committee. Substitutes, replacements or alternates may be
appointed at any time so long as both parties continue to comply with this Section 4.9(a) and so long as the party proposing such substitution, replacement or alternate gives the other party reasonable prior notice thereof. 
  
 (b) Meetings. The first meeting of the
Post-Development Committee shall occur prior to December 31, 2005. For the period of time beginning [**************] and ending on the date of acceptance for filing by the FDA of the first NDA for a Licensed Product, the Post-Development Committee
shall meet once per calendar year. For the period beginning on the date of acceptance for filing by the FDA of the first NDA for a Licensed Product and ending on the fifth anniversary thereof, the Post-Development Committee shall meet semi-annually.
Thereafter, the Post-Development Committee shall meet annually. All meetings of the Post-Development Committee will be held in person at a mutually agreeable time and a location to be designated by each party in turn in New York, Connecticut or
Massachusetts, or at another location agreed upon by the parties, unless the parties agree that any given meeting is not necessary or can be held by videoconference or teleconference. The committee chair shall be responsible for scheduling the
meetings. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 25 

 (c) Expenses. PFIZER and COLEY shall each bear all expenses of their respective
members relating to their participation on the Post-Development Committee. 
  
 (d) Medical Symposia, Advisory Boards or other Meetings with Key Opinion Leaders. PFIZER agrees that, if it is planning to hold such a meeting, at least one member of COLEY’s management shall have the
right to attend (at COLEY’s sole expense) at least one major advisory board meeting in the United States that addresses the use of the Compound for the Coley Indication; provided that such COLEY person shall attend only for the portion
of such meeting that is directly related to the Coley Indication. With PFIZER’s prior consent, COLEY may plan medical symposia, advisory board meetings or other meetings with key opinion leaders or outside experts that address the use of the
Compound for the Coley Indication; provided that, at PFIZER’s sole cost, at least one PFIZER representative shall have the right to participate therein. 
  
 4.10 Coley Commercialization Rights. COLEY shall have the option to Detail the Product in the United States for the
Coley Indication, subject to the following terms and conditions: 
  
 (a) No later than five (5) months before the anticipated filing with the FDA by PFIZER for Regulatory Approval of the Coley Indication, PFIZER will deliver to COLEY a draft of [*********************** **********] for
the Coley Indication. No later than three (3) months before the anticipated filing with the FDA by PFIZER for Regulatory Approval of the Coley Indication, PFIZER shall notify COLEY of such anticipated filing, and no later than sixty (60) days
thereafter, COLEY shall have the right to elect, upon notice to PFIZER, to Detail the Product for the Coley Indication to Specialty Dermatologists as provided herein. 
  
 (b) Any Detailing by COLEY of the Product for the Coley Indication shall be for a [*************] period,
commencing on the date of Launch in the United States of the Product for the Coley Indication. COLEY shall have the right to terminate Detailing of the Product for the Coley Indication on the [**********************************************]
anniversaries of the Launch in the United States of the Product for the Coley Indication upon ninety (90) days’ notice to PFIZER. If PFIZER agrees, COLEY may extend the initial [*************] period for [***********************] by giving
PFIZER notice no later than six (6) months prior to the expiration of such [*************] period. If COLEY fails to give such notice of extension, COLEY’s rights to Detail the Product hereunder shall terminate at the end of such
[*************] period. If COLEY gives such notice of extension and PFIZER approves the extension, COLEY’s rights to Detail the Product for the Coley Indication hereunder shall terminate on the [************************] of the Launch in the
United States of the Product for the Coley Indication. 
  
 (c) COLEY’s right to Detail the Product shall be contingent upon COLEY’s employment of (i) sales representatives who at the time of employment by COLEY have not less than two (2) years of branded, single-source prescription
pharmaceutical sales experience in the United States (collectively, the “Coley Sales Representatives”), (ii) 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 26 

 at least [************************] for every [*************************************] to manage and
monitor the COLEY sales representatives, with each such sales manager having at the time of employment by COLEY not less than two (2) years of experience in supervising pharmaceutical sales representatives and (iii) at least two (2) sales force
trainers who at the time of employment by COLEY have not less than two (2) years of experience in adult training and platform and facilitator skills in the pharmaceutical industry, including part-time experience (the “Coley Sales Force
Trainers”, and, together with the Coley Sales Representatives and the Coley sales manager(s), collectively, the “Coley Sales Force”). The parties agree that the Coley Sales Force Trainers may be independent contractors of
COLEY, so long as each such Coley Sales Force Trainer enters into an appropriate confidentiality agreement. 
  
 (d) COLEY shall have sole responsibility for all costs and expenses in connection with the Coley Sales Force, including, without
limitation, salaries, travel expenses and other expenses, providing benefits, deducting federal, state and local payroll taxes, FICA contributions, FUI, DUI and any similar taxes and paying Workers’ Compensation premiums, unemployment insurance
contributions and any other payments required by Law to be made on behalf of employees. Nothing in this Agreement shall be construed to conclude that any member of the Coley Sales Force or any other agents or employees of COLEY are agents or
employees of PFIZER or subject to PFIZER’s direction and control. COLEY shall have sole authority over the terms and conditions of the Coley Sales Force employment, including their selection, management and discharge. 
  
 (e) Each member of the Coley Sales Force Detailing the
Product shall have successfully completed the Training Program (as defined below) (either as provided by PFIZER, by one of the Coley Sales Force Trainers who has received training by PFIZER or another Coley Sales Force Trainer) prior to conducting
any Details of the Product. A member of the Coley Sales Force shall have successfully completed the Training Program if he or she has received at least as high a grade on all quizzes and exams that make up the Training Program as PFIZER requires of
its own sales representatives at the time such Training Program is conducted. Each member of the Coley Sales Force may take a quiz or exam that makes up the Training Program [*********] times. If after the [**********] time such individual has not
received at least as high a grade on such quiz or exam as PFIZER requires of its own sales representatives at the time, under no circumstances can such individual remain a member of the Coley Sales Force or Detail the Product for the Coley
Indication. For the avoidance of doubt, unless PFIZER’s prior consent has been obtained, no member of the Coley Sales Force may promote the Product or discuss disease concepts with any medical professional, including without limitation any
Specialty Dermatologist, until after both (x) the Launch of the Product for the Coley Indication in the United States and (y) he or she has successfully completed the Training Program. After COLEY has notified PFIZER pursuant to Section 4.10(a) that
it desires to Detail the Product, PFIZER shall provide general sales and product training for the Product for the Coley Indication for no less than [*****] and no more than [*****] Coley Sales Representatives and no more than an aggregate of [*****]
Coley personnel (inclusive of all members of the Coley Sales Force) in accordance with the training program described in Schedule 4.10(e) 
 (the “Training Program”). PFIZER shall only conduct the Training Program once, with all 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 27 

 COLEY personnel attending at the same time. PFIZER shall not be obligated to provide any training for any
additional COLEY personnel, other than as expressly set forth in this Section 4.10(e). On an as-needed basis, PFIZER shall provide ongoing training relating to the Product for the Coley Indication for the Coley Sales Force Trainers who will train
any additional or replacement Coley Sales Representatives to the same standard as the Coley Sales Representatives trained by PFIZER. In accordance with Section 4.10(d), all travel and lodging and other expenses for the Coley Sales Force to attend
the Training Program will be paid by COLEY. In addition, COLEY will pay PFIZER an aggregate of [********] for the COLEY personnel attending the Training Program. Except as provided in this Section 4.10(e), the implementation of all ongoing training
programs for the Coley Sales Force will be the responsibility of COLEY and at its sole expense. In any event, COLEY shall be responsible, at its sole expense, for training the Coley Sales Force on general business and regulatory topics, including,
without limitation, computer training, call management training, company car policy, expense reporting and human resources policies. 
  
 (f) PFIZER shall provide to COLEY, [********************], reasonable quantities of training materials adequate to train the Coley Sales
Force for Detailing the Product for the Coley Indication. On an as-needed basis, PFIZER shall update the training materials used by the Coley Sales Force Trainer’s and provide to COLEY, [*************] reasonable quantities of the updated
materials. PFIZER shall own all rights to all training materials so provided, including all copyrights thereto. In training the COLEY sales representatives to Detail the Product, the Coley Sales Force Trainers may only use the training materials
provided by PFIZER. PFIZER shall have the right to review all general training or non-product-specific materials that are used by the Coley Sales Force Trainers to train any Coley Sales Representative who will be Detailing the Product for the Coley
Indication. 
  
 (g) At all times during which
COLEY is Detailing the Product hereunder, COLEY shall have no more than [*****************] Coley Sales Representatives with responsibility for Detailing the Product for the Coley Indication. No later than sixty (60) days prior to the start of each
calendar year during which COLEY will be Detailing the Product for the Coley Indication, PFIZER, in consultation with COLEY, shall establish an annual detailing plan that shall include a list of the Specialty Dermatologists approved by PFIZER and an
annual detail volume (“ADV”) for such period. The ADV will be pro-rated as needed for any periods during which COLEY will be Detailing the Product that are not a full calendar year. For any calendar year during which COLEY will be
Detailing the Product for the Coley Indication, (i) the ADV shall not be less than [******] nor more than [********] for such year and (ii) the parties shall meet semi-annually, at a mutually agreeable time, to update the list of Specialty
Dermatologists. 
  
 (h) Subject to the last
sentence of this Section 4.10(h), PFIZER shall pay COLEY, on a calendar quarter basis, [****] per Detail performed hereunder by each Coley Sales Representative. COLEY shall establish an adequate computer-based system, in consultation with PFIZER,
that shall accurately record and track all Details by the Coley Sales Representatives, which system shall be subject to audit by PFIZER. No later 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 28 

 than thirty (30) days after the end of each calendar quarter, COLEY shall deliver to PFIZER a report
indicating the number of Details conducted by the Coley Sales Force during such calendar quarter. With respect to the first three calendar quarters of each year, PFIZER shall pay COLEY for such Details within twenty (20) Business Days after its
receipt of the applicable report. With respect to the last calendar quarter of each year, PFIZER shall pay COLEY for Detailing the Product as follows: (i) if the aggregate number of Details for such calendar year are less than [********************]
of the ADV for such period, then PFIZER shall not make any payment to COLEY for such calendar quarter, (ii) if the aggregate number of Details for such calendar year are between [********************] and [***************************] of the ADV for
such calendar year, then PFIZER shall, within twenty (20) Business Days after its receipt of the applicable Detail report from COLEY, pay COLEY on a per Detail basis, as set forth in the first sentence of this Section 4.10(h), for Details conducted
during such calendar quarter and (iii) if the aggregate number of Details for such calendar year are greater than [***************************] of the ADV for such period, then (x) PFIZER shall, within twenty (20) Business Days after its receipt of
the applicable Detail report from COLEY, pay COLEY on a per Detail basis, as set forth in the first sentence of this Section 4.10(h), for Details conducted during such calendar quarter that, together with the Details conducted during the previous
three calendar quarters equal [***************************] of the ADV for such calendar year and (y) PFIZER shall not make any payment to COLEY for Details conducted during such calendar quarter that are greater than [***************************]
of the ADV for such calendar year. 
  
 (i) The
Coley Sales Force will only utilize promotional, advertising, communication and educational materials, including, without limitation, all written, graphic, electronic, audio and video pieces and including journal advertisements and sales aids (i.e.,
pens, cups, note pads and the like) relating to the Product (collectively “Promotional Materials”) and only conduct promotional activities for the Product that, in each case, have been approved by PFIZER. All Detailing activities
conducted by the Coley Sales Representatives shall be consistent with the Promotional Materials so approved. PFIZER shall own all rights to all Promotional Materials, including all copyrights thereto. All Promotional Materials used in the Detailing
of the Product by COLEY for the Coley Indication shall identify COLEY as the licensor of the Product and include the logos of COLEY and PFIZER. All Promotional Materials to be used by the Coley Sales Representatives to Detail the Product for the
Coley Indication will be supplied by PFIZER at no cost to COLEY. At no time may any member of the Coley Sales Force conduct any sample drops; provided that if PFIZER’s sales representatives that are Detailing the Product are conducting
sample drops of the Product, the Coley Sales Representatives may provide business reply cards to the persons they are Detailing so that such persons may receive samples of the Product from PFIZER; such business reply cards to be supplied to COLEY by
PFIZER in reasonable quantities, at PFIZER’s cost. Any clinical trial or medical inquiries received by any member of the Coley Sales Force with respect to the Compound, any Research Compound or any Licensed Product at any time (whether in the
course of Detailing the Product or otherwise) shall be promptly referred to Pfizer Medical Information (or any successor group or division notified by PFIZER to COLEY) following receipt thereof in accordance with the 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 29 

 procedures that are agreed between the parties. PFIZER agrees to address any such inquiries referred to
it by COLEY in the same manner in which it would address similar inquiries received by PFIZER directly. 
  
 (j) All activities of COLEY in Detailing the Product shall be in accordance with the terms of this Agreement and in compliance with (i)
all applicable Laws, (ii) Code on Interactions with Healthcare Professionals (as amended from time to time) promulgated by the Pharmaceutical Research and Manufacturers of America (PhRMA), (iii) the American Medical Association Guidelines on Gifts
to Physicians, (as amended from time to time), (iv) Office of the Inspector General, Department of Health and Human Services, Compliance Program Guidance for Pharmaceutical Manufacturers (published in Federal Regulation May 5, 2003) (as amended from
time to time), and (v) all additional or future codes or guidelines adopted by PFIZER for its own promotion and detailing activities in the United States; provided that PFIZER shall notify COLEY of all such codes or guidelines adopted by
PFIZER. 
  
 (k) If at any time after COLEY has
exercised its option to Detail the Product for the Coley Indication in accordance with Section 4.10(a) and during which COLEY is actually Detailing the Product for the Coley Indication, the Product is approved for any other indication(s) which
PFIZER reasonably determines, in consultation with COLEY, is appropriate to Detail to Specialty Dermatologists, then COLEY shall also have the right to Detail the Product to Specialty Dermatologists for such indication(s) pursuant to the terms of
this Section 4.10. If PFIZER decides to Detail the Product for a new indication(s) to dermatologists in the United States, then such indication(s) shall be deemed appropriate for COLEY to Detail to Specialty Dermatologists pursuant to the terms of
this Section 4.10. 
  
 (l) For each calendar year
during which COLEY will be Detailing the Product for the Coley Indication, PFIZER shall provide COLEY with [*********************************************************************************** ************]. The [*********************] shall include
information deemed appropriate by PFIZER in its reasonable discretion and may include information relating to [************************************************************ ***************************************** ******************************].
PFIZER shall provide COLEY with [****************************] for the Product for the Coley Indication and shall update [**************] on an as-needed basis. PFIZER shall also train the Coley Sales Trainers in the use of
[********************************] and any updates thereto. PFIZER will use reasonable efforts to [********************************] it deems relevant in order to [*****************************************************************
******************************* ************************************** ************************************] in the same manner as it would treat similar indications for which [***************************]. 
  
 (m) If COLEY shall substantially fail to comply with any of
its commitments or obligations included in Sections 4.10(e), (i) and (j), as determined in accordance with 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 30 

 Section 14, then PFIZER shall have the right to terminate COLEY’s rights to Detail
the Product. In addition, if there is a Change of Control of COLEY, PFIZER shall have the right to terminate COLEY’s rights to Detail the Product. If COLEY shall fail to comply with any commitment or obligation under this Section 4.10 (other
than subsections (e), (i) and (j)), and such failure shall remain uncured at the end of the sixty (60)-day period following COLEY’s receipt of a notice from PFIZER of such failure, then PFIZER shall have the right to terminate COLEY’s
rights to Detail the Product, such termination to be effective at the expiration of such sixty (60)-day notice period. 
  
 Section 5. MILESTONE PAYMENTS AND ROYALTIES. 
  
 5.1 Event Milestone Payments. In consideration of the rights granted to PFIZER hereunder, in consideration of COLEY’s investment in the Coley
Patent Rights and Coley Technology, and subject to the terms and conditions of this Agreement, PFIZER shall make the following non-refundable payments described in this Section 5.1 to COLEY with respect to the Licensed Products (collectively, the
“Event Milestone Payments”). The payments described in Sections 5.1(a) and 5.1(b) are also non-creditable. All other Event Milestone Payments are creditable only to extent provided in Section 5.1(d)(ii) below: 
  
 (a) Fifty Million Dollars ($50,000,000), payable on the
fifth (5th) Business Day following the Effective Date [*********] of this payment is paid in consideration for the
license and development rights related to [*****************] of this payment is paid in consideration for the license and development rights related to [*******]; provided that PFIZER shall pay to COLEY interest on such amount, in accordance
with Section 6.4, for the period beginning on the Effective Date and ending on the date such payment is made at a rate equal to the seven (7) day U.S. dollar LIBOR rate effective for the Effective Date, as published by The Wall Street
Journal; 
  
 (b)
[******************************************], payable on the twentieth (20th) Business Day after [**********
*********************** *********************************************************************] and 
  
 (c) [************************************] payable on the twentieth (20th) Business Day after [***************** ***************************** *********************************************************]. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 31 

 (d) In addition to the payments outlined in Sections 5.1(a) through (c), PFIZER shall pay
to COLEY the following amounts pursuant to this Section 5.1(d) solely with respect to any ProMune Product (collectively, the “Regulatory Event Milestone Payments”) upon satisfaction in full of the applicable events described under
the column titled “Regulatory Events” (each a “Regulatory Event”) with respect to any Indication: 
  

							
	 Regulatory Events

	  	 Major
 Indication

	  	 Intermediate
 Indication

	  	 Minor
 Indication

	 (1) Acceptance for filing of [***************
 **************************************]
	  	[***********]	  	[***********]	  	[***********]
				
	 (2) Filing of an application for Regulatory Approval
 [***********************************
 ********************************************************]
	  	[***********]	  	[***********]	  	[***********]
				
	 (3) Acceptance of filing of an application for Regulatory Approval
 [***********************************
 **********************************************]
	  	[***********]	  	[***********]	  	[***********]
				
	(4) Regulatory Approval of [*********************************************************]	  	[***********]	  	[***********]	  	[***********]
				
	(5) (i) Launch in [************************************] with respect to the first Indication for a Licensed Product or (ii) the earlier of (x) first detail in such countries by a sales
representative of a subsequent indication for a Licensed Product and (y) publication of the first advertisement in such countries for a subsequent indication for a Licensed Product, in the case of each of clauses (x) and (y), after payment has been
made to COLEY pursuant to clause (i) for such Licensed Product (the event in clause (ii) being a “Subsequent Launch”)	  	[***********]	  	[***********]	  	[***********]
				
	(6) (i) Launch in [*****] with respect to the first Indication for a Licensed Product or (ii) a Subsequent Launch	  	[***********]	  	[***********]	  	[***********]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 32 

 (i) Payment. PFIZER shall pay to COLEY the applicable Regulatory Event Milestone
Payments on or prior to the twentieth (20th) Business Day following the occurrence of the applicable Regulatory
Event and will identify whether the ProMune Product for which the Regulatory Milestone Event Payment is due is a Product, Combination Product or Vaccine Product. 
  
 (ii) Limitations. Each of PFIZER and COLEY acknowledge and agree that: 
  
 (A) Notwithstanding anything to the contrary contained
herein, all ProMune Products for any single Tumor Type shall be treated as if they were a single ProMune Product for purposes of calculating the amount of any Regulatory Event Milestone Payments payable by PFIZER to COLEY and, therefore, subject to
Section 5.1(d)(ii)(B) below, any Regulatory Event Milestone Payment payable upon satisfaction in full of a given Regulatory Event shall only be paid once for any single Tumor Type, regardless of how many ProMune Products satisfy such Regulatory
Event within such Tumor Type. 
  
 (B) With
respect to all ProMune Products for a single Tumor Type that satisfy in full a Regulatory Event: (x) the aggregate Regulatory Event Milestone Payments for all such ProMune Products for any one Regulatory Event that PFIZER shall pay to COLEY shall
not exceed the amount payable for a Major Indication for the applicable Regulatory Event; and (y) if PFIZER satisfies in full a Regulatory Event for an Intermediate Indication for such Tumor Type prior to satisfying in full a Regulatory Event for a
Major Indication for the same Tumor Type, the Regulatory Event Milestone Payment that shall be payable as a result of the satisfaction in full of such Regulatory Event for the Major Indication shall be equal to the difference between (A) the amount
of the Regulatory Event Milestone Payment payable with respect to the satisfaction in full of such Regulatory Event for the Major Indication and (B) the amount of the Regulatory Event Milestone Payment previously paid with respect to the
satisfaction in full of such Regulatory Event for the Intermediate Indication. 
  
 (C) Notwithstanding anything to the contrary contained herein, all Minor Indications for all ProMune Products shall be treated as if they
were a single ProMune Product for purposes of calculating the amount of any Regulatory Event Milestone Payments payable by PFIZER to COLEY and, therefore, for the avoidance of doubt, the aggregate maximum amount of Regulatory Event Milestone
Payments that PFIZER shall pay to COLEY for the satisfaction in full of all Regulatory Events with respect to all Minor Indications shall be [************************** ******************************************] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 33 

 (D) Notwithstanding anything to the contrary contained herein, the aggregate maximum
amount of Regulatory Event Milestone Payments that PFIZER shall pay to COLEY for the satisfaction in full of all Regulatory Events in all Indications for all ProMune Products shall be [***********************************************
*********************] (the “Milestone Ceiling”). Following the payment by PFIZER to COLEY of Regulatory Event Milestone Payments for all ProMune Products that, in the aggregate, equal the Milestone Ceiling, PFIZER shall have no
further payment obligations to COLEY under Section 5.1(d). For the avoidance of doubt, the Milestone Ceiling amount is exclusive of (i) the Event Milestone Payments set forth in Sections 5.1(a), (b) and (c) (ii) the Research Milestone Payments set
forth in Section 5.1 (e) and (iii) the Commercial Milestone Payment (as defined in Section 5.2 below). 
  
 (iii) Skipped Milestone Payments. If any of Regulatory Events (1), (2) or (3) as specified in the table in Section 5.1(d) for a
given Indication and ProMune Product is achieved without triggering an Event Milestone Payment pursuant to Section 5.1(b) or Section 5.1(c) for the same Indication and the same ProMune Product (each, a “Skipped ProMune Milestone
Payment”), then PFIZER shall pay to COLEY both the Skipped ProMune Milestone Payment and the Regulatory Event Milestone Payment on the date that such Regulatory Event Milestone Payment is due. 
  
 (e) Research Milestone Payments In addition to the
payments outlined in Sections 5.1(a) through (d), PFIZER shall pay to COLEY the following amounts pursuant to this Section 5.1(e) with respect to each of the Research Compounds (collectively, the “Research Compound Milestone
Payments”) upon satisfaction in full of the applicable events described under the column titled “Research Regulatory Events” (each a “Research Regulatory Event”). The Research Compound Milestone Payments shall
only be paid once per Research Compound per Research Regulatory Event, without regard to the Indication, number of Indications for which such Licensed Product containing the Research Compound is approved or whether a Research Product, Research
Combination Product or Research Vaccine Product is involved. PFIZER shall pay to COLEY the Research Compound Milestone Payments pursuant to this Section 5.1(e) even if the Milestone Ceiling set forth in Section 5.1(d)(ii)(D) has been met.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 34 

			
	 Research Regulatory Events

	  	 First Licensed
Product Containing
 each Research
 Compound

	 (1) Acceptance for filing of
 [****************************
 *****************************
 *******************************************]
	  	[**********]
		
	 (2) Commencement of [**********
 ******************************
 *********************************************]
	  	[**********]
		
	 (3) Acceptance of filing of [*********************
 *********************************************
 **********************************************
 *********************************]
	  	[**********]
		
	 (4) [*******] (i) [**************************
 *************************] (ii) [*************
 *******************************************
 *******************************************]
 (iii) [***************************************
 *********************************]
	  	[**********]

  
 (i)
Payment. PFIZER shall pay to COLEY the applicable Research Compound Milestone Payments on or prior to the twentieth (20th) Business Day following the occurrence of the applicable Research Regulatory Event and will identify the Research Compound for which the Research Compound Milestone Payment is due. 
  
 (ii) Skipped Research Milestone Payments. If Research
Regulatory Event (3) for a given Research Compound is achieved without triggering Research Compound Milestone Payment (2) for the same Research Compound, then PFIZER shall pay to COLEY both Research Compound Milestone Payments (2) and (3) on the
date that Research Compound Milestone Payment (3) is due for such Research Compound. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 35 

 5.2 Commercial Milestone Payment. In addition to the Event Milestone Payments, in consideration of
the rights granted to PFIZER hereunder, and subject to the terms and conditions of this Agreement, PFIZER shall pay to COLEY a non-refundable and non-creditable milestone payment of [*****************************************] (the
“Commercial Milestone Payment”) if during the period beginning on the date of the Launch of the first Licensed Product and ending on the tenth anniversary thereof, the aggregate Net Sales of all Licensed Products exceeds
[********************************************] in any period consisting of four (4) consecutive Pfizer Quarters (i.e. rolling annual sales of more than [***********]. PFIZER shall pay to COLEY the Commercial Milestone Payment within sixty (60) days
after the end of the relevant Pfizer Quarter. For the avoidance of doubt, the Commercial Milestone Payment shall only be paid once. 
  
 5.3 Royalty Payments. In addition to the payments under Sections 5.1 and 5.2, PFIZER shall pay to COLEY, in consideration for the licenses granted
to PFIZER under the Coley Patent Rights and the Coley Technology with respect to the Licensed Products as further described herein, and subject to the terms and conditions of this Agreement PFIZER shall pay to COLEY the following royalties
(collectively, the “Royalty Payments”): 
  
 (a) Product Royalties. 
  
 (i) Patent Royalties. In accordance with Section 5.4, PFIZER shall, on a country-by-country basis, pay to COLEY with respect to each Product embraced by a Valid Claim in such country: (x) a royalty of
[***************] of the Net Sales of each such Product for the portion of such Net Sales in the Territory in a Pfizer Year below or equal to [********************************] and (y) a royalty of [*******************] of the Net Sales of each such
Product for the portion of such Net Sales in the Territory in a Pfizer Year in excess of [********************] (the royalty rates in clauses (x) and (y) being referred to as the “Base Patent Royalty Rates”). Notwithstanding
anything to the contrary contained herein: (A) for the period beginning on the Effective Date and ending on the last day of Pfizer Year [******] the Sales of [******************************************************************************** ********
************************************* ***] for the purpose of determining whether Net Sales of [**********************] has been achieved in the Territory in any Pfizer Year and PFIZER shall pay to COLEY royalties on [*************] at the Base
Royalty Rate (as defined below), [*************]; and (B) thereafter, the [***************] shall be calculated [***************************************************************] for the purpose of determining whether Net Sales of
[************************] has been achieved in the Territory in any Pfizer Year, and PFIZER shall pay to COLEY royalties on Net Sales of [*****************************] from [**************************************** 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 36 

 *****************************************************] and [********************] at the Base Royalty
Rate. 
  
 (ii) Coley Know-How Royalties.
In accordance with Section 5.4, PFIZER shall pay to COLEY a royalty of [****************] (the “Base Know-How Royalty Rate”) of Net Sales of all ProMune Products in the Territory in a Pfizer Year. 
  
 (b) Combination Product and Vaccine Product
Royalties. In accordance with Section 5.4, PFIZER shall pay to COLEY royalties on Net Sales of each Combination Product and Vaccine Product as follows: (x) for the period beginning on the Effective Date and ending on the last day of Pfizer Year
[*********] the Net Sales [******************** 
 *****] and [********************************************************************] for the
purpose of determining whether Net Sales of [************************************] Net Sales has been achieved in the Territory in 
 any
Pfizer year and Pfizer shall pay to Coley royalties on [***************] at the Base Royalty Rate. [***************]; and (y) thereafter, the Net Sales of [***********] and [********************] shall be calculated [******************* 

************************] for purposes of determining whether Net Sales of [**********************] has been achieved in the Territory in any Pfizer
year, and PFIZER shall pay to COLEY royalties on [*************************** 
 *******************************] as follows: 
  
 (i) Where Pfizer Substances Involved. For any
Combination Product or Vaccine Product that contains the Compound and a Pfizer Substance, in accordance with Section 5.4, PFIZER shall pay to COLEY royalties on Net Sales of each such Combination Product or Vaccine Product at a royalty rate equal to
the sum of (x) the applicable Base Patent Royalty Rate (determined by whether Net Sales for such Combination Product or Vaccine Product exceed [***************************************] and (y) the applicable Base Know-How Royalty Rate (such sum, the
“Base Royalty Rate”) but adjusted as set forth below: 
  
 (A) If Market Prices are available separately for both pharmaceutical products that contain as the sole active ingredient (i) the Compound and (ii) the Pfizer Substance, then the royalty rate used to determine the
amount of royalties payable by PFIZER to COLEY on Net Sales of such Combination Product or Vaccine Product, as applicable, shall be calculated by (x) adding together the appropriate per-unit or per dosage Market Price of each such pharmaceutical
product containing the Compound and the Pfizer Substance that is also contained in such Combination Product or Vaccine Product (the “Combination Price”), (y) calculating the ratio of the applicable Compound price to the Combination
Price and (z) multiplying (i) the Net Sales of such Combination Product or Vaccine Product, as applicable, by (ii) the ratio referred to in clause (y) and by (iii) the Base Royalty Rate; provided that
[******************************************************** **************************** 
 *****] of the product of (I) the Net Sales of such
Combination Product or Vaccine Product, as applicable and (II) the Base Royalty Rate, without taking into account the adjustments required by this Section 5.3(b)(i)(A). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 37 

 (B) If Market Prices are not available separately for either or both of the
pharmaceutical products that contain as the sole active ingredient (i) the Compound and (ii) the Pfizer Substance, then the royalty rate used to determine the amount of royalties payable by PFIZER to COLEY on Net Sales of such Combination Product or
Vaccine Product, as applicable, shall be equal to the Base Royalty Rate, minus [**] and the Royalty Payment shall be calculated by multiplying such rate by the Net Sales of such Combination Product or Vaccine Product, as applicable. 
  
 (C) Notwithstanding the foregoing, if any Combination
Product or Vaccine Product contains a substance owned or controlled by PFIZER or any of its Affiliates and such substance or compound enhances the therapeutic effect of the Compound included in such Combination Product or Vaccine Product, as
applicable, but is not itself an independently therapeutically active substance, then the royalty rate used to determine the amount of royalties payable by PFIZER to COLEY on Net Sales of such Combination Product or Vaccine Product, as applicable,
shall and, therefore [**********************]. 
  
 (ii) Where Pfizer Substances Not Involved. For any Combination Product or Vaccine Product that contains the Compound and either (A) an independently therapeutically active substance or (B) a substance that enhances the therapeutic
effect of the Compound, in either case, where such substance is not a Pfizer Substance (such substance, a “Third Party Substance”), in accordance with Section 5.4, PFIZER shall pay to COLEY royalties on Net Sales of each such
Combination Product or Vaccine Product at a royalty rate equal to the Base Royalty Rate, but adjusted as set forth below: 
  
 (A) If Market Prices are available separately for both pharmaceutical products that contain as the sole active ingredient (i) the
Compound and (ii) the Third Party Substance, then the royalty rate used to determine the amount of royalties payable by PFIZER to COLEY on Net Sales of such Combination Product or Vaccine Product, as applicable, shall be calculated by (x) adding
together the appropriate per-unit or per dosage Market Price of each such pharmaceutical product containing the Compound and the Third Party Substance that is also contained in such Combination Product or Vaccine Product (the “Third Party
Combination Price”), (y) calculating the ratio of the applicable Compound price to the Third Party Combination Price, and (z) multiplying (i) the Net Sales of such Combination Product or Vaccine Product, as applicable, by (ii) the ratio
referred to in clause (y) and by (iii) the Base Royalty Rate, provided that [******************************************************* **********************] of the of the product of (I) Net Sales of such Combination Product or Vaccine Product, as
applicable, and (II) the Base Royalty Rate before taking into account the adjustments required by this Section 5.3(b)(ii)(A). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 38 

 (B) If (i) Market Prices are not available separately for either or both of the
pharmaceutical products that contain as the sole active ingredient the Compound and the Third Party Substance and (ii) PFIZER or any Affiliate licenses or otherwise acquires from any Third Party any patents, know-how or other intellectual property
relating to any Third Party Substance that are required in order to make, have made, use, sell, offer to sell or import such Third Party Substance as part of such Combination Product or Vaccine Product, then the royalty rate used to determine the
amount of royalties payable by PFIZER to COLEY on Net Sales of such Combination Product or Vaccine Product, as applicable, shall be equal to the difference between (x) the product of (I) the Base Royalty Rate and (II) the applicable Net Sales of
such Compound Product or Vaccine Product, minus (y) 100% of any and all royalties paid by PFIZER to any Third Party in any applicable Pfizer Year solely for the use of such Third Party Substance in the Combination Product or Vaccine Product;
provided that [*********************************************** 
 **********************************************] of the product of
(aa) the Net Sales of such Combination Product or Vaccine Product, as applicable, and (bb) the Base Royalty Rate, without taking into account the adjustments required by this Section 5.3(b)(ii)(B). 
  
 (c) Research Product Royalties. 
  
 (i) Patent Royalties. In accordance with Section
5.4, PFIZER shall pay to COLEY royalties on Net Sales of each Research Product as follows: (x) from the period beginning on the Effective Date and ending on the last day of Pfizer Year [*******] the Net Sales of[***********************] shall be
[******************] for the purpose of determining whether Net Sales of [**********************************************] in the has been achieved in the Territory in any Pfizer Year, and PFIZER shall pay to COLEY royalties [******************] at
the Base Royalty Rate, [****************************] and (y) thereafter, the [**********] of [***********************] shall be calculated without [********************************************* ********************] for the purpose of determining
whether Net Sales of [**************] has been achieved in the Territory in any Pfizer Year, and PFIZER shall pay to COLEY royalties on [************] as follows: with respect to [************************]: (i) a royalty of [****************] of the
aggregate Net Sales of all such Research Products for the portion of such Net Sales in the Territory in a Pfizer Year below or equal to [**************************************] and (ii) a royalty of [******************] of the aggregate Net Sales of
all such Research Products for the portion of such Net Sales in the Territory in a Pfizer Year in excess of [**************************************] (the royalty rates in clauses (x) and (y) being referred to as the “Research Product Base
Patent Royalty Rates”. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 39 

 (ii) Coley Know-How Royalties. In accordance with Section 5.4, PFIZER shall pay
to COLEY a royalty on Net Sales of all Research Products, Research Combination Products or Research Vaccine Products, as applicable, in the Territory in a Pfizer Year based on [*******************************************************]. 
  
 (d) Research Combination Product and Research Vaccine
Product Royalties. In accordance with Section 5.4, PFIZER shall pay to COLEY royalties on Net Sales of each Research Combination Product and Research Vaccine Product as follows: (x) for the period beginning on the Effective Date and ending on
the last day of Pfizer Year [****] the Net Sales of [*************************] and [************************** ***************************************** **********] for the purpose of determining whether Net Sales of [***********************] has
been achieved in the Territory in any Pfizer Year, and PFIZER shall pay to COLEY royalties on [*****************] at the Base Royalty Rate, [******************************] and (y) thereafter, the Net Sales of [*****************************] and
[************************************************************************************] for the purpose of determining whether Net Sales of [************************] has been achieved in the Territory in any Pfizer Year, and PFIZER shall pay to
COLEY royalties on [**************************************] and [****************** *********] separately, as follows: 
  
 (i) Where Pfizer Substances Involved. For any Research Combination Product or Research Vaccine Product that contains a Research
Compound and a Pfizer Substance, in accordance with Section 5.4, PFIZER shall pay to COLEY royalties on Net Sales of each such Research Combination Product or Research Vaccine Product at a royalty rate equal to the sum of (x) the applicable Research
Product Base Patent Royalty Rate and (y) the Base Know-How Royalty Rate (such sum, the “Base Research Product Royalty Rate”), but adjusted as set forth below: 
  
 (A) If Market Prices are available separately for both pharmaceutical products that contain as the sole
active ingredient (i) the Compound and (ii) the Pfizer Substance, then the royalty rate used to determine the amount of royalties payable by PFIZER to COLEY on Net Sales of such Research Combination Product or Research Vaccine Product, as
applicable, shall be calculated by (x) adding together the appropriate per-unit or per dosage Market Price of each such pharmaceutical product containing the Compound and the Pfizer Substance that is also contained in such Research Combination
Product or Research Vaccine Product (the “Research Combination Price”), (y) calculating the ratio of the applicable Compound price to the Research Combination Price, and (z) multiplying (i) the Net Sales of such Research Combination
Product or Research Vaccine Product, as applicable by (ii) the ratio referred to in clause (y) by (iii) the applicable Research Product Base Royalty Rate, provided that 
 [******************************************************************************************* 
 ****] of the Net Sales of such Research Combination Product or Research Vaccine Product, as applicable. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 40 

 (B) If Market Prices are not available separately for either or both of the
pharmaceutical products that contain as the sole active ingredient (i) Compound and (ii) the Pfizer Substance, then the royalty rate used to determine the amount of royalties payable by PFIZER to COLEY on Net Sales of such Research Combination
Product or Research Vaccine Product, as applicable, shall be [***********************************] and the Royalty Payment shall be calculated by multiplying such rate by the Net Sales of such Research Combination Product or Research Vaccine
Product, as applicable. 
  
 (C) Notwithstanding
the foregoing, if any Research Combination Product or Research Vaccine Product contains a substance owned or controlled by PFIZER or any of its Affiliates and such substance enhances the therapeutic effect of the Compound included in such Research
Combination Product or Research Vaccine Product, as applicable, but is not itself an independently therapeutically active substance, then the royalty rate used to determine the amount of royalties payable by PFIZER to COLEY on Net Sales of such
Research Combination Product or Research Vaccine Product [******************] and, therefore, [*****************] to the [******************************** *******]. 
  
 (ii) Where Pfizer Substances Not Involved. For any Research Combination Product or Research Vaccine
Product that contains the Compound and a Third Party Substance, in accordance with Section 5.4, PFIZER shall pay to COLEY royalties on Net Sales of each such Research Combination Product or Research Vaccine Product at a royalty rate equal to the
applicable Base Research Product Royalty Rate but adjusted as set forth below: 
  
 (A) If Market Prices are available separately for both pharmaceutical products that contain as the sole active ingredient (i) the
Compound and (ii) the Third Party Substance, then the royalty rate used to determine the amount of royalties payable by PFIZER to COLEY on Net Sales of such Research Combination Product or Research Vaccine Product, 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 41 

 as applicable, shall be calculated by (x) adding together the appropriate per-unit or per dosage Market
Price of each such pharmaceutical product containing the Compound and the Third Party Substance that is also contained in such Research Combination Product or Research Vaccine Product (the “Third Party Combination Research Price”),
(y) calculating the ratio of the applicable Compound price to the Third Party Combination Research Price, and (z) multiplying (i) the Net Sales of such Research Combination Product or Research Vaccine Product, as applicable by (ii) the ratio
referred to in clause (y) by (iii) the applicable Base Research Product Royalty Rate; provided that [******************************************************************************************] of the Net Sales of such Research Combination
Product or Research Vaccine Product, as applicable. 
  
 (B) If (i) Market Prices are not available separately for either or both of the pharmaceutical products that contain as the sole active ingredient the Compound and the Third Party Substance on a separate, stand-alone basis and (ii) PFIZER
or any Affiliate licenses or otherwise acquires from any Third Party any patents, know-how or other intellectual property allowing for the use of any Third Party Substance that are required in order to make, have made, use, sell, offer to sell or
import the Third Party Substance as part of such Research Combination Product or Research Vaccine Product, then the royalty rate used to determine the amount of royalties payable by PFIZER to COLEY on Net Sales of such Research Combination Product
or Research Vaccine Product shall be equal to the difference between (x) the product of the applicable Base Research Product Royalty Rate and the applicable Net Sales of such Research Compound Product or Research Vaccine Product minus (y)
100% of any and all royalties paid to any Third Party in any applicable Pfizer Year solely for the use of such Third Party Substance in the Research Combination Product or Research Vaccine Product; provided that
[**************************************************** ***************************************************] of the Net Sales of such Research Combination Product or Research Vaccine Product, as applicable. 
  
 (e) Royalties on [****************]. If at any time
the only Valid Claim under the Coley Patent Rights embracing a Licensed Product is a [****************], then PFIZER shall pay to COLEY royalties on Net Sales of such Licensed Product at a rate equal to the sum of applicable Research Product Base
Patent Royalty Rate and the Base Know-How Royalty Rate in accordance with Section 5.3(c). 
  
 (f) Existing Agreements. COLEY shall be responsible for and shall pay, in full, all royalties and other amounts owed under
agreements to which COLEY is a party as of the Effective Date which relate to Licensed Products, including, without limitation, the OHRI License Agreement and the UIRF License Agreement. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 42 

 5.4 Duration of Royalty Payments. 
  
 (a) Coley Know-How Royalties. With respect to Net Sales of any Licensed Product sold in any country
in the Territory, PFIZER shall pay to COLEY Royalty Payments on Net Sales of Licensed Products that are based on the [*********** 
 **********] pursuant to Sections 5.3(a)(ii) and 5.3(c)(ii) until the [*******] (i) [********************* ************************************************************************************************* ***********************] or (ii)
[****************************************************************** 
 **********************]; it being understood and agreed that PFIZER
shall thereafter have a royalty-free, exclusive, perpetual, license to the applicable Coley Technology with respect to such Licensed Product in such country in the Field. For the avoidance of doubt, in countries where there is no Valid Claim
embracing the applicable Licensed Product when such Licensed Product is Launched in such country, PFIZER shall pay to COLEY Royalty Payments on Net Sales of such Licensed Product that are based on the [******************************] pursuant to
Sections 5.3(a)(ii) and 5.3(c)(ii) [****************** *********************************************************************************************]; 
 it being understood and agreed that PFIZER shall thereafter have a royalty-free, exclusive, perpetual, license to the applicable COLEY Technology with respect to such Licensed Product in such country in the Field.

  
 (b) Coley Patent Right Royalties. With
respect to Net Sales of any Licensed Product sold in any country in the Territory, PFIZER shall pay to COLEY Royalty Payments on Net Sales of such Licensed Product on a country-by-country and a Licensed Product-by-Licensed Product basis in
accordance with Section 5.3 until the [******************************* ********************************************************************************************* *****************]; provided that (x) if, at any time, the Generic Market
Share for the Generic Product with respect to such Licensed Product is [*********************************************] then the Base Patent Royalty Rates or the Base Research Product Patent Royalty Rates, as applicable, shall be reduced by [***] and
(y) if, at any time, the Generic Market Share for the Generic Product with respect to such Licensed Product [******************************] then the Base Patent Royalty Rates or the Base Research Product Royalty Rates, as applicable shall be
reduced by [***]. 
  
 5.5 Limits on Royalty Payment
Reductions. The parties agree that (i) in no event will the applicable Base Patent Royalty Rate or the applicable Research Product Base Patent Royalty Rate, as the case may be, used to calculate Royalty Payments on Net Sales of any Licensed
Product be reduced by more than [***] as a result of the application of both Section 5.4(b) and Section 13.2(a) at any given time and (ii) at any given time, each of Section 5.3(b) and Section 5.3(d) may be applied at the same time as either of
Section 5.4(b) or Section 13.2(a) and in any such case, the applicable provisions for each such Section shall be applied in accordance with their terms. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 43 

 Section 6. ACCOUNTING AND PROCEDURES FOR PAYMENT. 
  
 6.1 Inter-Company Sales. Sales between or among PFIZER, its
Affiliates or sublicensees shall not be subject to Royalty Payments; Royalty Payments shall only be calculated with respect to Net Sales to a Third Party. PFIZER shall be responsible for royalty payments payable to COLEY on Net Sales by its
Affiliates or sublicensees. 
  
 6.2 Calculation of Net
Sales. 
  
 (a) All Royalty Payments shall be
computed and paid in United States dollars. For the purpose of determining the amount of Royalty Payments due for the relevant Pfizer Quarter, the amount of Net Sales in any foreign currency shall be converted into United States Dollars in a manner
consistent with the methodology used to prepare PFIZER’s audited financial statements for external reporting purposes. 
  
 (b) For the purpose of determining whether the Commercial Milestone Payment is payable, the amount of Net Sales in any foreign currency
for the relevant Pfizer Quarter shall be converted to United States Dollars in a manner consistent with the methodology used to prepare PFIZER’s audited financial statements for external reporting purposes. 
  
 6.3 Royalty Payments. PFIZER shall make Royalty Payments with respect
to each Pfizer Quarter within sixty (60) days after the end of each such period, and each payment shall be accompanied by a report identifying the Licensed Product as either a Product, Combination Product, Vaccine Product, Research Product, Research
Combination Product or Research Vaccine Product, the country, Net Sales for each such country, and the amounts payable to COLEY, as well as computation thereof. Said reports shall be deemed Pfizer Confidential Information and not disclosed to any
other party, other than COLEY’s accountants, and such information and reports shall only be used for purposes of this Agreement; provided that, to the extent required by the UIRF License Agreement and the OHRI License Agreement, Coley
shall be permitted to disclose summaries of reports provided under this Section 6.3 by PFIZER to COLEY, subject to appropriate confidentiality agreements, to each of UIRF and OHRI. 
  
 6.4 Method of Payments. All payments hereunder shall be made by electronic transfer in immediately available funds
via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at PFIZER’s election, to Fleet Bank, 100 Federal Street, Boston, MA 02110, Account No.: 9428418652, Account Name:
Coley Pharmaceutical Group, Inc., ABA No.: 011-000-138, or to such other bank accounts as COLEY shall designate in writing at least five (5) Business Days before the payment is due. All payments under this Agreement shall bear interest from the date
due until paid at a rate equal to the thirty (30) day U.S. dollar LIBOR rate effective for the date that payment was due, as published by The Wall Street Journal. 
  
 6.5 Inspection of Records. PFIZER shall, and shall cause its Affiliates and sublicensees to, keep accurate books and
records setting forth gross sales of each Licensed Product, Net Sales of each Licensed Product, the deductions used to calculate Net Sales and amounts payable hereunder to COLEY for each such Licensed Product. PFIZER shall permit 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 44 

 COLEY, by independent qualified public accountants employed by COLEY and reasonably acceptable to PFIZER, to examine such
books and records at any reasonable time upon reasonable notice, but not later than three (3) years following the rendering of any corresponding reports, accountings and payments pursuant to Section 6.3. The foregoing right of examination may be
exercised only once during any twelve (12)-month period. If any such examination shows an underpayment of more than five percent (5%) of the amount due for any applicable period, COLEY shall have the right, by independent qualified public
accountants employed by COLEY and reasonably acceptable to PFIZER, to conduct an additional examination of the sales and royalty books and records to determine if the cause of the underpayment has been corrected. Any such examination shall be in
addition to COLEY’s annual right to examine such books and records and must be conducted during the twelve (12)-month period immediately following the completion of the examination which identified the underpayment of more than five percent
(5%). Such accountants may be required by PFIZER to enter into a reasonably acceptable confidentiality agreement, and in no event shall such accountants disclose to COLEY any information, other than such information as relates to the accuracy of
reports and payments made or due hereunder. The opinion of such accountants regarding such reports, accountings and payments shall be binding on the parties, other than in the case of manifest error. COLEY shall bear the cost of any such
examination; provided that if the examination shows an underpayment of Royalty Payments of more than five percent (5%) of the amount due for the applicable period, then PFIZER shall promptly reimburse COLEY for all costs incurred in
connection with such examination. PFIZER shall promptly pay to COLEY the amount of any underpayment of Royalty Payments (plus interest as provided in Section 6.4 above) revealed by an examination and review. Any overpayment of Royalty Payments by
PFIZER revealed by an examination shall be fully creditable against future Royalty Payments due under Section 5.3. 
  
 6.6 Tax Matters. It is understood and agreed between the parties that any milestone payments made pursuant to Section 5.1 or 5.2 of this Agreement
are inclusive of any value added tax imposed upon such payments. In addition, if any of the payments made by PFIZER pursuant to Section 5 become subject to withholding taxes under the Laws of any jurisdiction, PFIZER shall deduct and withhold the
amount of such taxes for the account of COLEY to the extent required by Law, all such amounts payable to COLEY shall be reduced by the amount of taxes deducted and withheld, and PFIZER shall pay the amounts of such taxes to the proper Governmental
Authority in a timely manner and promptly transmit to COLEY an official tax certificate or other evidence of such tax obligations, together with proof of payment from the relevant Governmental Authority of all amounts deducted and withheld
sufficient to enable COLEY to claim such payment of taxes. If any such withholding tax shall become payable as a result of an assignment by either party (as permitted by Section 15.7), then the assigning party shall promptly notify the other party
of such assignment. COLEY shall provide to PFIZER any tax forms (including, without limitation, Internal Revenue Service Forms W-9 and W-8BEN) that may be reasonably necessary in order for PFIZER to not withhold tax or to withhold tax at a reduced
rate under an applicable bilateral income tax treaty. COLEY shall use reasonable efforts to provide any such tax forms to PFIZER at least thirty (30) days prior to the due date for any payment for which COLEY desires that PFIZER apply a reduced
withholding tax rate. Any such withholding taxes required under applicable Law to be paid or withheld shall be an expense of, and borne solely by, COLEY. PFIZER will provide COLEY with reasonable assistance to enable COLEY to recover such taxes as
permitted by Law.  
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 45 

 Section 7. PATENTS AND INFRINGEMENT. 
  
 7.1 Filing and Prosecution of Patents. COLEY and PFIZER shall cooperate in connection with the continued prosecution
and maintenance by COLEY of the patents under the Coley Patent Rights applicable to the Field, with COLEY having responsibility for such activities. [*********************************************************************************************
*******************************************************]. If PFIZER desires that COLEY file any application for a patent on improvements and variations upon inventions disclosed in the patents under the Coley Patent Rights applicable to the Field or
otherwise relating to the Compound, any Research Compound or any Licensed Product, PFIZER shall advise COLEY of such improvements, variations or inventions. Provided that COLEY has no reasonable objection thereto, COLEY shall thereupon file patent
applications as requested, and PFIZER shall pay reasonable, out-of-pocket expenses, including reasonable fees for outside patent counsel, for filing and prosecuting such requested patent applications. COLEY shall consult PFIZER and keep PFIZER
informed of all material matters relating to the preparation, filing, prosecution and maintenance of Coley Patent Rights applicable to the Field, including, without limitation, any matters relating to the matter set forth on Schedule
10.1(a)(ii). In addition, COLEY shall provide PFIZER with copies of all material correspondence with all applicable patent offices in such a manner as to allow PFIZER a meaningful opportunity to comment, and PFIZER shall have reasonable access
to all documentation, filings and communications to or from the applicable patent offices. COLEY, its agents and its attorneys shall give due consideration to all suggestions and comments of PFIZER regarding any aspect of such patent preparation,
filing, prosecution and maintenance. In addition, COLEY shall take all necessary steps to maintain for the full life thereof all patents under the Coley Patent Rights applicable to the Field. With respect to reasonable out-of-pocket costs in
connection with the prosecution and maintenance of the Coley Patent Rights applicable to the Field, PFIZER shall pay [****] of such costs for those patents listed in Section I of Exhibit A attached hereto and [****] of such costs for all
other Coley Patent Rights applicable to the Field. In addition, if, at any time, COLEY licenses or otherwise transfers to a Third Party any Rejected Program ODN (as defined in the Screening and Evaluation Agreement) or any Rejected Candidate ODN (as
defined in the Screening and Evaluation Agreement), COLEY shall reimburse PFIZER for [****] of PFIZER’s reasonable out-of-pocket costs incurred by PFIZER in connection with the prosecution, filing and maintenance of the Coley Patent Rights that
relate to the Rejected Program ODN Patent Rights (as defined in the Screening and Evaluation Agreement) and Rejected Candidate ODN Patent Rights (as defined in the Screening and Evaluation Agreement), as applicable. Prosecution of the Coley Patent
Rights includes all activities before patent offices throughout the world and appeals therefrom. 
  
 7.2 Maintenance of Patents. COLEY agrees that it will, and will cause its Affiliates to, (i) execute and file those notices and other filings as
PFIZER shall request be made, from time to time with the United States Patent and Trademark Office (or any successor agency) with respect to the rights granted under this Agreement, (ii) maintain at all times during the term of this Agreement the
rights to the Coley Patent Rights and the Coley Technology, necessary and sufficient to perform COLEY’s obligations under this Agreement; free and clear of any liens, encumbrances, charges, security interests, mortgages, liabilities or grants
of license to Third Parties or other restrictions, and (iii) as a condition to any transfer of any Coley Patent Rights applicable to the Field or Coley Technology applicable to the Field on and after the date hereof to 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 46 

 any Affiliate (to the extent permitted in this Agreement), require such Affiliate to be obligated to perform all of
COLEY’s obligations relating to the transferred Coley Patent Rights applicable to the Field or Coley Technology applicable to the Field under this Agreement as if it were a party hereto. 
  
 7.3 Patent Term Extensions. PFIZER shall have the right to designate
and to seek, or have COLEY seek, at PFIZER’s expense, patent term extensions or supplemental patent protection in any country in the Territory with respect to the Coley Patent Rights relating to the Licensed Products. 
  
 7.4 Interpretation of Patent Judgments. If any claim relating to a
patent under the Coley Patent Rights becomes in any country the subject of a judgment, decree or decision of a court, tribunal, or other authority of competent jurisdiction, which judgment, decree, or decision is or becomes final (there being no
further right of review) and adjudicates the validity, enforceability, scope, or infringement of the same, the construction of such claim in such judgment, decree or decision shall be followed thereafter in such country in determining whether a
product is licensed hereunder, not only as to such claim but also as to all other claims in the Territory to which such construction reasonably applies. If at any time there are in any country two or more conflicting final judgments, decrees, or
decisions with respect to the same claim, the decision of the higher tribunal shall thereafter control in such country, but if the tribunal be of equal rank, then the final judgment, decree, or decision more favorable to such claim shall control
unless and until the majority of such tribunals of equal rank adopt or follow a less favorable final judgment, decree, or decision, in which event the latter shall control.  
  
 7.5 Infringement Actions.  
  
 (a) COLEY and PFIZER shall promptly notify each other of any infringement of or unauthorized use of any
Coley Patent Rights in the Field or Coley Technology in the Field which may come to their attention to the extent that such infringement or unauthorized use relates to the Compound, any Research Compound or any Licensed Product. Subject to Section
7.5(b) below, PFIZER has the exclusive right, at its sole discretion and expense, to elect to undertake legal action with respect to any such infringement or unauthorized use or bring suit against any such infringer or unauthorized user. Any suit by
PFIZER shall be either in the name of PFIZER, the name of COLEY, or jointly by PFIZER and COLEY, as may be required by the law of the forum. COLEY, upon request of PFIZER and at PFIZER’s expense, agrees to join any such suit and agrees to use
diligent efforts to obtain the joinder of any Third Parties as may be legally necessary or advisable, as determined by PFIZER. For this purpose, COLEY shall execute such legal papers and participate as necessary for the prosecution of such suit as
may be reasonably requested by PFIZER. In addition, COLEY, at its option and at its own expense, shall have the right to participate in any such suit relating to the Field. 
  
 (b) If PFIZER determines not to pursue an action with respect to any Third Party infringement or
unauthorized use of Coley Patent Rights in the Field or Coley Technology in the Field within 120 days after notice from COLEY, then COLEY may, in its sole discretion and expense, (i) obtain a discontinuance of the alleged infringing operation or
unauthorized use or (ii) undertake legal action with respect to such Third 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 47 

 Party. Subject to legally privileged information, PFIZER shall inform COLEY of the
circumstance of such infringement or unauthorized use, to the extent known by PFIZER, including such evidence of infringement or unauthorized use as PFIZER may possess and the numbers of the patents and patent applications so infringed or Coley
Technology misused. Any suit by COLEY shall be either in the name of COLEY, or jointly by COLEY and PFIZER, as may be required by the law of the forum. For this purpose, PFIZER shall execute such legal papers necessary for the prosecution of such
suit as may be reasonably requested by COLEY.  
  
 (c) It is understood and agreed that the party to this Agreement that institutes the suit or action under this Section 7.5 shall bear solely all of its costs and expenses associated therewith. If PFIZER institutes the claim or suit, then
COLEY shall be entitled to receive [******************] of any and all sums received, obtained, collected or recovered whether by judgment, settlement or otherwise from a Third Party based upon any such claim or suit after deducting PFIZER’s
out-of-pocket expenses (including, without limitation, counsel fees and expenses) in pursuing such claim. If COLEY institutes the claim or suit COLEY shall be entitled to retain and keep any and all sums received, obtained, collected or recovered
whether by judgment, settlement or otherwise, as a result of such claim or suit. 
  
 7.6 Assignment of [*****************]. [************************************************************] promptly after the issuance of any patent containing such claim. The parties agree that any
[*****************] shall be deemed “Coley Patent Rights” under Section 1.8. [************] means any claims contained in any issued patent hereafter during the Term of this Agreement [**************************************] which claims
are directed to the[*****************] of a [********] covered by [**************************************** 
 **********************]. 
  
 Section 8. COVENANTS. 
  
 8.1 Technical Assistance. In connection with the transfer to PFIZER
of the Coley Technology, COLEY shall provide PFIZER or any of its Affiliates, at PFIZER’s request, with technical assistance reasonably necessary to enable PFIZER to enjoy fully all the rights granted to PFIZER pursuant to this Agreement.
PFIZER shall reimburse COLEY for COLEY’s reasonable, out-of-pocket costs owed to Third Parties in connection with providing such technical assistance. Nothing under this Section 8.1 shall require COLEY to undertake any additional studies or
additional technical work. 
  
 8.2 Non-Competition.

  
 (a) Coley Non-Compete
[**************************************** *****]. During the Term, neither COLEY nor any of its Affiliates shall (i) directly or indirectly (by license or otherwise), conduct research on, develop or commercialize the Compound, a Research
Compound, a Variant or prodrug of a Compound or Research Compound or a Generic Product outside the Field except for such ongoing research being conducted pursuant to the agreements listed in Schedules 8.2(a) and 8.2(a)-1 and (ii) 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 48 

 except pursuant to the agreement with its Third Party licensee as in effect as of the date hereof and
listed on Schedule 1.28, directly or indirectly (by license or otherwise), grant to any other Third Parties a license to, or collaborate with a Third Party to, conduct research on, develop or commercialize the Compound, a Research Compound, a
Variant or prodrug of a Compound or Research Compound or a Generic Product outside the Field. Notwithstanding the foregoing, COLEY or any of its Affiliates may, directly or indirectly (by license or otherwise), and may hereafter grant to Third
Parties a license to or collaborate with a Third Party to, [***************************************** **********************************************] provided that [***************************] (x) [************************************] and
(y) [********************** *********************]. 
  
 (b) Coley Non-Compete [*********************************************************]. Except pursuant to the Third Party license agreement as in effect as of the date hereof and listed in Schedule 1.28 and except as expressly
provided in Section 4.10, during the Term, neither COLEY nor any of its Affiliates shall, directly or indirectly (by license or otherwise), market, sell, detail, promote or distribute any product in the Field that
[********************************************] or [***********************************************************************************] the [**************] in the [******************************] to the [*************************************].

  
 (c) Pfizer Non-Compete
[*********************************************************]. Except for the Licensed Products, during the Term, neither PFIZER nor any of its Affiliates shall, directly or indirectly (by license or otherwise), market, sell, detail, promote or
distribute any product in the Field that [***********************************] or [****************************************************************************************************** *******] in the [************************************] to the
[***********************]. 
  
 (d) Coley
Non-Compete [******************]. Notwithstanding anything to the contrary in this Agreement, during the Term, neither COLEY nor any of its Affiliates shall, directly or indirectly (by license or otherwise), conduct any clinical studies outside
the Field [*****************************************************] except for (i) [**********************] and (ii) [*********************************] or [****************************]. In addition, COLEY and its Affiliates, directly, or indirectly
(by license or otherwise), may only conduct research on, develop or commercialize a product for the [****************] or [*******************************] if the [******************] and [*************
**************************************************]. 
  
 (e) Acquisition Divestitures. Notwithstanding the provisions of Section 8.2(c) to the contrary, which provisions shall not be deemed breached as a result of an acquisition or merger described in this Section 8.2(e), if PFIZER
acquires a competing product whose sale or distribution would violate Section 8.2(c) through acquisition or merger with the whole or substantially the whole of the business or assets of a Third 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 49 

 Party, PFIZER shall, within sixty (60) days from the date of PFIZER’s board approval of such
acquisition or merger, notify COLEY of such merger or acquisition and as to whether PFIZER intends to divest its interest in such competing product. If PFIZER elects to divest its interest in such competing product, PFIZER shall use reasonable
efforts to identify a Third Party purchaser to whom PFIZER will divest its interest in such competing product and to enter into a definitive agreement with such Third Party for such divestiture as soon as reasonably practicable under the
circumstances (which may be subject to a Hold Separate Transaction (as defined below) as applicable). If PFIZER elects not to divest its interest in such competing product (other than as part of a Hold Separate Transaction) within six (6) months
after the closing of the acquisition or merger for which PFIZER has provided COLEY with notice, or if such divestiture is subject to the terms of a Hold Separate Transaction, within twelve (12) months after the closing of the acquisition or merger
for which PFIZER has provided COLEY with notice, then COLEY shall have the option, upon notice to PFIZER given no later than ninety (90) days after the earlier of (i) PFIZER’s election not to divest such competing product and (ii) the end of
such six (6) or twelve (12) month period described above, as applicable, to terminate this Agreement, such termination to be effective upon the expiration of such ninety (90)-day notice period, unless waived by COLEY during such period. As used
herein, a “Hold Separate Transaction” shall mean any “hold separate” transaction (whether through the establishment of a trust or otherwise) involving the proposed sale of the applicable competing product pursuant to an
agreement with any Governmental Authority responsible for antitrust laws. 
  
 8.3 Trademark. COLEY hereby assigns to PFIZER all of its right, title and interest in and to the ProMune trademark in all countries in the Territory. Each such trademark is set forth on Schedule 8.3
attached hereto (collectively, the “Trademarks”). PFIZER shall, in its sole discretion, be free to use or not use the Trademarks for any products or to abandon such Trademarks. 
  
 Section 9. CONFIDENTIALITY; PUBLICATION. 
  
 9.1 Confidentiality. 
  
 (a) PFIZER and COLEY each agree that during the Term and for
the [*************] period following the expiration or termination hereof, it will keep confidential, and will cause its Affiliates to keep confidential all Coley Confidential Information or Pfizer Confidential Information, as the case may be, that
is disclosed to it, or to any of its Affiliates pursuant to this Agreement. 
  
 (b) Neither PFIZER nor COLEY nor any of their respective Affiliates shall use Coley Confidential Information or Pfizer Confidential Information, as the case may be, except as expressly permitted in this Agreement.

  
 (c) PFIZER and COLEY each agree that any
disclosure (i) by PFIZER or any of its Affiliates of Coley Confidential Information, or (ii) by COLEY or any of its Affiliates of Pfizer Confidential Information, to any director, officer, employee, 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 50 

 subcontractor, consultant, licensee or agent of the other party shall be made only if and to the extent
necessary to carry out its responsibilities under this Agreement. Except as permitted by Section 9.1(d) below, PFIZER agrees not to disclose any Coley Confidential Information and COLEY agrees not to disclose any Coley Confidential Information or
Pfizer Confidential Information to any Third Parties, other than its directors, subcontractors, consultants, licensees and agents as permitted under this Section 9.1(c), or to the extent necessary under the UIRF License Agreement and the OHRI
License Agreement, under any circumstance without written permission from the other party. PFIZER and COLEY each agree to take such action, and to cause its Affiliates to take such action, to preserve the confidentiality of Coley Confidential
Information and/or Pfizer Confidential Information, as the case may be, as it would customarily take to preserve the confidentiality of its own confidential information. PFIZER and COLEY each agree, upon the other’s request, to return all Coley
Confidential Information or Pfizer Confidential Information, as the case may be, disclosed to the other party pursuant to this Agreement, including all copies and extracts of documents, as promptly as practicable following such request upon the
termination of this Agreement, except for one (1) copy which may be kept for the purpose of complying with continuing obligations under this Agreement. 
  
 (d) COLEY and PFIZER each represent that all of its directors, officers, employees, and any subcontractors, consultants, investigators,
licensees or agents of such party, who shall have access to Pfizer Confidential Information or Coley Confidential Information are bound to maintain such information in confidence. Notwithstanding the foregoing, PFIZER may disclose Coley Confidential
Information (i) to Governmental Authorities (a) to the extent reasonably useful to obtain or maintain Regulatory Approvals, Price Approvals, privileges or rights for any Licensed Product within the Territory and (b) in order to respond to inquiries,
requests or investigations; (ii) to outside consultants, scientific advisory boards, managed care organizations, contract manufacturers and non-clinical and clinical investigators to the extent reasonably useful to develop, manufacture, register or
market any Licensed Product; provided that PFIZER shall obtain the same confidentiality obligations from such Third Parties as it obtains with respect to its own similar types of proprietary information; and (iii) to the extent reasonably
useful to PFIZER in exercising its rights under this Agreement; provided that in the case of each of clauses (i), (ii) and (iii), PFIZER shall treat the Coley Confidential Information in the same manner that it would treat its own similar
types of proprietary information in similar situations. 
  
 (e) Nothing in this Section 9.1 shall be construed to limit the right of PFIZER’s or COLEY’s clinical investigators to publish the results of their studies. 
  
 9.2 Publication. Subject to Section 9.1(e), none of COLEY, its
Affiliates, or any of its or its Affiliates’ employees, subcontractors, consultants, investigators, licensees or agents may publish or present any information, including, without limitation, the results of any work performed under the Screening
and Evaluation Agreement, or preclinical or clinical studies with respect to the Compound, any Research Compound or any Licensed Product without PFIZER’s prior consent (which may be withheld in its sole discretion). Neither party shall have the
right to publish or present Confidential Information of the other party. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 51 

 9.3 Publicity. The press release announcing the signing of the transactions contemplated by this
Agreement will be in substantially the same form as Exhibit D attached hereto and will be promptly disseminated following signing. In addition, either party may make a public statement, including in analyst meetings, concerning this Agreement
or the progress of the Compound, the Research Compounds or the Licensed Products where such statement: (a) is required by Law, applicable stock exchange regulation or legal proceedings, (b) concerns one of the events described in Schedule
9.3; provided that COLEY may only make a public statement concerning one of the events described in Schedule 9.3 as follows: (i) jointly with PFIZER, (ii) with PFIZER’s prior consent and in compliance with the other provisions
of this Section 9.3 or (iii) after PFIZER has made a public statement with respect thereto, so long as COLEY’s public statement is consistent therewith; provided, further, that PFIZER shall either make a public statement
concerning the events described in Schedule 9.3 in a manner consistent with its public statements for its other pharmaceutical products or permit COLEY to make a public statement in accordance with clause (ii) of this Section 9.3, or (c) is
contained in PFIZER’s financial statements prepared in accordance with generally acceptable accounting principles in the United States. In connection with any such statement, the party proposing to make such statement shall, if possible,
endeavor to obtain confidential treatment of economic and trade secret information. In any event, the parties agree to use reasonable efforts, consistent with such party’s practice regarding its own similar types of proprietary information, to
avoid disclosure of Confidential Information, except as permitted hereunder, and shall cooperate with each other with respect to all such disclosures. The party that is required to or has otherwise decided to make a written or oral public statement
pursuant to this Section 9.3 shall give the other party sufficient advance notice of the text of any proposed statement so that the other party will have the opportunity to comment upon the statement, and such comments will be given due
consideration by the party making the statement. Once a statement has been approved by both parties in accordance with this Section 9.3, then either party may communicate the information contained in such statement in a manner that is consistent
with such statement. Except as provided above in this Section 9.3, neither party will make any public statement (whether written or oral or to the public press or its stockholders or otherwise) relating to the terms of, or events related to, this
Agreement without the prior consent of the other party. 
  
 9.4
Registration and Filing of this Agreement. To the extent, if any, that a party concludes that it is required under applicable Laws to file or register this Agreement or a notification thereof with any Governmental Authority, including,
without limitation, the US Securities and Exchange Commission, the FTC or the DOJ, such party may do so; provided that such party shall provide the other party with a written copy of all proposed filings, registrations or notifications within
such time frame as to allow for a reasonably sufficient time for review and comment by the other party prior to the submission of such proposed filing, registration or notification. The other party shall cooperate with such filing, registration or
notification and shall execute all documents reasonably required in connection therewith. To the extent permitted by applicable Law, the parties will request confidential treatment of sensitive provisions of the Agreement. The parties shall promptly
inform each other as to the activities or inquiries of any such Governmental Authority relating to this Agreement and shall cooperate to respond to any request for further information therefrom. Each party shall be responsible for its own legal and
other external costs in connection with any such filings, registrations or notifications. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 52 

 Section 10. REPRESENTATIONS. 
  
 10.1 COLEY Warranties. As of the date hereof and as of the Effective Date, each of the Coley Entities hereby
represents and warrants to PFIZER as follows: 
  
 (a) To the knowledge of each such Coley Entity and its Affiliates, the issued patents encompassed within the Coley Patent Rights applicable to the Field are valid and enforceable patents, and no Third Party (i) is infringing any such
patents in the Field relating to the Compound or the Product in development as of the Effective Date or (ii) except as indicated in Schedule 10.1(a)ii has challenged the extent, validity or enforceability of such patents (including by way of
example through the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any equivalent foreign entity). Exhibit A contains a complete
and correct list of all patents and patent applications owned by, or otherwise controlled by each of the Coley Entities (and indicating which entity owns or controls each patent and patent application and which are owned and which are controlled)
relating to the Compound or any Product. To the knowledge of COLEY and its Affiliates, none of the manufacture, use, sale, offer for sale or importation by COLEY of the Compound or any Product would infringe or constitute a misappropriation or other
violation of the rights of any Third Party. Each of the Coley Entities, as the case may be, is the legal and beneficial owner of, or has the right to grant to PFIZER the rights granted herein pursuant to (x) the OHRI License Agreement, the UIRF
License Agreement or any other assignment of inventorship, (y) all the Coley Patent Rights in the Field and (z) all Coley Technology in the Field. Except for the license identified in Schedule 1.28, and except for research licenses for
non-commercial purposes granted to academic or non-profit research entities or to other Third Parties involved in research for non-commercial purposes, no person, firm, corporation or other entity (including without limitation any direct or indirect
subsidiary or Affiliate of any Coley Entity and any agreements and licenses by and between or among any Coley Entities and their respective Affiliates) has any right, interest or claim in or to, and neither COLEY nor any of its Affiliates has
entered into any agreement granting any right, interest or claim in or to, any Coley Patent Rights applicable to the Field or Coley Technology applicable to the Field. Except for the rights granted to COLEY under the OHRI License Agreement and the
UIRF License Agreement, none of the rights of COLEY or its Affiliates under the Coley Patent Rights in the Field or Coley Technology in the Field have been licensed or otherwise made available (including without limitation pursuant to any immunity
from suit arrangement) to COLEY or its Affiliates from a Third Party. COLEY and/or its Affiliates own or control valid and enforceable rights in the Coley Patent Rights and Coley Technology in the Field, in each case, free of any lien, encumbrance,
charge, security interest, mortgage or other similar restriction. 
  
 (b) Each of the Coley Entities has heretofore disclosed to PFIZER all material information known to it or its Affiliates with respect to the safety and efficacy of the Compound and the Product. 
  
 (c) Each of the Coley Entities has the corporate power and
authority to execute and deliver this Agreement, and Coley Inc. has the corporate power and authority 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 53 

 to execute and deliver the Screening and Evaluation Agreement and the Stock Purchase Agreement and to
perform its respective obligations hereunder and thereunder, and the execution, delivery and performance of this Agreement by each of them and the Screening and Evaluation Agreement and Stock Purchase Agreement by Coley Inc. have been duly and
validly authorized and approved by proper corporate action on the part of each of them, and each of the Coley Entities has taken all other action required by Law, its certificate of incorporation, by-laws or other organizational documents or any
agreement to which it is a party or to which it may be subject required to authorize such execution, delivery and performance (other than compliance with all applicable requirements of the HSR Act). Assuming due authorization, execution and delivery
on the part of PFIZER, each of this Agreement, the Screening and Evaluation Agreement and the Stock Purchase Agreement constitutes a legal, valid and binding obligation of each of the Coley Entities that are party hereto or thereto, enforceable
against each of them in accordance with its terms. 
  
 (d) The execution and delivery of this Agreement, the Screening and Evaluation Agreement and the Stock Purchase Agreement by each of the Coley Entities that are party hereto or thereto and the performance by each of them contemplated
hereunder and thereunder does not and will not violate any Laws or any order of any court or Governmental Authority where such violation would have an adverse impact on PFIZER’s rights hereunder. 
  
 (e) Except for filings pursuant to the HSR Act, neither the
execution and delivery of this Agreement, the Screening and Evaluation Agreement or the Stock Purchase Agreement, nor the performance hereof or thereof by any Coley Entity requires any of them to obtain any permits, authorizations or consents from
any Governmental Authority or from any other person, firm or corporation, and such execution, delivery and performance will not result in the breach of, give rise to any termination of, rescission, renegotiation or acceleration under or trigger any
other rights under any agreement or contract to which (i) any of the Coley Entities may be a party that relates to the Coley Patent Rights, the Coley Technology, the Compound, or the Product or (ii) to the knowledge of COLEY and its Affiliates, OHRI
or UIRF is a party that relates to the Coley Patent Rights, the Coley Technology, the Compound, or the Product. 
  
 (f) Except as listed on Schedule 10.1(a)(ii), to the knowledge of COLEY and its Affiliates, there is no action, claim, demand,
suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in Law or in equity, pending or relating to or, to the knowledge of COLEY and its Affiliates,
threatened against COLEY, any of the parties to the OHRI License Agreement or the UIRF License Agreement, or any of their respective Affiliates, in each case in connection with the Compound, the Product or any Coley Patent Rights or Coley Technology
or against or relating to the transactions contemplated by this Agreement, the Screening and Evaluation Agreement or the Stock Purchase Agreement.  
  
 (g) Except for (x) the OHRI License Agreement, (y) the UIRF License Agreement and (z) the agreements listed on Schedule 10.1(g)(i),
there are no agreements to which COLEY or any of its Affiliates is a party pursuant to which COLEY or any of 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 54 

 its Affiliates has a license, or an option to obtain a license, or holds an immunity from suit, with
respect to patents which (i) are pending, applied for, granted or registered, and (ii) but for COLEY’s and its Affiliates’ rights under such agreements, could be asserted by Third Parties to be infringed by the manufacture, distribution,
use, or sale of the Compound or the Product. Each of the OHRI License Agreement and the UIRF License Agreement constitutes a valid and legally binding obligation of each of Coley Inc. and the other parties thereto, enforceable in accordance with its
terms, and is in full force and effect. The OHRI License Agreement and the UIRF License Agreement will continue to be in full force and effect on identical terms immediately following the execution of this Agreement, and there have not been any
amendments or alterations thereto that have not been heretofore disclosed to PFIZER. The OHRI License Agreement represents the complete agreement and understanding between OHRI and COLEY and its Affiliates relating to the Coley Patent Rights and the
Coley Technology that are the subject of the OHRI License Agreement. The UIRF License Agreement represents the complete agreement and understanding between UIRF and Coley and its Affiliates relating to the Coley Patent Rights and the Coley
Technology that are the subject of the UIRF License Agreement. Each of Coley Inc. and its Affiliates has performed all of its obligations under each of the OHRI License Agreement and the UIRF License Agreement, and none of COLEY or any of its
Affiliates is (with or without the lapse of time or the giving of notice, or both) in breach or default thereunder, and, to the knowledge of COLEY and its Affiliates, no other party to such agreements is (with or without the lapse of time or the
giving of notice, or both) in breach or default thereunder. None of the other parties to the OHRI License Agreement or the UIRF License Agreement has given any notice to or made a claim against COLEY or any of its Affiliates with respect to any
breach or default under the OHRI License Agreement or the UIRF License Agreement. Complete and correct copies of (w) the Agreements listed on Schedules 8.2(a) and 1.28 attached hereto (including all amendments, supplements and waivers thereto
in effect as of the Effective Date), (x) the OHRI License Agreement (including all amendments, supplements and waivers thereto in effect as of the Effective Date), (y) the UIRF License Agreement (including all amendments, supplements and waivers
thereto in effect as of the Effective Date) and (z) all agreements of COLEY and its Affiliates with any Third Parties regarding the supply and manufacture of goods relating to the Compound and the Product (including all amendments, supplements and
waivers thereto) in effect as of the Effective Date have heretofore been delivered to PFIZER. 
  
 (h) Intentionally Left Blank 
  
 (i) Each of the Coley Entities has heretofore disclosed to PFIZER all material correspondence and contact information between each of the
Coley Entities and/or their respective Affiliates and the FDA and any other Regulatory Authorities regarding the Compound and the Product. 
  
 (j) Schedule 10.1(j), sets forth a complete and accurate list of all of Coley Inc.’s subsidiaries, and for each such
subsidiary Coley Inc. is the legal and beneficial holder and owner of one hundred percent (100%) of the outstanding capital stock of such subsidiary and any all rights and options to capital stock to such subsidiary. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 55 

 For purposes of this Section 10.1, “to the knowledge of COLEY and its Affiliates” shall mean to the knowledge
of COLEY and its Affiliates (including, without limitation, the knowledge of those officers and department heads of COLEY and its Affiliates whose duties include responsibility for the matters specified above). 
  
 10.2 PFIZER Warranties. As of the date hereof and as of the Effective
Date, PFIZER hereby represents and warrants to COLEY as follows: 
  
 (a) PFIZER has the corporate power and authority to execute and deliver this Agreement and the Screening and Evaluation Agreement and to perform its obligations hereunder and thereunder, and the execution, delivery
and performance of this Agreement and the Screening and Evaluation Agreement by PFIZER have been duly and validly authorized and approved by proper corporate action on the part of PFIZER, and PFIZER has taken all other action required by Law, its
certificate of incorporation or by-laws or any agreement to which it is a party or to which it may be subject required to authorize such execution, delivery and performance (other than compliance with all applicable requirements of the HSR Act).
Assuming due authorization, execution and delivery on the part of the Coley Entities, each of this Agreement and the Screening and Evaluation Agreement constitutes a legal, valid and binding obligation of PFIZER, enforceable against PFIZER in
accordance with its terms. 
  
 (b) The execution
and delivery of this Agreement and the Screening and Evaluation Agreement and the performance by PFIZER contemplated hereunder and thereunder does not and will not violate (subject to obtaining appropriate governmental health, pricing and
reimbursement approvals) any Laws or any order of any court or Governmental Authority where such violation would have an adverse effect on COLEY’s or its Affiliates’ rights hereunder. 
  
 (c) Except for filings pursuant to the HSR Act, neither the
execution and delivery of this Agreement or the Screening and Evaluation Agreement nor the performance hereof or thereof by PFIZER requires PFIZER to obtain any permits, authorizations or consents from any Governmental Authority (subject to
obtaining all necessary FDA and other Governmental Authority approvals with respect to the manufacture, use or sale of the Compound and the Product) or from any other person, firm or corporation and such execution, delivery and performance will not
result in the breach of or give rise to any termination of any agreement or contract to which PFIZER may be a party, except for those that would not reasonably be expected to adversely affect PFIZER’s ability to perform its obligations under
this Agreement or the Screening and Evaluation Agreement. 
  
 (d) To the knowledge of PFIZER, there is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or
otherwise, in Law or in equity, pending or relating to or, to the knowledge of PFIZER, threatened against PFIZER in connection with or relating to the transactions contemplated by this Agreement or the Screening and Evaluation Agreement. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 56 

 For purposes of this Section 10.2, “to the knowledge of PFIZER” shall mean to the knowledge of PFIZER
(including, without limitation, the knowledge of those officers and employees of PFIZER whose duties include responsibility for the matters specified above). 
  

10.3 Covenants of Coley 
  
 (a) COLEY covenants and agrees with PFIZER that COLEY shall maintain in effect the OHRI License Agreement and the UIRF License Agreement
and shall not take any actions (or omit to take any actions) that would result in a breach of the OHRI License Agreement or the UIRF License Agreement or any termination of either such agreement prior to the applicable stated term of such agreement
in effect as of the date hereof. COLEY agrees that it shall not amend, modify or supplement the OHRI License Agreement or the UIRF License Agreement, or waive any terms or conditions thereunder, that would have an adverse effect on PFIZER’s
rights hereunder, without the prior consent of PFIZER. COLEY shall provide to PFIZER advance notice as is reasonable under the circumstances (but in any event not less than five (5) calendar days) of any amendment, modification, supplement or waiver
of the OHRI License Agreement or the UIRF License Agreement that has a material effect on PFIZER’s rights hereunder. In addition, COLEY shall not sell, assign, convey, pledge, hypothecate or otherwise transfer the OHRI License Agreement or the
UIRF License Agreement or COLEY’s rights or obligations thereunder, or otherwise make any commitment in a manner that conflicts with PFIZER’s rights hereunder without the prior consent of PFIZER. COLEY shall immediately notify PFIZER upon
receipt by COLEY or its Affiliates of any notice from any of the parties to the OHRI License Agreement or the UIRF License Agreement (other than Coley) of any actual or alleged default or breach or of such party’s intent to terminate the OHRI
License Agreement or the UIRF License Agreement, respectively, exercise such party’s respective rights or remedies thereunder, or otherwise take any action that may adversely affect PFIZER’s rights under this Agreement. 
  
 (b) COLEY hereby covenants and agrees that, during the Term
of this Agreement, COLEY shall not sell, assign or otherwise transfer, or permit any direct or indirect subsidiary of COLEY to sell, assign or otherwise transfer to any person (i) any Coley Patent Rights applicable to the Field that are registered
in the name of or owned or controlled by COLEY or any direct or indirect subsidiary of COLEY, (ii) any Coley Technology applicable to the Field or (iii) any capital stock or securities of (A) any direct or indirect subsidiary of Coley Inc. or (B)
any direct or indirect subsidiary (other than Coley Inc.) of any direct or indirect parent holding company of Coley Inc. where, in the case of any such subsidiary described in this clause (iii), such subsidiary owns or controls Coley Patent Rights
applicable to the Field or Coley Technology applicable to the Field (any such direct or indirect subsidiary and “IP Subsidiary”); it being understood and agreed that COLEY and any IP Subsidiary may sell, assign or otherwise transfer
Coley Patent Rights applicable to the Field and/or Coley Technology applicable to the Field to any wholly-owned direct or indirect subsidiary of Coley Inc. that (x) is and continues to be at all times incorporated and domiciled (including with
respect to principal headquarters) in any state of the United States of America and (y) prior to any such sale, assignment or transfer to such Person described in clause (x), has acknowledged and confirmed in writing to PFIZER, all in a manner
reasonably acceptable to PFIZER, that 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 57 

 effective as of such sale, assignment or other transfer such transferee shall be bound by this Agreement
as if it were a party to it as and to the identical extent applicable to the transferee with respect to Coley Patent Rights applicable to the Field and/or Coley Technology applicable to the Field. In addition, COLEY hereby covenants and agrees that,
during the Term of this Agreement, COLEY shall not incur or permit to exist (and shall cause each IP Subsidiary not to incur or permit to exist) any indebtedness for which any Coley Patent Rights and/or Coley Technology (A) constitutes collateral
for such indebtedness, or (B) is subject to any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties or other restriction with respect to such indebtedness. 
  
 Section 11. TERM 
  
 11.1 This Agreement shall be effective as of the Effective Date and shall
remain in effect during the Term. 
  
 11.2 Prior to the Effective
Date, neither COLEY nor PFIZER shall have any rights or obligations hereunder. Notwithstanding the foregoing, effective as of the date of this Agreement, each of PFIZER and COLEY covenant and agree that (a) Sections 3 (HSR), 9 (Confidentiality) and
14 (Governing Law and Arbitration) shall be in full force and effect, and (b) neither COLEY nor its Affiliates shall negotiate, engage in or otherwise enter into any transaction involving (i) any sale or grant of any rights or licenses to the Coley
Patent Rights in the Field or the Coley Technology in the Field in the Territory or (ii) any joint venture, co-promotion or similar relationship involving the Coley Patent Rights in the Field or the Coley Technology in the Field in the Territory.
The obligations set forth in this Section 11.2 shall terminate ninety (90) days after the date of this Agreement if the Effective Date has not occurred on or before such date. 
  
 Section 12. TERMINATION. 
  
 12.1 Termination. This Agreement shall terminate as follows: 
  
 (a) COLEY shall have the rights set forth below in this Section 12.1(a) by notice to PFIZER, and PFIZER
shall have the rights set forth below in this Section 12.1(a) by notice to COLEY: 
  
 (i) Upon COLEY’s notice to PFIZER that a Material Default by PFIZER has occurred, the parties will meet to discuss in good faith
whether a plan to remedy the Material Default can be mutually agreed. If the parties fail to so agree within thirty (30) days after the date of such notice, Section 12.1(a)(ii) below shall apply. 
  
 (ii) Subject to the terms hereof, upon the occurrence of any
Material Default by PFIZER or PFIZER’s default of its payment obligation under Section 2.1 of the Stock Purchase Agreement (after the exhaustion of all remedies and cure periods thereunder), COLEY may, upon five (5) days’ prior notice,
terminate this Agreement, with such termination to be effective upon the expiration of such five (5)-day period; provided, however, that in case of a default of a payment obligation, such notice will lapse without effect if PFIZER
cures such default within such time. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 58 

 (iii) Upon PFIZER’s notice to COLEY that a Material Default by COLEY has occurred,
the parties will meet to discuss in good faith whether a plan to remedy the Material Default can be mutually agreed. If the parties fail to so agree within thirty (30) days after the date of such notice, Section 12.1(a)(iv) below shall apply.

  
 (iv) Subject to the terms hereof, upon the
occurrence of any Material Default by COLEY, PFIZER may, upon five (5) days’ prior notice, terminate this Agreement, with such termination to be effective upon the expiration of such five (5)-day period; provided, however, that in
case of a default of a payment obligation, such notice will lapse without effect if COLEY cures such default within such time. 
  
 (v) The provisions of Section 12.1(a)(ii) and 12.1(a)(iv) shall be stayed during the pendancy of the matters (including, without
limitation, the notice, meeting and arbitration processes) contemplated by Section 14.2. 
  
 (vi) Notwithstanding COLEY’s right of termination described in this Section 12.1(a), COLEY acknowledges and agrees that it shall have
no claim whatsoever against PFIZER under this Agreement, and no right to terminate this Agreement, for any breach or alleged breach by PFIZER or any of its Affiliates of any one or more of the Ancillary Agreements (other than with respect to a
default of the payment obligation under Section 2.1 of the Stock Purchase Agreement pursuant to Section 12.1(a)(ii) above), and that, under the above circumstances, this Agreement shall remain in full force and effect. 
  
 (b) This Agreement may be terminated by either COLEY or
PFIZER, effective upon notice to the other party, if the Effective Date shall not have occurred on or prior to the date that is one hundred eighty (180) days after the parties make their respective HSR filings pursuant to the terms and conditions of
this Agreement. 
  
 (c) If either party is
generally unable to meet its debts when due, or makes a general assignment for the benefit of its creditors, or there shall have been appointed a receiver, trustee or other custodian for such party for all or a substantial part of its assets, or any
case or proceeding shall have been commenced or other action taken by or against such party in bankruptcy or seeking the reorganization, liquidation, dissolution or winding-up of such party or any other relief under any bankruptcy, insolvency,
reorganization or other similar act or Law, and any such event shall have continued for ninety (90) days undismissed, unstayed, unbonded and undischarged, then the other party may, upon notice to such party terminate this Agreement, such termination
to be effective upon such party’s receipt of such notice. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 59 

 (d) At any time (i) prior to first Launch of the first Licensed Product, upon one hundred
twenty (120) days’ notice to COLEY or (ii) after the first Launch of the first Licensed Product, upon one hundred eighty (180) days’ notice to COLEY, PFIZER shall have the right (at PFIZER’s sole discretion), to terminate this
Agreement, such termination to be effective upon the expiration of such one hundred twenty (120) or one hundred eighty (180)-day notice period, as applicable. During the applicable notice period prior to the effective date of any such termination,
PFIZER agrees (w) to continue all preclinical and clinical studies relating to the Compound, any Research Compound or any Licensed Product, consistent with the terms of this Agreement, until they are either completed or transferred to COLEY, (x) to
cooperate with COLEY with respect to any public statements relating to this Agreement, the Compound, any Research Compound or any Licensed Product in accordance with Section 9.3, (y) not to terminate or abandon any Regulatory Approvals or Pricing
Approvals with respect to a Licensed Product, and (z) not to terminate any contracts relating to preclinical or clinical studies of the Compound, any Research Compound or any Licensed Product that are transferable to COLEY (each, individually, an
“Ongoing Study” and collectively, the “Ongoing Studies”). In connection with clause (z) of this Section 12.1(d), the parties agree to comply with the following procedures: (A) promptly after PFIZER delivers to COLEY
a notice of termination under this Section 12.1(d), PFIZER will provide to COLEY a list of all Ongoing Studies, (B) no later than thirty (30) days after its receipt of the list of Ongoing Studies, COLEY will provide notice to PFIZER indicating which
Ongoing Studies COLEY would like PFIZER to transfer to it (collectively, the “Transfer Studies”), (C) PFIZER will use reasonable efforts to transfer the Transfer Studies to COLEY during the applicable notice period prior to the
effective date of any such termination, but in no event, shall PFIZER be required by any Third Party to retain any obligations or liabilities in connection with any such Ongoing Study or Transfer Study after the effective date of any such
termination, and (D) COLEY hereby releases PFIZER from any and all liabilities in connection with any transfer of the Transfer Studies pursuant to this Section 12.2(d). 
  
 (e) In addition to the termination rights specified in this Section 12.1, PFIZER shall have the termination
rights specified in Section 4.10(m) and Section 12.4. 
  
 12.2
Rights Upon Termination. 
  
 (a) Except as
set forth in this Section 12.2, termination of this Agreement for any reason (x) shall be without prejudice to COLEY’s right to receive all Royalty Payments, in each case, accrued prior to the effective date of such termination, and any other
remedies that either party may otherwise have and (y) shall not release a party hereto from any indebtedness, liability or other obligation incurred hereunder by such party prior to the effective date of such termination, except that no payments
that are payable by PFIZER to COLEY under Section 5.1 or Section 5.2 shall accrue during any notice period provided for in this Article 12. 
  
 (b) Upon any termination of this Agreement pursuant to Section 12.1(b), all licenses shall terminate. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 60 

 (c) Upon any termination of this Agreement pursuant to Section 12.1, other than Section
12.1(b), the licenses and rights granted herein to PFIZER and to COLEY shall terminate, including, without limitation, the licenses granted pursuant to Sections 2.1, 2.2, 2.3 and 2.5; provided, however, the licenses granted to COLEY
and PFIZER pursuant to Section 2.4 shall survive. 
  
 (d) PFIZER shall, promptly after termination, unless PFIZER terminates this Agreement under Section 12.1(a)(iv): 
  
 (i) Regulatory Matters. Deliver and transfer to COLEY or its designee possession and ownership of all Regulatory Approvals, filings
and correspondence with Regulatory Authorities (including all INDs and NDAs (and their foreign equivalents)), global safety database information maintained by PFIZER and information relating to any marketing or post-marketing approval monitoring
required by any Required Authority, in each case, relating solely to the Licensed Products and in the same form in which PFIZER maintains such items; 
  
 (ii) Pre-Clinical and Clinical Matters. Deliver and transfer to COLEY or its designee possession and ownership of all pre-clinical
and clinical data and information owned or controlled by PFIZER, including, without limitation, copies of all reports, records, correspondence related thereto and information with respect to clinical sites, contract research organizations and
consultants related to Ongoing Studies, in each case relating solely to the Licensed Products and in the same form in which PFIZER maintains such items; 
  
 (iii) Manufacturing Matters. Deliver and transfer to COLEY or its designee possession and ownership of all technology used solely
in connection with the manufacture of the Licensed Products, solely for use in connection with the manufacture of the Licensed Products. At COLEY’s option, PFIZER agrees to sell, at PFIZER’s full cost, bulk active substance for Licensed
Products (provided, such meets PFIZER’s release specifications) then on hand and/or raw materials (provided, such meets PFIZER’s release specifications) used for the processing of Licensed Products for which PFIZER has no other use;
provided, however, PFIZER shall not be obligated to sell any such bulk active substance or raw materials if PFIZER, in its reasonable judgment, believes that continued use or sale of such Licensed Products by COLEY involves reasonable
safety concerns. COLEY shall be fully responsible for its use of such raw materials and bulk active substances and shall fully indemnify PFIZER for all Losses relating thereto resulting from any claims or actions of Third Parties. 
  
 (iv) Commercial Matters. Deliver to COLEY or its
designee a list of the names and contact information for any person or entity to which PFIZER has directly shipped Licensed Products within the twelve (12)-month period prior to the effective date of termination; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 61 

 (v) License Grant. Grant to COLEY a non-exclusive, royalty-free, perpetual
license, with the right to sublicense, under PFIZER’s and its Affiliates’ rights in Pfizer Technology (other than any Pfizer Technology that PFIZER acquired from a Third Party (by license or otherwise), but including any such technology
that is exclusively used in connection with the Compound, any Research Compound or any Licensed Product) solely for the purpose of developing, making, having made, using, selling, offering for sale and importing Licensed Products in the Territory;
provided that with respect to any Pfizer Technology that PFIZER acquired from a Third Party (by license or otherwise) exclusively for use in connection with the Compound, any Research Compound or any Licensed Product, (x) PFIZER shall only be
required to grant COLEY a license to such Pfizer Technology to the extent permitted under its agreement with such Third Party (it being understood that PFIZER shall negotiate in good faith with any such Third Party to obtain the right to grant COLEY
such license and (y) to the extent that PFIZER incurs any applicable milestone or additional royalty obligations to such Third Party as a direct result of the license granted to COLEY, COLEY shall pay PFIZER such additional royalty obligation
amounts, and COLEY shall execute such documentation reasonably satisfactory to PFIZER to such effect; 
  
 (vi) Assignment of Trademarks. Assign to COLEY or its designee all of PFIZER’s and its Affiliates’ right, title and
interest in and to the Trademarks in the Territory and any other trademark that PFIZER is using in connection with a Licensed Product on the effective date of termination. 
  
 In the case of each of clauses (i) through (vi) of this Section 12.2(d), COLEY shall reimburse PFIZER for
amounts specified therein and for any out-of-pocket expenses incurred by PFIZER in connection with such deliveries, transfers and assignments within [************************] days of receiving notice from PFIZER containing a reasonable detailed
accounting of such costs. The parties agree that (A) any failure by PFIZER to provide immaterial data, information, reports, records, correspondence or other materials to COLEY pursuant to this Section 12.2(d) shall not be a breach of PFIZER’s
obligations under this Section 12.2(d); (B) in no event shall PFIZER be required by any Third Party to retain any obligations or liabilities relating to the Licensed Products following any delivery, transfer or assignment pursuant to this Section
12.2(d); and (C) COLEY hereby releases PFIZER from any and all liabilities in connection with any delivery, transfer or assignment pursuant to this Section 12.2(d). For purposes of this Section 12.2(d), all of the defined terms and related
provisions used in or referenced by this Section 12.2(d) shall survive termination of this Agreement. PFIZER shall execute all documents and take such further actions as may be reasonably requested by COLEY in order to give effect to the foregoing
clauses (i) through (vii). 
  
 12.3 Bankruptcy. PFIZER may,
in addition to any other remedies available to it by law or in equity, exercise the rights set forth below in this Section 12.3 by notice to COLEY, in the event COLEY shall have become insolvent or bankrupt, or shall have made a general assignment
for the benefit of its creditors, or there shall have been appointed a trustee or receiver of COLEY or for all or a substantial part of its property, or any case or proceeding shall have 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 62 

 been commenced or other action taken by or against COLEY in bankruptcy or seeking reorganization, liquidation,
dissolution, winding-up arrangement, composition or readjustment of its debts or any other relief under any bankruptcy, insolvency, reorganization or other similar act or law of any jurisdiction now or hereafter in effect, and any such event shall
have continued for ninety (90) days undismissed, unbonded and undischarged. All rights and licenses granted under or pursuant to this Agreement by COLEY are, and shall otherwise be deemed to be, for purposes of Article 365(n) of the U.S. Bankruptcy
Code, licenses of rights to “intellectual property” as defined under Article 101 of the U.S. Bankruptcy Code. The parties agree that PFIZER, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its
rights and elections under the U.S. Bankruptcy Code. The parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against COLEY under the U.S. Bankruptcy Code, PFIZER shall be entitled to a complete duplicate of
(or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in their possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy
proceeding upon its written request therefor, unless COLEY elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of COLEY upon written
request therefor by PFIZER. 
  
 12.4 Change of Control. In
the event of any Change of Control, COLEY shall notify PFIZER promptly, but in no event later than five (5) Business Days, following approval by COLEY’s board of directors of any transaction that constitutes a Change of Control and PFIZER shall
have the right upon sixty (60) days’ notice following any such Change of Control, to elect that any one or more of the following shall be deleted, in whole or in part, from this Agreement: Sections 2.5, 4.3, 4.5, 4.6, 4.8, 4.9, 4.10 and the
Coley Work Plan. In addition, in the event of any Change of Control, all licenses granted to COLEY under Section 2.5 shall terminate. In the event that PFIZER makes any election as provided in this Section 12.4 to delete any Section, each of the
parties hereto will enter into an appropriate and customary written amendment and no party shall have any further obligations with respect to any such deleted Section. For the avoidance of doubt, PFIZER shall be entitled, in its sole discretion, to
make the elections provided for in this Section 12.4 upon each occurrence of a Change of Control. 
  
 Section 13. INDEMNIFICATION. 
  
 13.1 Indemnification. 
  
 (a) Subject to this Section 13, PFIZER will indemnify, defend and hold COLEY and its Affiliates, directors, officers and employees (collectively, the “Coley Parties”) harmless from and against any and
all Losses (as defined below) incurred, suffered or sustained by the Coley Parties, arising out of or resulting from a claim by a Third Party, (i) based on any misrepresentation or breach of any representation, warranty, covenant or agreement of
PFIZER contained in (x) this Agreement or (y) any agreement by and among the parties and/or their Affiliates entered into in connection with this Agreement (a “Related Agreement”) or [**************************]. Notwithstanding
anything to the contrary contained herein, the indemnification contained in this Section 13.1(a) shall not apply: (a) to the extent that any Losses are the result of any misrepresentation or breach of any representation, warranty, covenant or
agreement contained in this Agreement or any Related Agreement by any Coley Party, or 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 63 

 
of any gross negligence or willful misconduct of any Coley Party; or (b) to the extent that any such Losses are the subject of the co-indemnification
provisions set forth in Section 13.2 below. 
  
 (b) Subject to this Section 13, COLEY will indemnify, defend and hold PFIZER and its Affiliates, directors, officers and employees (collectively, the “Pfizer Parties”) harmless from and against any and all Losses incurred,
suffered or sustained by the Pfizer Parties, arising out of or resulting from a claim by a Third Party, based on any misrepresentation or breach of any representation, warranty, covenant or agreement of COLEY contained in (x) this Agreement or (y)
any Related Agreement. Notwithstanding anything to the contrary contained herein, the indemnification contained in this Section 13.1(b) shall not apply: (a) to the extent that any Losses are the result of any misrepresentation or breach of any
representation, warranty, covenant or agreement contained in this Agreement or any Related Agreement by any Pfizer Party or of any gross negligence or willful misconduct of any Pfizer Party; or (b) to the extent that any such Losses are the subject
of the co-indemnification provisions set forth in Section 13.2 below. 
  
 13.2 Co-Indemnification. 
  
 (a)
Co-Indemnification. 
  
 (i)
Subject to Section 13.4(c), PFIZER shall indemnify, defend and hold COLEY and the Coley Parties harmless from and against [************************] of the amount of any and all Losses arising out of or resulting from a claim by a Third Party
involving any [*************************************] resulting from the use, promotion, manufacture, commercialization, distribution, offering for sale, sale or importation by PFIZER or any of its Affiliates of a Licensed Product (but in all cases
excluding Losses for which one party is obligated to indemnify the other party pursuant to Section 13.1) (any and all such Losses, the “Co-Indemnity Liability”), and COLEY shall indemnify, defend and hold PFIZER and the Pfizer
Parties harmless from and against [**************************] of the amount of any and all of such Co-Indemnity Liability; it being understood and agreed that the purpose of the provisions of this sentence is that, subject to Section 13.4(c),
PFIZER and COLEY shall pay for and otherwise share the cost of the Co-Indemnity Liability on [**************************] and [**************************] basis, respectively. 
  
 (ii) The parties hereto understand and agree that [*************** *******************] Section 13.2(a) of this Agreement
[************************] as follows: (a) [***************************************** ***********************************************************************************************] pursuant to [**********] this Agreement
[******************************] and (b) [**********************] and [************************************************************************************************ ***************************************] or
[********************************************** 
 ************ 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 64 

 ************************************************] of the [*******************] pursuant to
[**************] this Agreement [**************** ********] then [************************ 
 ***************************
****************************************************] in this Section 13.2(a)(ii). 
  
 (b) For purposes of this Agreement, PFIZER shall be entitled to become the “Indemnifying Party” as that term is used in Section
13.4 (but subject to the sharing of liability as provided in Section 13.2(a)) and, therefore, PFIZER shall have full control of any such claim from a Third Party involving Co-Indemnity Liability as contemplated in Section 13.4; provided,
however, that PFIZER shall notify COLEY of any claim asserted against it by a Third Party for which PFIZER is entitled to co-indemnification by COLEY under Section 13.2(a). 
  
 13.3 Losses. For purposes of this Agreement, “Losses” shall mean any and all (a) claims,
losses, liabilities, damages, fines, royalties, governmental penalties or punitive damages, deficiencies, interest, awards, and judgments, and (b) with respect to Third Parties, settlement amounts and all of the items referred to in clause (a) above
which include, subject to the limitations set forth in Section 13.6, special, indirect, incidental and consequential damages (including without limitation lost profits), and (c) any and all reasonable, out-of-pocket costs and expenses incurred in
connection with all of the items referred in clauses (a) and (b) above (including reasonable out-of-pocket attorneys’ fees and all other expenses reasonably incurred in investigating, preparing or defending any litigation or proceeding,
commenced or threatened). 
  
 13.4 Defense Procedures;
Procedures for Third Party Claims. In the event that any Third Party asserts a claim with respect to any matter for which any Coley Party or Pfizer Party (the “Indemnified Party”), as applicable, is entitled to indemnification
hereunder with respect to such Indemnified Party (a “Third Party Claim”), then the Indemnified Party shall promptly notify in writing the party obligated to indemnify the Indemnified Party under the terms of this Agreement (the
“Indemnifying Party”) thereof; provided, however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and
then only to the extent that) the Indemnifying Party is prejudiced thereby. 
  
 (a) The Indemnifying Party shall have the right, exercisable by written notice to the Indemnified Party within ten (10) Business Days following receipt of notice from the Indemnified Party of the commencement of or
assertion of any Third Party Claim, to assume and conduct the defense of such Third Party Claim which involves solely monetary damages, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party;
provided that (i) the Indemnifying Party has sufficient financial resources, in the reasonable judgment of the Indemnified Party, to satisfy the amount of any adverse monetary judgment that is sought; and (ii) the Third Party Claim solely
seeks (and continues to seek) monetary damages; and (iii) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge
the Third Party Claim in full. (The conditions set forth in (i), (ii) and (iii) above are collectively referred to as the “Litigation Conditions”). Notwithstanding anything to the contrary contained herein, in the case of any Third
Party Claim which is the subject of Section 13.2, PFIZER shall be entitled to control the defense of such Third Party Claim. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 65 

 (b) Within ten (10) Business Days after the Indemnifying Party has given notice to the
Indemnified Party of its intended exercise of its right to defend a Third Party Claim, the Indemnified Party shall give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party
reasonably so objects, the Indemnified Party shall continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn,
the Indemnifying Party shall be entitled, at its sole cost and expense, to assume and conduct such defense, with counsel selected by the Indemnifying Party, until such time as the Indemnified Party shall give notice that any of the Litigation
Conditions, in its reasonable judgment, are no longer satisfied. During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party shall cooperate, and shall cause its Affiliates and agents to
cooperate upon request of the Indemnifying Party in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or
appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party fails to satisfy the Litigation Conditions or does not notify the Indemnified Party in writing of the Indemnifying Party’s intent to
defend any Third Party Claim within ten (10) Business Days after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying
Party’s reasonable expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying Party or the Indemnified Party, as the case may be, shall have the right to join in
(including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any Third Party Claim which the other party is defending as provided in
this Agreement. The Indemnified Party shall have the right, but not the obligation, to be represented by counsel of its own selection and at its own expense; provided, however, that if COLEY, upon the advice of counsel, reasonably
determines that the interests of COLEY and PFIZER in connection with such Third Party Claim involving Co-Indemnity Liability pursuant to Section 13.2(a) are conflicting, then the reasonable cost and expense of such counsel shall be included in the
Co-Indemnity Liability. 
  
 (c) The Indemnifying
Party shall not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement which commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party shall have the sole and
exclusive right to settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but, subject to Section 13.2(c) and this Section
13.4(c), shall not have the right to settle such Third Party Claim to the extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Notwithstanding the foregoing, (a) PFIZER shall deliver to
COLEY all offers of settlement relating to any Co-Indemnity Liability (any such offer, an 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 66 

 “Offer of Settlement”); (b) COLEY shall not be obligated to pay any amounts pursuant to
Section 13.2(a) with respect to any Offer of Settlement of any Co-Indemnity Liability (in no event to include any judgment of any competent court or tribunal) unless COLEY has expressly agreed to pay its applicable amount of such Offer of Settlement
pursuant to Section 13.2; (c) if COLEY does not, within five (5) Business Days of its receipt of any Offer of Settlement from PFIZER, notify PFIZER that it is prepared to pay its applicable portion of the Co-Indemnity Liability pursuant to Section
13.2 regarding such Offer of Settlement or if at any time thereafter COLEY does not commit to or otherwise pay its applicable portion of the Co-Indemnity Liability pursuant to Section 13.2 regarding such Offer of Settlement, then (x) PFIZER shall be
entitled to enter into any such settlement solely with respect to PFIZER and any Pfizer Parties and specifically excluding COLEY and all Coley Parties and (y) the provisions of Section 13.2 shall be null and void solely with respect to such Offer of
Settlement so that neither COLEY nor PFIZER shall be obligated to indemnify the other party with respect to such settlement pursuant to Section 13.2; and (d) for the avoidance of doubt, amounts due or owing with respect to Section 13.2 resulting
from any judgment rendered by any competent court or tribunal shall not require the consent of COLEY. 
  
 13.5 Exclusive Remedy. The indemnification rights provided in Section 13 shall be the exclusive remedy of the parties with respect to the matters
covered therein. 
  
 13.6 Limitation of Liability. IN NO
EVENT SHALL PFIZER OR COLEY BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOSS OF PROFITS) SUFFERED BY PFIZER OR COLEY, RESPECTIVELY UNDER THIS AGREEMENT, EXCEPT (A) TO THE EXTENT OF ANY SUCH
DAMAGES PAID TO A THIRD PARTY AS PART OF A THIRD PARTY CLAIM, (B) FOR PURPOSES OF INDEMNIFICATION PURSUANT TO THIS SECTION 13, FOR [******************************************* 
 **********************] AND (C) FOR PURPOSES OF INDEMNIFICATION PURSUANT TO THIS SECTION 13, [************************************************************************************************]. 
  
 Section 14. GOVERNING LAW; ARBITRATION AND JURISDICTION 
  
 14.1 Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York, without regard to its conflict of laws provisions. 
  
 14.2 Arbitration. 
  
 (a) The parties recognize that a bona fide dispute as to certain matters may from time to time arise during the term of the Agreement. In
the event of the occurrence of any dispute, controversy or claim arising out of or relating to the validity, construction, enforceability or performance of the Agreement including disputes relating to an actual or alleged breach or termination of
the Agreement (but in all cases excluding any disputes 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 67 

 regarding matters decided as a result of an audit by the accountants hired to conduct such audit pursuant
to Section 6.5, intellectual property matters relating to the validity or enforceability of such intellectual property (including, without limitation, the provisions of Section 7) or any suits for specific performance or injunctive relief
(collectively, the “Excluded Matters”)), it shall be settled in the manner set forth below; provided, however, that the arbitrators referred to below shall give effect to the provisions of the Agreement and shall not
adjust, modify or change the effects of the provisions as set forth in the Agreement. For the avoidance of doubt, no party shall be required to submit any Excluded Matter (including, without limitation, any applicable validity, construction,
enforceability, breach or default dispute or issue under this Agreement involving such Excluded Matter) to arbitration pursuant to this Section 14.2. 
  
 (b) If a party intends to begin to resolve a dispute under this Section 14.2, such party shall provide written notice (the “ADR
Request”) to the other party informing such party of such intention and the issues to be resolved. The notice shall explain the nature of the complaint and refer to the relevant sections of the Agreement upon which the complaint is based.
The complaining party shall also set forth a proposed solution to the problem, including a suggested time frame within which the parties must act. 
  
 (c) The non-complaining party must respond within forty-five (45) days of receiving notice with an explanation, including references to
the relevant provisions of the Agreement and a response to the proposed solution and suggested timeframe for action. The non-complaining party may add additional issues to be resolved. 
  
 (d) Within fifteen (15) days of receipt of the response from the non-complaining party, the parties shall
meet and discuss options for resolving the dispute at either the Development Committee or Screening and Evaluation Committee, as appropriate. At least one officer or executive of each party will attend the Development Committee or Screening and
Evaluation Committee meeting, as applicable, and both parties will attempt in good faith to resolve the dispute. The complaining party must initiate the scheduling of this resolution meeting. If the dispute is not resolved at the applicable
committee meeting, then COLEY shall make its President or CEO available and PFIZER shall make a senior executive responsible for development or a senior executive responsible for the pharmaceutical business (as applicable) available to meet and
confer with the other party. 
  
 (e) Except for
Excluded Matters and as otherwise provided herein, any dispute under this Agreement that cannot be resolved pursuant to Sections 14.2(b), (c) and (d) above shall be resolved through binding arbitration as follows: 
  
 (i) A party may submit such dispute to arbitration by
notifying the other party, in writing, of such dispute (the “Arbitration Notice”). Unless otherwise agreed to by the parties, all arbitration proceedings shall be conducted in English and held in New York City, New York. The parties
agree to use a panel of three arbitrators, selected from the American Arbitration Association (“AAA”) Arbitration Panels from the jurisdiction in which the arbitration is to be held. Each party shall select one (1) arbitrator within
thirty (30) days after receipt of such 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 68 

 Arbitration Notice, and the third (3rd) arbitrator must be a former United States federal judge who shall be selected by the parties’ chosen arbitrators within thirty (30) days of the
parties’ chosen arbitrators being selected; provided, however, that if the parties’ arbitrators cannot agree on a third (3rd) arbitrator within such thirty (30)-day period, the third (3rd)
arbitrator shall be a former United States federal judge selected by the New York, New York office of the AAA. The arbitrators shall, in rendering a decision, apply the substantive law of New York. 
  
 (ii) Within thirty (30) days after the designation of the
arbitrators, the arbitrators and the parties shall meet, at which time the parties shall be required to set forth in writing all disputed issues and a proposed ruling on the merits of each such issue. During the meeting, the parties shall negotiate
in good faith the issues to be tried and the scope and schedule of discovery relating to depositions, document production and other discovery devices, taking into account the nature of the dispute submitted for resolution. If the parties are unable
to reach agreement at such meeting as to the scope and schedule of discovery, then the arbitrators may order such discovery as they deem necessary but in accordance with the following: (x) the Federal Rules of Evidence and the Federal Rules of Civil
Procedure shall apply and (y) to the extent practicable, taking into account the nature of the dispute submitted for resolution, such discovery shall be completed in no less than sixty (60) days and no more than one hundred twenty (120) days, as
determined by the arbitrators, taking into consideration the needs of the parties. Such discovery shall be conducted in accordance with the Federal Rules of Civil Procedure. 
  
 (iii) The arbitrators shall set a date for a hearing, which shall be no later than thirty (30) days after
the close of discovery. Except as provided herein, the arbitration shall be governed by the Commercial Arbitration Rules of AAA; provided, however, that R-31 and R-32 of those rules will be modified to the extent that the Federal Rules
of Evidence shall apply with regard to admissibility of evidence. The arbitration shall continue from day-to-day until completed. The arbitrators may then request oral summations by the parties if they deem such summations to be useful. At the
hearing, each party shall submit to the arbitrators and each other party all requested dispositive motions with respect to the claims in arbitration. At such hearing, the parties shall have the right to be represented by counsel. Within thirty (30)
days following the above hearing, both parties shall be entitled to submit post-hearing briefs and findings of fact. 
  
 (iv) The arbitrators shall use their best efforts to rule on each disputed issue within forty-five (45) days after the completion of the
hearings described in this Section 14.2. The arbitrations shall issue an opinion with findings of fact and conclusions of law. In making the award, the arbitrators shall rule on each disputed issue. Resolution of disputes under this Section 14.2
shall be the sole and exclusive means of resolving disputes arising out of or relating to this Agreement (other than Excluded Matters); provided, however, that nothing herein shall preclude a party hereto from seeking in any court of
competent jurisdiction injunctive or other equitable relief. The arbitration proceeding shall be 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 69 

 confidential and, except as required by Law, neither party shall make (or instruct the arbitrators to
make) any public announcement with respect to the proceedings or decision of the arbitrators without the prior consent of the other party. The existence of any dispute submitted pursuant to this Section 14.2, and the award of the arbitrators, shall
be kept in confidence by the parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise required by applicable Law. All rulings of the arbitrator shall be in writing and shall be delivered to the
parties. 
  
 (v) The (x) attorneys’ fees of
the parties in any arbitration, (y) fees of the arbitrators and (z) costs and expenses of the arbitration shall be borne by the parties as determined by the arbitrators. Any arbitration award may be entered in and enforced by any court of competent
jurisdiction. 
  
 (vi) Nothing contained herein
shall be construed to permit the arbitrators to award punitive, exemplary or any similar damages. By entering into the Agreement and exercising their rights to arbitrate, the parties expressly waive any claim for punitive, exemplary or any similar
damages. The only damages recoverable under this Agreement are those permitted pursuant to Section 13. 
  
 14.3 Jurisdiction. With respect to any suit, action or proceeding relating to this Agreement (each, a “Proceeding”), each party
irrevocably (i) subject to this Section 14.3, agrees and consents to be subject to the exclusive jurisdiction of the United States District Court for the District of Delaware or any Delaware state court sitting in Wilmington, Delaware (any such
court, the “Court”) and (ii) waives any objection which it may have at any time to the laying of venue of any Proceeding brought in any such Court as provided in this Section 14.3, waives any claim that such Proceeding has been
brought in an inconvenient forum and further waives the right to object, with respect to such Proceeding, that such Court does not have any jurisdiction over such party. Notwithstanding the foregoing, (a) if the Court adjudicating such Proceeding
refuses for any reason to exercise jurisdiction over the dispute, either party shall be free to bring such Proceeding in any other Court in such state as provided above and, in the event such other Court refuses for any reason to exercise
jurisdiction over the dispute, either party shall be free to bring such Proceeding in any other court, and (b) if any party (the “initiating party”) commences a Proceeding in any Court, the other party (the “defending party”)
shall possess and retain the right to assert in that same Proceeding all claims and defenses that the defending party may have against the initiating party, including, without limitation, all counterclaims and setoffs. Each of Coley Inc., Coley
Canada and Coley Germany shall at all times maintain an agent for service of process and any other documents in proceedings in Wilmington, Delaware and hereby designates Coley Pharmaceutical Group, Inc. as its agent. Each of Coley Canada and Coley
Germany shall promptly provide PFIZER with written notice of any change in the identity of such agent. Any pleading, judgment or other notice of legal process shall be sufficiently served on each of Coley Inc., Coley Canada and Coley Germany if
delivered to its agent at its then current address. Notwithstanding anything to the contrary contained herein, each party shall be entitled to seek injunctive relief and specific performance in any court in the world. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 70 

 Section 15. MISCELLANEOUS. 
  
 15.1 Force Majeure. Neither party hereto shall be liable to the other party for any losses or damages attributable to
a default in or breach of this Agreement which is the result of war (whether declared or undeclared), acts of God, revolution, acts of terror, fire, earthquake, flood, pestilence, riot, enactment or change of Law, accident(s), labor trouble, or
shortage of or inability to obtain material, equipment or transport or any other cause beyond reasonable control of such party (in no event to include the obligation to pay money). 
  
 15.2 Severability. If and solely to the extent that any provision of this Agreement shall be invalid or
unenforceable, or shall render this entire Agreement to be unenforceable or invalid, such offending provision shall be of no effect and shall not affect the validity of the remainder of this Agreement or any of its provisions; provided,
however, the parties shall use their respective reasonable efforts to renegotiate the offending provisions to best accomplish the original intentions of the parties. 
  
 15.3 Accrued Obligation. Except as provided herein, termination of this Agreement for any reason shall not release
any party hereto from any liability which at the time of such termination has already accrued to the other party or which is attributable to a period prior to such termination, nor shall it preclude either party from pursuing all rights and remedies
it may have hereunder or at law or in equity with respect to any breach of this Agreement. 
  
 15.4 Waivers. Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written
instrument duly executed by or on behalf of the party or parties waiving such term or condition. Neither the waiver by any party of any term or condition of this Agreement, nor the failure on the part of any party, in one or more instances, to
enforce any of the provisions of this Agreement or to exercise any right or privilege, shall be deemed or construed to be a waiver of such term or condition for any similar instance in the future or of any subsequent breach hereof. All rights,
remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement. 
  
 15.5 Entire Agreements; Amendments. This Agreement, together with the
Ancillary Agreements, (together with Agreement and Option dated March 9, 2005, with each of Ottawa Health Research Institute and University of Iowa Research Foundation) sets forth the entire agreement and understanding among the parties as to the
subject matter hereof and supersedes all agreements or understandings, verbal or written, made between COLEY and PFIZER before the date hereof with respect to the subject matter hereof. None of the terms of this Agreement shall be amended,
supplemented or modified except in writing signed by both parties. 
  
 15.6 Survival. The provisions of Sections 2.4, 4.8(c) 6.5, 6.6, 9.1, 12.2, 13, 14 and 15 shall survive according to their respective provisions the expiration or any termination of this Agreement. 
  
 15.7 Assignment. This Agreement may not be assigned or otherwise
transferred by either party without the prior written consent of the other party; provided, however, subject to 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 71 

 this Section 15.7, either party may, without such consent, assign this Agreement and its rights and obligations hereunder
in whole or in part: (i) to any of its respective Affiliates so long as such party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned; (ii) in connection with the transfer or sale of all or
substantially all of its assets or stock, or in the event of its merger or consolidation or similar transaction; or (iii) to a Large Pharmaceutical Company (as defined in the definition of Change of Control) if such party or its Affiliates is
required to, or reasonably believes that it will be required to, divest any of the Licensed Products or a competing product in order to comply with Law or the order of any Governmental Authority as a result of a merger or acquisition;
provided, that if permitted by the Law or applicable Governmental Authority, (x) the other party shall be invited to submit a bid for the rights to be divested and (y) the divesting party grants to the other party a non-exclusive right to
negotiate for a period of thirty (30) days to acquire the rights to be divested; provided, further, that, in the case of PFIZER, PFIZER’s rights and obligations under Section 8.2(e) shall take precedence over this right. Any
purported assignment in violation of this Section 15.7 shall be void. Subject to this Section 15.7, any permitted assignee shall assume all obligations of its assignor under this Agreement. 
  
 15.8 Independent Contractor. The relationship between COLEY and PFIZER
is that of independent contractors. COLEY and PFIZER are not joint venturers, partners, principal and agent, employer and employee, and have no other relationship other than independent contracting parties. 
  
 15.9 Non-Solicitation of Employees. During the term of this Agreement,
neither party shall, directly or indirectly, recruit or solicit any employee of the other party with whom such party has come into contact or interacted for the purposes of performing this Agreement, without the prior consent of the other party,
except pursuant to general solicitations not targeted at such employees. 
  
 15.10 Joint and Several Liability. The parties understand and agree that notwithstanding anything to the contrary contained herein, all obligations and liabilities of Coley Inc., Coley Canada and Coley Germany
under this Agreement shall be joint and several. 
  
 15.11
Designation of Coley Inc as Agent. Each of Coley Canada and Coley Germany hereby designates and authorizes Coley Inc., on behalf of Coley Canada and Coley Germany, respectively, to receive all notices, to give all consents, waivers, approvals
or to take any other action pursuant to this Agreement. Each of Coley Canada and Coley Germany hereby irrevocably appoints Coley Inc. as its attorney-in-fact, subject to the terms hereof, to carry out the matters authorized by this Section 15.11,
including, without limitation, to amend, modify, waive, assign and transfer any rights and obligations relating to the Coley Patent Rights and the Coley Technology. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 72 

 15.12 Notices. All notices, consents, approvals, or other communications required hereunder given
by one party to the other hereunder shall be in writing and made by registered or certified air mail, facsimile, express overnight courier or delivered personally to the following addresses of the respective parties: 
  

					
	If to COLEY:	  	Coley Pharmaceutical Group, Inc.
	 	  	93 Worcester Street, Suite 101
	 	  	Wellesley, MA 02481
	 	  	U.S.A.	  	 
			
	 	  	Attention:	  	Vice President and General Counsel
	 	  	Facsimile:	  	781-431-6403
			
	If to PFIZER:	  	Pfizer Inc.	  	 
	 	  	235 East 42nd Street
	 	  	New York, New York 10017-5755
	 	  	U.S.A.	  	 
			
	 	  	Attention:	  	President, Pfizer Human Health
	 	  	Facsimile:	  	212-808-8652
			
	with a copy to:	  	Attention:	  	Vice Chairman and General Counsel
	 	  	Facsimile:	  	212-808-8924

  
 Notices hereunder shall be deemed to
be effective (a) upon receipt if personally delivered, (b) on the tenth (10th) Business Day following the date of
mailing if sent by registered or certified air mail, and (c) on the second Business Day following the date of transmission or delivery to the overnight courier if sent by facsimile or overnight courier. A party may change its address listed above by
sending notice to the other party in accordance with this Section 15.12. 
  
 15.13 Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any third party, including, without limitation, any creditor of either party. No such
third party shall obtain any right under any provision of this Agreement or shall by reasons of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either party. 
  
 15.14 Binding Effect. This Agreement shall be binding upon and inure
to the benefit of the parties hereto and their respective heirs, successors and permitted assigns. 
  
 15.15 Counterparts. This Agreement may be executed in any two or more counterparts, each of which, when executed, shall be deemed to be an original
and all of which together shall constitute one and the same document. 
  
 15.16 Headings. Headings in this Agreement are included herein for ease of reference only and shall have no legal effect. References to Sections, Schedules, and Exhibits are to Sections, Schedules and Exhibits to this Agreement
unless otherwise specified. 
  
 Remainder of Page Intentionally
Left Blank 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 73 

 IN the parties hereto have caused this Agreement to be executed by their duly authorized officers upon
the date first above written. 
  

									
	COLEY PHARMACEUTICAL GROUP, INC.	 	 	 	PFIZER INC.
					
	By:	 	 /s/ Robert L. Bratzler

	 	 	 	By:	 	 /s/ Lisa Ricciardi

	Name:	 	Robert L. Bratzler	 	 	 	Name:	 	Lisa Ricciardi
	Title:	 	President & CEO	 	 	 	Title:	 	Licensing & Development

  
 COLEY PHARMACEUTICAL GROUP, LTD.

  

			
	By:	 	 /s/ Robert L. Bratzler

	Name:	 	Robert L. Bratzler
	Title:	 	Chairman

  
 COLEY PHARMACEUTICAL, GmbH.

  

			
	By:	 	 /s/ Charles E. Yon

	Name:	 	Charles E. Yon
	Title:	 	Charles E. Yon

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 74 

 EXHIBIT A 
  
 COLEY PATENT RIGHTS 
  
 Section I – Patents and Applications 
  

													
	 WG&S ID

	  	 SN

	  	 FILING
DATE

	  	 INVENTORS

	  	 ASSIGNEES

	  	 TITLE

	  	 STATUS

	 [***************]
	  	[************]	  	[******]	  	 [*****]
 [******]
	  	 [****]
 [****]
	  	 [***********************
 **********************
 ****************]
	  	 Issued US 6,653,292
 11/25/03

							
	 [***************]
	  	 [**********]
 [**************]
	  	[********]	  	 [*****]
 [******]
	  	 [****]
 [****]
	  	 [**********************
 *********************

******************]
	  	Published
							
	 [***************]
	  	 [************]
 [************]
	  	[********]	  	 [******]
 [********]
	  	 [****]
 [********]
	  	 [**********************
 *********************

******************]
	  	 Pending
 Published 02-06-2003

							
	 [*********]
 [******]
 [******]
 [*****]
	  	 [**********]
 [*******]
 [********.*]
 [***********]
	  	[********]	  	 [******]
 [********]
	  	 [****]
 [********]
	  	 [**********************
 *********************

*****************]
	  	 Pending
 Pending
 Published 04/02/03 1296714
 Pending

							
	 [*************]
	  	 [************]
 [************]
	  	[*******]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************]
 [****************]
	  	 Pending
 CON of C1039.70029US
 Published 5/6/04

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-1 

 Section II – Patents and Applications 
  

													
	 WG&S ID

	  	 SN

	  	 FILING
DATE

	  	 INVENTORS

	  	 ASSIGNEES

	  	 TITLE

	  	 STATUS

	 [***************]
	  	[************]	  	[********]	  	 [*********]
 [*****]
	  	 [****]
 [****]
	  	 [*********************
 ***********************]
	  	Pending
							
	 [***************]
	  	[************]	  	[********]	  	 [*********]
 [*****]
	  	 [****]
 [****]
	  	 [*********************
 ***********************]
	  	Pending
							
	 [***************]
	  	 [**************]
 [**********]
	  	[********]	  	 [*********]
 [*****]
	  	 [****]
 [****]
	  	 [*********************
 ***********************]
	  	 Expired, Entered National Phase
 Published
12/02/99

							
	 [*********]
 [******]
 [******]
 [******]
 [********]
 [******]
 [*****]
 [**********]
 [***********]
	  	 [********]
 [***********]
 [*******]
 [**********]
 [**********]
 [******]
 [***********]
 [******]
 [*********]
	  	[********]	  	 [*********]
 [*****]
	  	 [****]
 [****]
	  	 [*********************
 ***********************]
	  	 Granted 761899
 Published
 Pending
 Published 1077722
 Pending
 Pending
 Published 2002-516294
 Granted 508927
 Granted 20006765

							
	 [***************]
	  	 [**********]
 [**************]
	  	[********]	  	 [******]
 [*******]
	  	 [*******]
 [*******]
	  	 [********************
 ******************
 ********************
 ****************]
	  	 Published 11/25/04
 CON of 09/241,653, filed
2/2/99

							
	 [***************]
	  	 [**********]
 [**************]
	  	[********]	  	 [******]
 [*******]
	  	 [*******]
 [*******]
	  	 [********************
 ******************
 ********************
 ****************]
	  	 Published 11/25/04
 CON of 09/241,653, filed
2/2/99

							
	 [***************]
	  	 [**********]
 [**************]
	  	[********]	  	 [******]
 [*******]
	  	 [*******]
 [*******]
	  	 [********************
 ******************
 ********************
 ****************]
	  	 Published 11/25/04
 CON of 09/241,653, filed
2/2/99

							
	 [***************]
	  	 [**********]
 [**********]
	  	[********]	  	 [******]
 [*******]
	  	 [********]
 [********]
	  	 [********************
 **********************

****************]
	  	 Published 11/18/99
 Nat’l Phase
11/02/00

							
	 [*********]
 [******]
 [******]
 [******]
 [*****]
 [**********]
 [***********]
	  	 [********]
 [*******]
 [**********]
 [******]
 [***********]
 [******]
 [*********]
	  	[********]	  	 [******]
 [*******]
	  	 [********]
 [********]
	  	 [********************
 **********************

****************]
	  	 Granted 9/4/2003 as 760795
 Published
 Granted Register in UK,DE and FR
 Published – laid open as
2002-514397
 Granted 508650
 Granted August 29, 2001
2000/7071

							
	 [***************]
	  	 [**************]
 [**********]
 [************]
	  	 [********]
 [*******]
	  	 [******]
 [*******]
 [****]
	  	 [********]
 [********]
 [********]
	  	 [**************
 ***********************
 *****************
 *******************
 ************************]
	  	 PCT prosecuted by Wachenfeld
 PCT Published
07/30/98
 National Filing/Pending
 EP
ABANDONED

							
	 [***************]
	  	[************]	  	[*******]	  	 [******]
 [*******]
 [****]
	  	 [********]
 [********]
 [********]
	  	 [**************
 ***********************
 *****************
 *******************
 ************************]
	  	 Pending
 CON 09/355,254 filed7/23/99

							
	 [***************]
	  	[**********]	  	[********]	  	 [******]
 [*******]
 [****]
	  	 [********]
 [********]
 [********]
	  	 [**************
 ***********************
 *****************
 *******************
 ************************]
	  	Pending
							
	 [***************]
	  	 	  	 	  	 [*******]
 [********]
	  	 [********]
 [********]
	  	 [***********************
 *******************]
	  	On Hold Per Client

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-2 

													
	 WG&S ID

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEES

	  	 TITLE

	  	 STATUS

	 [***************]
	  	 [************]
 [************]
	  	[********]	  	 [*******]
 [*****]
 [******]
	  	 [********]
 [********]
 [********]
	  	 [************************
 ********************
 *************************]
	  	Allowed
							
	 [***************]
	  	[**********]	  	[********]	  	 [*******]
 [*****]
 [******]
	  	 [********]
 [********]
 [********]
	  	 [************************
 ********************
 *************************]
	  	Pending
							
	 [***************]
	  	 [**************]
 [******************]
 [**********]
	  	[********]	  	 [*******]
 [*****]
 [******]
	  	 [********]
 [********]
 [********]
	  	 [************************
 ********************
 *************************]
	  	 National Phase
 Published 03/21/02

							
	 [*********]
 [******]
 [******]
 [*****]
 [**********]
	  	 [**********]
 [******]
 [**********]
 [***********]
 [******]
	  	[********]	  	 [*******]
 [*****]
 [******]
	  	 [********]
 [********]
 [********]
	  	 [************************
 ********************
 *************************]
	  	 Pending
 Pending
 Published 12/03/03 1366077
 Pending
 Pending

							
	 [***************]
	  	 [**************]
 [***********]
	  	[********]	  	 [*******]
 [********]
	  	 [********]
 [********]
	  	 [***********************
 *******************]
	  	 Pending (designating US)
 Published 09/06/02

Nat’l Phase 06/04/03

							
	 [******]
	  	[**********]	  	[********]	  	 [*******]
 [********]
	  	 [********]
 [********]
	  	 [***********************
 *******************]
	  	Publication No. 1350262
							
	 [***************]
	  	 [************]
 [************]
	  	[********]	  	[***************]	  	 [********]
 [********]
	  	 [***********************
 *******************]
	  	 Continuation of C1041/7007 and C1041/7018WO
 Published
09-25-2003

							
	 [***************]
	  	 [**********]
 [*****************]
 [***********]
	  	[*******]	  	 [*******]
 [****]
 [********]
 [********]
 [*****]
	  	 [********]
 [********]
 [********]
 [********]
 [********]
	  	 [*********************
 *****************
 **********************]
	  	Published 11/4/04
							
	 [***************]
	  	[************]	  	[********]	  	 [*******]
 [*******]
 [*****]
 [****]
	  	 [********]
 [********]
 [********]
 [********]
	  	 [**********************
 *******************

************************]
	  	 Non-Provisional
 Pending

							
	 [***************]
	  	[*************]	  	[********]	  	 [*******]
 [*******]
 [*****]
	  	 [********]
 [********]
 [********]
	  	 [**********************
 ************
 ************************
 ************************
 **]
	  	 Pending
 PCT

							
	 [***************]
	  	 [************]
 [**************]
	  	[********]	  	 [******]
 [*******]
	  	 [********]
 [********]
	  	 [********************
 ******************
 ********************
 ****************]
	  	 Continuation of C1041/7002
 Pending
 Published

							
	 [***************]
	  	[************]	  	[********]	  	 [*****]
 [*******]
 [******]
 [****]
	  	 [********]
 [********]
 [********]
 [*********]
	  	 [*******************
 ************************

************************
 **************]
	  	Pending
							
	 [***************]
	  	[************]	  	[********]	  	 [**********]
 [******]
	  	 [********]
 [********]
	  	 [*******************
 ****************
 **********************]
	  	 Issued US 5,663,153
 09-02-97

							
	 [***************]
	  	[************]	  	[********]	  	 [**********]
 [******]
	  	 [********]
 [********]
	  	 [*******************
 ****************
 **********************]
	  	 Issued US 5,723,335
 03-03-98

							
	 [***************]
	  	[************]	  	[********]	  	 [**********]
 [******]
	  	 [********]
 [********]
	  	 [*******************
 ****************
 **********************]
	  	 Issued US 6,727,230
 4-27-2004
 Continuation filed (C1037.70049US00)

							
	 [***************]
	  	 [**********]
 [**************]
	  	[**********]	  	 [*****]
 [***********]
 [*******]
	  	 [********]
 [********]
 [********]
 [********]
	  	 [********************
 ************]
	  	 Pending
 Published 9/2/04

							
	 [***************]
	  	 [**********]
 [*************]
	  	[********]	  	 [*****]
 [*******]
 [****]
	  	 [*******]
 [*********]
 [*********]
	  	 [********************
 ************]
	  	Published

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-3 

													
	 WG&S ID

	  	 SN

	  	 FILING
DATE

	  	 INVENTORS

	  	 ASSIGNEES

	  	 TITLE

	  	 STATUS

	 [***************]
	  	 [**********]
 [************]
	  	[********]	  	[*****]	  	[********]	  	 [***********************
 ********************

*********]
	  	Published 04/08/04
							
	 [***************]
	  	 [**************]
 [*************]
	  	[********]	  	[*****]	  	[********]	  	 [***********************
 ********************

*********]
	  	 Published
 International Publication No. WO
2004/005476.

							
	 [***************]
	  	[**********]	  	[********]	  	[*****]	  	[********]	  	 [***********************
 ********************

*********]
	  	Pending
							
	 [***************]
	  	 [**********]
 [****************]
	  	[********]	  	[*****]	  	[********]	  	 [***********************
 ********************

*********]
	  	Published 03/18/04

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-4 

													
	 WG&S ID

	  	 SN

	  	 FILING
DATE

	  	 INVENTORS

	  	 ASSIGNEES

	  	 TITLE

	  	 STATUS

	 [***************]
	  	 [**********]
 [**************]
	  	[********]	  	[*****]	  	[********]	  	 [***********************
 ********************

*********]
	  	Published 8/5/04
							
	 [***************]
	  	 [**********]
 [**************]
	  	[********]	  	[*****]	  	[********]	  	 [***********************
 ********************

*********]
	  	Published 5/13/04
							
	 [***************]
	  	[**********]	  	[********]	  	 [****]
 [*****]
 [*******]
 [******]
 [**********]
 [*******]
 [*******]
	  	 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
	  	 [************************
 *****]
	  	Pending
							
	 [***************]
	  	 [**************]
 [*************]
	  	[********]	  	 [****]
 [*****]
 [*******]
 [******]
 [**********]
 [*******]
 [*******]
	  	 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
	  	 [************************
 *****]
	  	Published 2/26/04

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-5 

													
	 WG&S ID

	  	 SN

	  	 FILING
DATE

	  	 INVENTORS

	  	 ASSIGNEES

	  	 TITLE

	  	 STATUS

	 [*********]
 [*******]
 [*****]
 [*****]
 [**********]
 [*********]
 [**********************]
 [********]
 [******]
 [*******]
 [********]
 [*******]
 [********]
 [******]
 [********]
 [****]
 [******]
 [********]
 [*******]
 [*********]
  
 [*********]
 [******]
 [******]
 [*****]
 [**]
 [*****]
 [*********]
 [******]
 [*****]
 [**********]
 [******]
 [**********]
 [******]
 [***********]
 [****************]
 [*********]
 [*********]
 [*******]
 [*******]
 [*******]
 [***********]
 [********]
 [*********]
 [*******]
 [*****]
 [*******]
 [*********]
 [****]
 [*****************]
 [*****]
 [*******]
	  	 [**********]
 [********]
 [********]
 [********]
 [**************]
 [**********]
 [********]
  
 [*************]
 [**************]
 [****]
 [**********]
 [********]
 [********]
 [********]
 [*****]
 [********]
 [********]
 [******]
 [******]
 [*********]
	  	 [********]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
  
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
 [*******]
  
 [********]
	  	 [****]
 [*****]
 [*******]
 [******]
 [**********]
 [*******]
 [*******]
	  	 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
	  	 [************************
 *****]
	  	 Pending
 Pending
 Pending
 Pending
  
 Pending
 Pending
  
 Pending
 Pending
 Pending
 Granted LE 6797 30-Oct-03
 Pending
 Granted-NI RP15525
 Pending
 Pending
 Pending
 Published
 Published
 Published
 Pending

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-6 

													
	 WG&S ID

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEES

	  	 TITLE

	  	 STATUS

	 [***************]
	  	[**********]	  	[*******]	  	 [**********]
 [******]
	  	 [********]
 [********]
	  	 [*******************
 ****************
 **********************]
	  	Pending
							
	 [***************]
	  	[**********]	  	[*******]	  	 [********]
 [********]
	  	 [********]
 [********]
	  	 [************************
 **************
 *********************
 ************************
 ******]
	  	 Pending
 CON of C1037.70017

							
	 [***************]
	  	[**********]	  	[********]	  	 [*******]
 [********]
	  	[********]	  	 [*********************
 ****************
 *********]
	  	Pending
							
	 [***************]
	  	[**********]	  	[**********]	  	 [*****]
 [**********]
 [*******]
 [*******]
	  	 [********]
 [********]
 [********]
 [********]
	  	 [****************
 *****************
 ****************]
	  	Pending
							
	 [***************]
	  	[************]	  	[********]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 Issued US 6,194,388 B1
 02/27/2001

							
	 [***************]
	  	 [*************]
 [**********]
	  	[********]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 National Stage
 Published 02/01/96

							
	 [*********]
 [******]
 [**]
 [*****]
	  	 [*********]
 [*******]
 [**********]
 [********]
	  	[********]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 Granted Patent No. 713040
 Published
 Published 0772619
 Granted 3468773

							
	 [***************]
	  	[************]	  	[********]	  	 [*****]
 [*****]
 [*******]
 [*********]
	  	 [****]
 [****]
 [***]
 [********]
	  	 [************************
 *************]
	  	 Issued US 6,207,646 B1
 03/27/01

							
	 [***************]
	  	[************]	  	[********]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [************************
 *************]
	  	 Issued US 6,239,116 B1
 05/29/01

							
	 [***************]
	  	 [***************]
 [**********]
	  	[********]	  	 [*****]
 [*****]
 [*******]
 [*********]
	  	 [****]
 [****]
 [***]
 [********]
	  	 [************************
 *************]
	  	 National Phase 04/14/99
 Published
05/07/98

							
	 [*********]
 [******]
 [*****]
 [**]
 [*****]
 [**********]
 [*********]
 [**********]
	  	 [********]
 [*******]
 [**********]
 [**********]
 [*********]
 [******]
 [*********]
 [*******]
	  	[********]	  	 [*****]
 [*****]
 [*******]
 [*********]
 [*******]
	  	 [****]
 [****]
 [***]
 [********]
 [****]
	  	 [************************
 *************]
	  	 Abandoned,
Divisional Filed
 Published
 Published 11/17/99 CN1235609A
 Published 10/13/99 0948510
 Published 03/13/01 2001-503267
 Granted 335397 – 03/08/01
 Granted 05/02/02 65171
 Pending

							
	 [***************]
	  	 [**************]
 [**********]
	  	[********]	  	 [*****]
 [******]
 [*****]
 [*******]
 [*********]
	  	 [****]
 [********]
 [****]
 [***]
 [********]
	  	 [*****************
 **********************
 *******************
 ********]
	  	 Entered National Phase 08/18/99
 Published
09/17/98

							
	 [*********]
 [******]
 [******]
 [*****]
	  	 [********]
 [*******]
 [**********]
 [********]
	  	 [********]
 [********]
 [********]
 [********]
	  	 [*****]
 [******]
 [*****]
 [*******]
 [*********]
	  	 [****]
 [********]
 [****]
 [***]
 [********]
	  	 [*****************
 **********************
 *******************
 ********]
	  	 Granted (753688)
 Pending
 Published 06/07/00
 Published 04/16/02

							
	 [***************]
	  	[************]	  	[********]	  	 [*****]
 [********]
	  	 [****]
 [****]
	  	 [************************
 ****************
 ************************]
	  	 Issued US 6,429,199 B1
 08/06/02

							
	 [***************]
	  	[************]	  	[********]	  	 [*****]
 [******]
	  	 [****]
 [****]
	  	 [***********************
 **********************
 ****************]
	  	 Issued US 6,653,292
 11/25/03

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-7 

													
	 WG&S ID

	  	SN

	 	 FILING
 DATE

	 	INVENTORS

	 	ASSIGNEES

	 	 TITLE

	  	 STATUS

	 [***************]
	  	[**********]
[**************]	 	[********]	 	[*****]
[******]	 	[****]
[****]	 	 [***********************
 **********************
 ****************]
	  	Published
							
	 [***************]
	  	[************]	 	[********]	 	[*****]	 	[****]	 	 [**********************
 *******************

*****************
 ****************]
	  	Allowed-RCE filed 01/27/02
							
	 [***************]
	  	[************]	 	[********]	 	[*****]
[******]
[*****]	 	[****]
[********]
[****]	 	 [*****************
 **********************
 ***********************
 ********]
	  	 Issued US 6,406,705 B1
 06/18/02

							
	 [***************]
	  	[************]	 	[********]	 	[*****]
[******]	 	[****]
[****]	 	 [*********************
 ********************

***********
 *****************
 *******************
 *********]
	  	 Issued US 6,218,371 B1
 04/17/01

							
	 [***************]
	  	[**************]
[**********]	 	[********]	 	[*****]
[******]	 	[****]
[****]	 	 [*********************
 ********************

***********
 *****************
 *******************
 *********]
	  	 Entered National Stage
 Published
10/14/99

							
	 [*********]
 [******]
 [******]
 [********]
 [*****]
	  	[********]
[*******]
[**********]
[**********]
[***********]	 	[********]	 	[*****]
[******]	 	[****]
[****]	 	 [*********************
 ********************

***********
 *****************
 *******************
 *********]
	  	 Granted 760549
 Granted 2323929
 Published 01/17/01 EP 1067956
 Published 1034039
 Published 04/09/02 2002510644

							
	 [***************]
	  	[************]	 	[********]	 	[*****]
[********]
[*******]	 	[****]
[********]
[********]	 	 [************************
 *****]
	  	Pending (Nonprovisional of 70030,70031 and 70040)

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-8 

													
	 WG&S ID

	  	 SN

	  	FILING
DATE

	 	INVENTORS

	 	ASSIGNEES

	 	 TITLE

	  	 STATUS

	 [***************]
	  	 [**************]
 [**********]
	  	[********]	 	[*****]
[********]
[*******]	 	[****]
[********]
[********]	 	 [************************
 *****]
	  	 Entered National Stage 03/06/02
 Published
04/05/01

							
	 [******************]
 [*****]
 [*********]
 [******************]
 [********]
 [******]
 [******]
 [*****]
 [*******]
 [*************]
 [*******]
 [******]
 [********]
 [*******]
 [*****]
 [*********]
 [******]
 [*****]
 [******]
 [**********]
 [******]
 [****]
 [******]
 [*****************]
 [*********]
 [********]
 [***********]
 [**********]
 [******]
 [*******]
 [**********]
	  	 [********]
 [**************]
 [********]
 [**********]
 [******]
 [***********]
 [*******]
 [**********]
 [**********]
 [*********]
 [***********]
 [**********]
 [*********]
 [**********]
 [**********]
 [*********]
 [***********]
 [******]
 [**********]
 [***********]
 [******]
 [********]
 [**********]
 [*******]
 [**********]
 [***********]
 [***********]
 [*********]
 [***********]
 [**********]
 [**********]
 [*******]
	  	[********]	 	[*****]
[********]
[*******]	 	[****]
[********]
[********]	 	 [************************
 *****]
	  	 Abandoned
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending- Published
 Pending –
Published
 Pending
 Pending
 Pending – Published
 EP – Allowed
 Published 1221955
 Published
 Pending
 Pending
 Published
 Pending
 Pending
 Pending
 Granted 1496
 Pending
 Granted 12028
 Pending
 RU - Granted
 Pendign
 Granted 87982
 Pending
 Granted
 Published 20028509
 Pending

							
	 [***************]
	  	[********]	  	[********]	 	[*****]
[*******]
[*********]	 	[****]
[***]
[********]	 	 [****************
 ****************]
	  	 Granted No. 754463
 Issued 03/06/03

							
	 [***************]
	  	[************]	  	[********]	 	[********]
[********]
[*****]	 	[********]
[********]
[****]	 	 [****************
 ************************
 **********************]
	  	Allowed
							
	 [***************]
	  	 [**************]
 [**********]
	  	[********]	 	[********]
[********]
[*****]	 	[********]
[********]
[****]	 	 [****************
 ************************
 **********************]
	  	 Entered National Phase 02/28/02
 Published
04/05/01

							
	 [*********]
 [******]
 [******]
  
  
 [******]
 [*****]
 [******]
 [**********]
  
  
 [*********]
 [***********]
	  	 [********]
 [*********]
 [**********]
  
  
 [******]
 [**********]
 [***********]
 [******]
  
  
 [***********]
 [*********]
	  	[********]	 	[********]
[********]
[*****]	 	[********]
[********]
[****]	 	 [****************
 ************************
 **********************]
	  	 Pending
 Pending
 Published 07/10/02 1220684
 Pending
 Pending – Laid open under 2003-510290)
 Pending
 Granted 04/30/04 87690
  
 Issued 05/28/03
 Issued 2002/1959

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-9 

													
	 WG&S ID

	  	 SN

	  	FILING
DATE

	 	INVENTORS

	 	ASSIGNEES

	 	 TITLE

	  	 STATUS

	 [***************]
	  	[************]	  	[********]	 	[*****]
[*****]
[*******]
[*********]	 	[****]
[****]
[***]
[********]	 	 [************************
 ************]
	  	 Pending
 CON of 09/818,918, filed 3/27/01,
 which is a DIV of 08/738,652, filed 10/30/96, (Pat. 6,207,646B1),
 which is a
CIP of 08/386,063, filed 2/7/95 (Pat. No. 6,194,388), which is a CIP of 08/276,358, filed 7/15/94 (abandoned)

							
	 [***************]
	  	[************]	  	[********]	 	[*****]
[*****]
[*******]
[*********]	 	[****]
[****]
[***]
[********]	 	 [************************
 ************]
	  	 Pending
 CON of 09/818,918, filed 3/27/01,
 which is a DIV of 08/738,652, filed 10/30/96, (Pat. 6,207,646B1),
 which is a
CIP of 08/386,063, filed 2/7/95 (Pat. No. 6,194,388), which is a CIP of 08/276,358, filed 7/15/94 (abandoned)

							
	 [***************]
	  	[************]	  	[********]	 	[*****]
[*****]
[*******]
[*********]	 	[****]
[****]
[***]
[********]	 	 [************************
 ************]
	  	 Pending
 CON of 09/818,918, filed 3/27/01,
 which is a DIV of 08/738,652, filed 10/30/96, (Pat. 6,207,646B1),
 which is a
CIP of 08/386,063, filed 2/7/95 (Pat. No. 6,194,388), which is a CIP of 08/276,358, filed 7/15/94 (abandoned)

							
	 [***************]
	  	[************]	  	[********]	 	[*****]
[*****]
[*******]
[*********]	 	[****]
[****]
[***]
[********]	 	 [************************
 ************]
	  	 Pending
 CON of 09/818,918, filed 3/27/01,
 which is a DIV of 08/738,652, filed 10/30/96, (Pat. 6,207,646B1),
 which is a
CIP of 08/386,063, filed 2/7/95 (Pat. No. 6,194,388), which is a CIP of 08/276,358, filed 7/15/94 (abandoned)

							
	 [***************]
	  	[************]	  	[********]	 	[*****]
[*****]
[*******]
[*********]	 	[****]
[****]
[***]
[********]	 	 [************************
 ************]
	  	Pending
							
	 [***************]
	  	 [************]
 [************]
	  	[********]	 	[*****]
[******]	 	[****]
[****]	 	 [*********************
 ********************

***********
 *****************
 *******************
 *********]
	  	 Pending
 DIV of C1039.70026
 Published 05-30-2002

							
	 [***************]
	  	 [************]
 [************]
	  	[********]	 	[******]
[********]	 	[****]
[********]	 	 [*******************
 ************************

*****************]
	  	 Pending
 Published 02-06-2003

							
	 [***************]
	  	 [**************]
 [**********]
	  	[********]	 	[******]
[********]	 	[****]
[********]	 	 [*******************
 ************************

*****************]
	  	 Pending
 Published 12/27/01
 Nat’l phase 11/22/02

							
	 [*********]
 [******]
 [******]
 [*****]
	  	 [**********]
 [*******]
 [**********]
 [***********]
	  	[********]	 	[******]
[********]	 	[****]
[********]	 	 [*******************
 ************************

*****************]
	  	 Pending
 Pending
 Published 04/02/03 1296714
 Pending

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-10 

													
	 WG&S ID

	  	 SN

	  	 FILING
 DATE

	 	INVENTORS

	 	ASSIGNEES

	 	 TITLE

	  	 STATUS

	 [***************]
	  	[**********]	  	[********]	 	[*****]
[*******]
[*********]	 	[****]
[***]
[********]	 	 [*****************
 ****************]
	  	 Pending
 DIV of C1039.70001EP
 Published 01/02/02 1167378

							
	 [***************]
	  	[**********]	  	[********]	 	[*****]
[*******]
[*********]	 	[****]
[***]
[********]	 	 [*****************
 ****************]
	  	Pending
							
	 [[***************]
	  	 [************]
 [************]
	  	[********]	 	[*****]
[******]
[*****]	 	[****]
[********]
[****]	 	 [*****************
 **********************
 ***********************
 ********]
	  	 Pending
 DIV of C1039.70025
 Published 11-07-2002

							
	 [***************]
	  	[**********]	  	[********]	 	[*****]
[******]
[*****]	 	[****]
[********]
[****]	 	 [*****************
 **********************
 ***********************
 ********]
	  	 Pending
 CIP of C1039.70058, a DIV of
C1039.70025

							
	 [***************]
	  	[********]	  	[********]	 	[*****]
[*******]
[*********]	 	[****]
[***]
[********]	 	 [************************
 *************]
	  	 Granted 11/4/04
 775185
 DIV of C1039.70005AU
 Published 7/22/04 775185

							
	 [***************]
	  	[**********]	  	[********]	 	[*****]
[*******]
[*********]	 	[****]
[***]
[********]	 	 [************************
 *************]
	  	 Pending
 DIV of C1039.70059AU

							
	 [***************]
	  	 [************]
 [************]
	  	[********]	 	[*****]
[********]	 	[****]
[****]	 	 [************************
 ****************
 ************************]
	  	 Pending
 DIV of C1039.70017
 Published 05-29-2003

							
	 [***************]
	  	 [************]
 [************]
	  	[********]	 	[*****]
[*******]
[*******]	 	[****]
[********]
[********]	 	 [**********************
 ***********
 ********************
 ****************]
	  	 Pending
 Nonprovisional of C1039.70047 and
C1039.70064
 Published 03/06/03

							
	 [***************]
	  	 [**************]
 [***********]
	  	[********]	 	[*****]
[*******]
[*******]	 	[****]
[********]
[********]	 	 [**********************
 ***********
 ********************
 ****************]
	  	 Entered National Phase:
 02-17-2004
 Published 02/27/03

							
	 [*********]
 [******]
 [******]
 [*****]
 [*******]
 [******]
 [*****]
 [*********]
 [******]
 [*****]
 [********]
 [******]
 [**********]
 [*********]
 [***********]
 [**********]
 [*******]
	  	 [***********]
 [*******]
 [**********]
 [*********]
 [**********]
 [**************]
 [*************]
 [******]
 [***************]
 [******]
 [***********]
 [*********]
 [***************]
 [************]
	  	[*******]	 	[*****]
[*******]
[*******]	 	[****]
[********]
[********]	 	 [**********************
 ***********
 ********************
 ****************]
	  	 Pending
 ABANDONED
 Pending
 Pending
 Pending
 Published 1446162
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Published 4/30/04
2004-36714
 Pending

							
	 [***************]
	  	[***********]	  	[********]	 	[*****]
[*********]
[*******]	 	[****]
[********]
[***]	 	 [****************
 ****************]
	  	 Pending-Published 05/20/3
 DIV of 70001JP
 2003144184

							
	 [***************]
	  	[**********]	  	[********]	 	[*****]
[*********]
[*******]	 	[****]
[********]
[***]	 	 [****************
 ****************]
	  	Pending
							
	 [***************]
	  	 [************]
 [****************]
	  	[*******]	 	[*****]
[*******]
[*********]	 	[****]
[***]
[********]	 	 [************************
 *************]
	  	 Pending
 CON of C1039.70048US
 Published 7/29/04

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-11 

													
	 WG&S ID

	  	 SN

	  	 FILING
DATE

	  	 INVENTORS

	  	 ASSIGNEES

	  	 TITLE

	  	 STATUS

	 [***************]
	  	[**********]	  	[********]	  	[*****]	  	 	  	 [************************
 *************]
	  	Pending
							
	 [***************]
	  	[************]	  	[********]	  	[*****]	  	[****]	  	 [************************
 *************]
	  	 Pending
 CON of C1039.70023US

							
	 [***************]
	  	[***********]	  	[********]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 Pending
 Divisional of 70001JP

							
	 [***************]
	  	[***********]	  	[********]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 Pending
 Divisional of 70001JP

							
	 [*************]
	  	 [************]
 [************]
	  	[*******]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 Pending
 CON of C1039.70029US
 Published 5/6/04

							
	 [***************]
	  	 [*************]
 [************]
	  	[*******]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 Pending
 Published 8/5/04
 CON of C1039.70083US

							
	 [***************]
	  	 [*************]
 [*************]
	  	[*******]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 Pending
 Published 7/22/04
 CON of C1039.70083US

							
	 [***************]
	  	 [*************]
 [**************]
	  	[*******]	  	 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [********]
	  	 [****************
 ****************]
	  	 Pending
 Published 8/19/04
 CON of C1039.70083US

							
	 [***************]
	  	[***********]	  	[********]	  	 [*****]
 [*****]
 [*******]
 [*********]
 [*******]
	  	 [****]
 [****]
 [***]
 [********]
 [****]
	  	 [************************
 *************]
	  	Pending

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 A-12 

 EXHIBIT B – TRANSITION PLAN 
  

	1.	Transition Services 

  

	1.1	Document, Information, and Material Transfer 

  

	 	1.1.1	Immediate Requests. COLEY shall provide the documents, information, and materials identified in Attachment B-1 to PFIZER within five (5) days after the Effective Date.

  

	 	1.1.2	Requests Prior to the Comprehensive Request. Prior to the Comprehensive Request (defined below), PFIZER may, through the Pfizer Program Leader, request documents,
information, and physical samples needed to comply with PFIZER’s obligations under the License Agreement. COLEY shall use reasonable efforts to provide such documents, information, and materials in the requested format within fifteen (15) days
after receipt of any such request from PFIZER. 

  

	 	1.1.3	Trial Master Files. PFIZER shall provide written instructions to COLEY regarding the organization of trial master files for all clinical studies on the Compound. COLEY shall
forward such trial master files to PFIZER, organized in accordance with PFIZER’s written instructions (as may be amended by the Pfizer Program leader), on the following schedule: 

  

			
	 Clinical Study(ies)

	  	 Due Date

	 [************
 **********]
	  	 [***************
 ***************]

	 [***]
	  	 [**********************
 ***********]

	 [****]
	  	 [***************]

	 [**********]
	  	 [***************]

	 [************
 ******]
	  	 [**********************
 **********************]

  

	 	1.1.4	Comprehensive Request. PFIZER shall, through the Pfizer Program Leader, submit a single final comprehensive request for the transfer of documents, information, and materials
to COLEY, including but not limited to those requests currently set forth in Attachment B-2, within six (6) weeks after the Effective Date (the “Comprehensive Request”). COLEY shall use reasonable efforts to provide such
documents, information, and materials in the requested format within six (6) weeks after receipt of the final Comprehensive Request from PFIZER. For clarity, the Comprehensive Request is intended to capture a significant majority of the remaining
document, information, and material requests from PFIZER. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-1 

	 	1.1.5	Requests After the Comprehensive Request. PFIZER may, through the Pfizer Program Leader, request other documents, information, and physical samples on an as-needed basis
throughout the Term of the License Agreement. COLEY shall use reasonable efforts to provide such documents, information, and material transfers in the requested format within one (1) month after receipt of any such request from PFIZER.

  

	 	1.1.6	Compensation. PFIZER shall reimburse COLEY for actual out-of-pocket costs incurred pursuant to this Section 1.1, including without limitation storage costs associated with
storing documents, data, and other materials at third-party facilities. In addition, as an exception to Section 2.1, PFIZER shall reimburse COLEY for actual out-of-pocket photocopying costs and shipping costs that are incurred pursuant to Section
1.1.1 (immediate requests) prior to the Effective Date; notwithstanding the foregoing, it is understood that COLEY shall have no obligation to incur any such out-of-pocket photocopying or shipping costs incurred prior to the Effective Date, and any
decision to incur such costs shall be made in COLEY’s sole discretion. For clarity, PFIZER shall not reimburse COLEY for any out-of-pocket costs for photocopies that COLEY chooses to maintain for its own purposes. 

  

	1.2	Regulatory Applications 

  

	 	1.2.1	United States INDs. Within five (5) days after the Effective Date, COLEY shall execute documents to transfer the sponsorship to PFIZER of all United States INDs.

  

	 	1.2.2	Non-U.S. INDs. With respect to all non-US INDs, COLEY shall use reasonable efforts to execute documents to either (i) transfer the sponsorship for such INDs to PFIZER, or
(ii) permit PFIZER to file new INDs for the continuing treatment of clinical trial subjects in existing programs, in each case within one (1) month after the Effective Date. If neither of the foregoing options is viable in a given country, COLEY
shall continue to maintain the corresponding INDs for the Compound in such country at PFIZER’s direction and expense until the termination or completion of the corresponding clinical trials. 

  

	 	1.2.3	Interaction with Regulatory Authorities. PFIZER shall direct any interactions relating to the Compound between COLEY and any Regulatory Authority that occur after the
Effective Date. 

  

	 	1.2.4	Compensation. PFIZER shall reimburse COLEY for actual out-of-pocket costs incurred pursuant to this Section 1.2. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-2 

	1.3	Conduct of Ongoing Clinical Trials 

  

	 	1.3.1	[**********] Clinical Trials. COLEY shall continue to conduct the [**********] clinical trials, even after the regulatory sponsorship for such clinical trials transfers to
PFIZER in accordance with Section 1.2, until the Pfizer Program Leader requests, in writing, that the conduct of such clinical trials be transferred to PFIZER. For clarity, COLEY shall continue to conduct such clinical trials pursuant to its own
internal processes and procedures (consistent with past practices), except as may be reasonably requested otherwise by the Pfizer Program Leader. 

  

	 	1.3.2	Other Clinical Trials. COLEY shall continue to conduct the [****************] clinical trials, even after the regulatory sponsorship for such clinical trials transfers to
PFIZER in accordance with Section 1.2, until such trials are completed. For clarity, COLEY shall continue to conduct such clinical trials pursuant to its own internal processes and procedures (consistent with past practices), except as may be
reasonably requested otherwise by the Pfizer Program Leader. 

  

	 	1.3.3	Compensation. PFIZER shall reimburse COLEY for actual (GAAP) out-of-pocket costs incurred pursuant to this Section 1.3; provided, however, that PFIZER shall not be required
to reimburse COLEY for any such costs that exceed [**********]. 

  

	1.4	Supplies for Ongoing Studies 

  

	 	1.4.1	Ongoing Clinical Trials. COLEY shall continue to supply finished drug product and, upon PFIZER’s request, active pharmaceutical ingredients, for use by subjects in the
[*************************] clinical trials from COLEY’s available inventory, in each case at no cost to PFIZER, until such trials are completed. COLEY confirms that it has set aside sufficient materials from its currently available inventory
to complete such clinical trials in accordance with current projections. Notwithstanding the preceding sentence, if COLEY’s available inventory becomes insufficient to supply such clinical trials through no fault of COLEY, PFIZER shall supply
the additional finished drug product or active pharmaceutical ingredients required to complete such trials at PFIZER’s sole expense. 

  

	 	1.4.2	Ongoing Collaborative Agreements. COLEY shall continue to supply finished drug product and active pharmaceutical ingredients for use within the current scope of the ongoing
collaborative agreements (identified in Section 1.9.1) from COLEY’s available inventory, in each case at no cost to PFIZER, until each such agreement terminates. COLEY confirms that, it has set aside sufficient materials from its currently
available inventory to fulfill the obligations of such agreements in accordance with current projections. Notwithstanding the preceding sentence, 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-3 

	 	    	if COLEY’s available inventory becomes insufficient to fulfill such obligations through no fault of COLEY, PFIZER shall supply the additional finished drug product or active
pharmaceutical ingredients required to fulfill such obligations at PFIZER’s sole expense. 

  

	 	1.4.3	[*********************************]. If requested by PFIZER, COLEY shall supply finished drug product or active pharmaceutical ingredients to PFIZER for use pursuant to
[***************************]. For clarity, COLEY shall only supply such finished drug product or active pharmaceutical ingredients to PFIZER from COLEY’s available inventory. PFIZER shall reimburse COLEY solely for COLEY’s cost to acquire
any such finished drug product or active pharmaceutical ingredients, with no mark-up whatsoever. Notwithstanding the preceding sentence, if COLEY’s available inventory becomes insufficient to fulfill such obligations through no fault of COLEY,
PFIZER shall supply the additional finished drug product or active pharmaceutical ingredients required to fulfill such obligations at PFIZER’s sole expense. 

  

	1.5	Medical Writing 

  

	 	1.5.1	[********************] for the [*****************] The [********** ********************] to the [****** ************] for the
[**********************************************************************] to the [****************************************] for the [**********] with respect to [***************** *****************] and [***************** *****] and
[*********************] to [********] the [*********************************************] (a) [******************************************* *********] on the [***************] (b) [********] and (c) [**********]. Notwithstanding the foregoing,
[************************** **********************************************************] to the [*****************************************] and [***************** *****************] to the [****************************************** ***************].

  

	 	1.5.2	[**************] to the [********************************] of the [******************************** **************************************************************] for the
[************************* ***************************************************************************************] to the [***************************************** ***************] of the [******************************** *************
********************************************************] of the [******************* **************] In accoradance with the [************* *************] to [**********] For [************** ******************] for [*******] the [***************].

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-4 

	 	1.5.3	[********************] for the [************************] the [****************] for the [************ ***************************
***********************************************************] except for the [*****************************************************] and [******************************** ************************************************************************] and
[**************** ****] to [********************] for [******************] the [*************************************** *********************************************************************] to [**********************
*******************************] in order to [********************] to [***************]. 

  

	 	1.5.4	Other Clinical Study Reports. COLEY shall generate the clinical study reports for the [************************* *********************************]
*********************************] clinical trials in accordance with COLEY’s internal processes, procedures, and formats (consistent with past practices). In each case, COLEY shall provide the final clinical study report to PFIZER on the
following schedule: 

  

			
	 Clinical Study(ies)

	  	 Due Date

	[***************]
******]	  	 [*********************
 ***************]

	[*****]	  	[***************]
	[**************]	  	[***************]
	[***************]
****]	  	 [*************************
 ********************]

  

	 	1.5.5	Compensation. PFIZER shall pay COLEY the following amounts as the sole compensation for the completion of these services, in each case without regard to whether COLEY
provides such services using internal or external resources: 

  

			
	 Service

	  	 Charge

	 [****************************]
	  	 [*******]

	 [****************************]
	  	 [*******]

	 [***************]
	  	 [*******]

	 [***********************************]
	  	 [*********]

	 [************************************]
 ******************************]
	  	 [*******]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-5 

	 	    	For clarity, PFIZER shall not reimburse COLEY separately for any out-of-pocket costs associated with this Section 1.5. 

  

	1.6	Quality Assurance 

  

	 	1.6.1	Completion of Audit Reports. COLEY shall complete all preclinical, clinical, and manufacturing quality assurance audit reports relating to the use of the Compound within one
(1) month after the Effective Date or two (2) months after the audit visit, whichever is later. An audit report shall be considered to be complete only after the audited party has submitted a written response for all observations identified during
the audit. For clarity, COLEY shall not conduct any additional audits after the Effective Date. 

  

	 	1.6.2	Compensation. COLEY shall complete all outstanding audit reports under this Section 1.6 at no cost to PFIZER. 

  

	1.7	Pharmaceutical Sciences/Manufacturing 

  

	 	1.7.1	Stability Program Management. COLEY shall continue to oversee the [***] stability program at PFIZER’s direction and expense, until the Pfizer Program Leader requests, in
writing, that the oversight of such stability program be transferred to PFIZER; provided, however, that oversight of the stability program shall be transferred to PFIZER no later than twelve (12) weeks after the Effective Date.

  

	 	1.7.2	Compensation. PFIZER shall reimburse COLEY for actual out-of-pocket costs incurred pursuant to this Section 1.7, including without limitation storage costs associated with
storing documents, data, tissue samples, and clinical product inventory at third-party facilities. 

  

	1.8	Preclinical Studies 

  

	 	1.8.1	Tissue Analysis Reports. COLEY shall generate a final report for the following tissue analysis studies within three (3) months after the Effective Date:

  

	 	•	 	[***] 203-0655a 

  

	 	•	 	[***] 202-0632a 

  

	 	•	 	[***] 200-0457a 

  

	 	1.8.2	Plasma Analysis Reports. COLEY shall generate a final report on those plasma specimens that have been analyzed to date for study [***] 200-0457a within three (3) months after
the Effective Date. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-6 

	 	1.8.3	Toxicology Reports. COLEY shall amend the following toxicology reports to incorporate the results from the corresponding tissue and plasma analysis reports within six (6)
months after the Effective Date: 

  

	 	•	 	Study #0957-133 [***********************************************************************]; to be amended to add the toxicokinetic and tissue analysis report [***] 200-0457a

  

	 	•	 	Study #57695 [***********************************]; to be amended to add the tissue analysis report [***] 203-0655a 

  

	 	•	 	Study #57419 [******************************************]; to be amended to add the tissue analysis report [***] 202-0632a 

  

	 	1.8.4	Compensation. COLEY shall complete the services under this Section 1.8 at no cost to PFIZER. 

  

	1.9	Third Party Contracts Relating to the Compound 

  

	 	1.9.1	Collaborative Agreements. Within two (2) months after the Effective Date, the Pfizer Program Leader shall direct COLEY, in writing, to terminate or assign to PFIZER, to the
extent assignment is permissible, each ongoing Third Party collaborative agreement relating to the Compound, including without limitation material transfer agreements and supported research agreements. After the Effective Date, COLEY shall not enter
into any new collaborative agreement, or amend any such existing agreement to provide any additional funding (including without limitation the Compound or any clinical supplies), without the express written consent of the Pfizer Program Leader.

  

	 	1.9.2	Service Agreements. Except as expressly provided in the License Agreement or this Transition Plan, (i) within two (2) months after the Effective Date, the Pfizer Program
Leader shall direct COLEY, in writing, to terminate or assign to PFIZER, to the extent assignment is permissible, each Third Party service agreement relating to the Compound; and (ii) after the Effective Date, COLEY shall not enter into any new
service agreement, or amend any such existing agreement to provide any new services relating to the Compound without the express written consent of the Pfizer Program Leader. 

  

	 	1.9.3	Compensation. PFIZER shall reimburse COLEY for actual out-of-pocket costs incurred pursuant to this Section 1.9. For clarity, PFIZER shall not reimburse COLEY for any
unavoidable liquidated damages or termination fees. 

  

	1.10	Pre-planned Presentations 

  

	 	1.10.1	Presentations. COLEY shall use reasonable efforts to transfer to PFIZER the responsibility for all activities and materials relating to presentations on the Compound
(including without limitation posters, abstracts, and slide presentations 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-7 

	 	    	at medical conferences and other public meetings) within five (5) days after the Effective Date. After the Effective Date, PFIZER shall direct all activities relating to any such
presentation (including presentations that cannot be transferred to PFIZER), while COLEY will provide support as reasonably requested. 

  

	 	1.10.2	Compensation. PFIZER shall reimburse COLEY for actual out-of-pocket costs incurred pursuant to this Section 1.10. 

  

	2.	Accounting and Procedure for Payments 

  

	 	2.1	Out-of-Pocket Costs. Except as provided in Section 1.1.6, (a) PFIZER shall reimburse COLEY only for those out-of-pocket costs that are incurred by COLEY after the Effective
Date; and (b) PFIZER shall not reimburse COLEY for (i) any internal travel or entertainment expenses; or (ii) any out-of-pocket costs for services that were, prior to the Effective Date, conducted primarily using internal COLEY resources (including
without limitation contract employees who work primarily for COLEY). 

  

	 	2.2	No Internal Costs. Except as provided in Section 1.5.5, PFIZER shall not reimburse COLEY for any internal costs. 

  

	 	2.3	Timing of Payments. On a calendar quarterly basis, COLEY shall prepare an invoice for all transition services provided by COLEY during such quarter, and shall submit such
invoice to PFIZER within thirty (30) days after the end of each calendar quarter. PFIZER shall make payments for the services identified in each invoice within sixty (60) days after the end of each calendar quarter. 

  

	 	2.4	Method of Payments. All payments hereunder shall be made by electronic transfer in immediately available funds via either a bank wire transfer, an ACH (automated clearing
house) mechanism, or any other means of electronic funds transfer, to such bank accounts as COLEY shall designate in writing pursuant to Section 6.4 of the License Agreement. 

  

	 	2.5	Review of Records. COLEY shall keep accurate books and records setting forth the out-of-pocket costs for services provided pursuant to this Transition Plan. COLEY shall
permit PFIZER to examine such books and records at any reasonable time upon reasonable notice; provided, however, that such examination shall not take place more often than twice in any twelve (12) month period. PFIZER shall promptly
pay to COLEY the amount of any underpayment revealed by PFIZER’s examination and review. Any overpayment by PFIZER revealed by an examination shall either be promptly refunded to PFIZER or fully creditable against future payments due under this
Transition Plan or the License Agreement, at PFIZER’s option. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-8 

 Attachment B-1 – Immediate Requests 
  

			
	 Request

	  	 Format

	 1.      The available core elements of the INDs that were filed with the FDA and the United Kingdom Regulatory
Authority.
	  	MS Word format
		
	 2.      All documents pertaining to the current INDs that were filed with the FDA or the United Kingdom
Regulatory Authority.
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 3.      Copies of the protocols (with amendments) from each of the completed and ongoing clinical
trials.
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 4.      Any existing draft CMC amendment pertaining to the change/addition of drug product formulation to the
isotonic tonicity (including, without limitation, draft amendments prepared for United Kingdom, Canada, or Hungary Regulatory Authorities).
	  	MS Word format
		
	 5.      A list that identifies, with detail, all inquiries from any Regulatory Authority.
	  	Existing paper and/or electronic copies
		
	 6.      Access to the [*****] clinical trial database through COLEY’s designated contract research
organization (CRO).
	  	Access to the existing computer database
		
	 7.      A list that identifies the location and format of all databases that contain clinical or preclinical
data.
	  	Existing paper and/or electronic copies
		
	 8.      A list that identifies the location and nature of all tissue samples associated with clinical and
preclinical tests.
	  	Existing paper and/or electronic copies
		
	 9.      Copies of all published and draft abstracts, posters, articles, and manuscripts relating to the
Compound.
	  	Existing paper and/or electronic copies
		
	 10.    Copies of all continuing Third Party contracts relating to the Compound.
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 11.    A summary table that identifies which API batches were used for each drug product batch, and which drug product
batches were used for each preclinical or clinical study.
	  	Existing paper and/or electronic copies
		
	 12.    A summary table that identifies the disposition of any batches that were deemed unsuitable for clinical use
[*******************************************************].
	  	Existing paper and/or electronic copies

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-9 

			
	 Request

	  	 Format

	 13.    A list that identifies, as of the Effective Date, the location and quantity of all inventories of GMP drug product
that are suitable for use in the ongoing COLEY-sponsored and Third Party collaborator-sponsored clinical trials.
	  	Existing paper and/or electronic copies
		
	 14.    [********] vials from each arm (recommended and accelerated) of the stability
studies for the following drug product batches:
  
 [*********]
 [***********]
 [***********]
 [***********]
 [***********]
 [***********]
	  	Stability samples
		
	 15.    [***********] of API from each lot used in preclinical or clinical testing (if available).
	  	API samples
		
	 16.    [**] vials of drug product from each lot used in preclinical or clinical testing.
	  	Drug product samples
		
	 17.    [***********] of API reference standard
	  	API reference standard
		
	 18.    Information on methods used to characterize impurities.
	  	Report #RD3-0025-2003 (existing paper and/or electronic copies)
		
	 19.    Detailed report/plan on forced degradation studies
	  	Draft [***********] Stress Protocol. [*******] Forced Degradation Study (existing paper and/or electronic copies)
		
	 20.    Detailed report/study indicating API storage conditions and possible excursions
	  	Stability timepoint summaries (existing paper and/or electronic copies)
		
	 21.    Detailed report/timeline/plan assessing comparability for [*****************************************], including
other tests
	  	Report #RD3-0024-2004; Report #APS-04-0014 (existing paper and/or electronic copies)

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-10 

			
	 Request

	  	 Format

	 22.    Metabolite characterization of CPG7909
	  	Appendix 4 EOP2 briefing package (clinical); Report #RD1-0022-2001 (existing paper and/or electronic copies)
		
	 23.    Updated stability protocol for drug substance
	  	[********************] stability protocol, (existing paper and/or electronic copies)
		
	 24.    [************************************************** ***************************************************
************************************]
	  	[********************* ***********] (existing paper and/or electronic copies)
		
	 25.    Table summarizing the results of the new (non-stressed) stability studies and the status and of those studies
performed with optimized assays
	  	Stability data summary table from [********************] forward ( paper and/or electronic copies)
		
	 26.    Detailed report/plan on forced degradation studies for drug product
	  	Draft [*******] Stress Protocol. [*******] Forced Degradation Study (existing paper and/or electronic copies)
		
	 27.    Justification for, and any regulatory correspondence related to the
[*********************************************** ***********************************].
	  	[*************** *************************] (existing paper and/or electronic copies)
		
	 28.    Studies/reports detailing [***************************************************************]
	  	[*************** *************************] (existing paper and/or electronic copies)

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-11 

			
	 Request

	  	 Format

	 29.    Updated stability protocol for drug product
	  	[************] stability protocol (existing paper and/or electronic copies)
		
	 30.    The development report for release methods for API and drug product
	  	Report #RD3-0025-2003 (existing paper and/or electronic copies)
		
	 31.    Certificates of Analysis (COA) and history for all API and drug product used in preclinical or clinical
testing
	  	Existing paper and/or electronic copies
		
	 32.    All reference standard reports for the API
	  	[*************** ************************* **************** **************** *************************] (existing paper and/or electronic copies)
		
	 33.    Data and study reports for product development including pre-formulation, formulation and process development
studies
	  	 [*******] Draft Report [***********] dated [***********] entitled [**** *************** ************* **************** ****************
 ***************] and [*********] Draft Report [***********] entitled [**********
 **************** ****************
 ***************] (report undated but signed by [*****] QA on [**********]) (existing paper and/or electronic
copies).

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-12 

 Attachment B-2 – Draft Comprehensive Request 
  

			
	 Request

	  	 Format

	 1.      All completed preclinical, clinical, and manufacturing audit reports.
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 2.      All clinical trial SOPs in effect for
[*******************************************************************]
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 3.      All available executed API, drug product and final drug product batch files.
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 4.      All preclinical study reports, including without limitation tissue analysis, plasma analysis, and
toxicology reports.
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 5.      All meeting minutes and correspondence with any Regulatory Authority, including without limitation all
IND submissions and correspondence.
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 6.      Access to, or a copy of, all databases that contain clinical or preclinical data relating to the
Compound.
	  	Access to or an electronic copy of each computer database
		
	 7.      All tissue samples from preclinical and clinical tests.
	  	Tissue samples
		
	 8.      Quality control release data for all API and drug product batches used in preclinical or clinical
studies
	  	Existing paper and any scanned copies in Adobe Acrobat format
		
	 9.      Stability data for all API and drug product batches used in preclinical or clinical
studies
	  	Existing paper and any scanned copies in Adobe Acrobat format

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 B-13 

 EXHIBIT C 
  
 Coley Indication 
  
 

 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 C-1 

 EXHIBIT D 
  
 Pfizer/Coley press release DRAFT 
  
 PFIZER, COLEY PHARMACEUTICAL GROUP ENTER INTO EXCLUSIVE GLOBAL LICENSE 
 FOR THE DEVELOPMENT AND COMMERCIALIZATION 
 OF PROMUNE FOR CANCERS 
  
 New York and Wellesley, MA, March x 2005 – Pfizer Inc and Coley Pharmaceutical Group,
Inc. said today they have entered into an exclusive global license agreement to develop, manufacture and commercialize Coley’s ProMune (CPG 7909), a toll-like receptor 9 (TLR9) agonist delivered by subcutaneous injection for the potential
treatment, control and prevention of cancers in humans. 
  
 Under the terms of the
agreement, which is subject to government approval, Pfizer will make an initial payment of $50 million to Coley, with the potential for up to $455 million in additional milestone payments, plus royalties based on the successful development and
commercialization of ProMune. In addition, under certain circumstances, Pfizer will invest up to $10 million in Coley’s common stock upon an initial public offering by Coley. 
  
 Pfizer will fund future development of ProMune, including planned Phase III trials for treatment of non-small cell lung cancer. A variety of
additional tumor types also will be explored. Pfizer also will fund a collaboration with Coley to discover and develop next generation TLR9 agonists for cancers, which, if successful, could result in additional milestone payments and royalties to
Coley. 
  
 “Results of clinical studies conducted to date suggest that
ProMune has promising anti-cancer activity and may represent an important advance in treating a range of cancer indications,” said Karen Katen, Vice Chairman and President, Pfizer Human Health. “This agreement is a further step in our
strategy to augment Pfizer’s internal research activities with externally sourced products in key therapeutic areas such as oncology, where Pfizer is working to meet the needs of cancer patients.” 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 1 

 “We are extremely proud of our progress with ProMune, as shown in Coley’s randomized Phase II clinical
trials,” said Robert L. Bratzler, Ph.D., Coley’s President and Chief Executive Officer. “We look forward to working with the Pfizer team to realize ProMune’s remarkable potential as a highly potent and broadly applicable
anti-cancer therapy.” 
  
 ProMune has been evaluated in clinical studies
involving more than 900 subjects. Promising initial anti-cancer activity without substantial additional toxicity has been observed in both solid and hematologic tumors, both as a single agent and in combination with other treatments. The technology
licensed to Pfizer by Coley includes intellectual property licensed by Coley from the University of Iowa Research Foundation in Iowa City, Iowa and the Ottawa Health Research Institute in Ottawa, Canada. 
  
 Coley Pharmaceutical Group 
  
 Coley Pharmaceutical is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and
develops TLR TherapeuticsTM, a new class of drugs that direct the human immune system to treat cancers, infectious
diseases, asthma and allergy. The company has established a broad pipeline with four TLR Therapeutic drug candidates currently advancing through clinical development either independently or with partners, and has additional leads in early-stage
development. In addition to Pfizer, Coley has partnerships with sanofi aventis, GlaxoSmithKline, Chiron and the United States Government. For further information, please visit www.coleypharma.com. 
  
 ### 
  
 DISCLOSURE NOTICE: The information contained in this document is as of March     , 2005. Pfizer assumes no
obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 2 

 This release contains forward-looking information about a product in development and the potential efficacy of such
product that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainty of the success of the research and development activities; decisions by regulatory authorities regarding whether and
when to approve any new drug application for a product candidate that may result from the research, as well as their decisions regarding labeling and other matters that could affect the commercial potential of such product candidate; and competitive
developments. 
  
 A further list and description of risks and uncertainties can be
found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and in its reports on Form 10-Q and Form 8-K. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 3 

 SCHEDULE 1.28 
  
 THIRD PARTY LICENSEE AGREEMENT IN THE FIELD 
  
 Strategic Alliance: Non-Exclusive License Agreement, between Coley and Glaxo Group Limited, last signed on November 12, 2002. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 4 

 SCHEDULE 4.7(c) 
  
 [********************] MANUFACTURING COSTS 
  

	•	 	[******] payable by COLEY to the [*********************] pursuant to an agreement entitled [**********************
**********************************************************************************] executed October 7, 2004 for [***************] and documented in a written, final report. 

  

	•	 	[******] payable by COLEY [**********************] pursuant to an agreement entitled [*************************
****************************************************************************************************** *********************************************************************], executed February 9, 2005, for the completion of a [***************] and
documented in a written, final report. 

  

	•	 	[***************************] COLEY to [****************************] pursuant to a purchase order to be issued by Coley for
[**********************************************************************************] and documented in an invoice paid by COLEY. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 5 

 SCHEDULE 4.10(e) 
  
 The Training Program will be comparable to PFIZER’s then current Alliance Partner Training and will include the following features:

  

	 	•	 	home study 

  

	 	•	 	group training, including classroom sessions and a field-based preceptorship 

  

	 	•	 	General content to be covered: 

  

	 	•	 	Basic science (anatomy, medical terminology, pharmacology) 

  

	 	•	 	Disease state knowledge 

  

	 	•	 	Product knowledge 

  

	 	•	 	Selling skills 

  

	 	•	 	Competitive product knowledge 

  
 Modules and timeframes may be adjusted by PFIZER, as PFIZER deems appropriate in its reasonable discretion. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 6 

 SCHEDULE 8.2(a) 
 ACTIVE THIRD PARTY LICENSEES OUTSIDE THE FIELD 
  
 [********************************************************************************************************** 
 *********************************************************************] 
  
 [***********************************************************************************] 
  
 [********************************************************************************************************** 
 ******************************************************************************************************* ***************] 
  
 [********************************************************************************************************** 
 ******************************************************************************************************** ******************] 
  
 Cooperative Research and Development Agreements (CRADAs): 
  
 [********************************************************************************************************** 
 ****************************************************] 
  
 [********************************************************************************************************* 
 **********************] 
  
 [********************************************************************************************************** 
 *******************************************************************] 
  
 NIAID Grant (COLEY Subcontracts): 
  
 [********************************************************************************************************** 
 ******************************************************] 
  
 [********************************************************************************************************* 
 *******************************************************] 
  
 [********************************************************************************************************* 
 *********************************************************************] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 7 

 [********************************************************************************************************** 

****************************************************************] 
  
 [********************************************************************************************************* 
 ************************************************] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 8 

 SCHEDULE 8.2(a)-1 
  
 [********************************************************************************************************* 
 ************************************************************] 
  
 [********************************************************************************************************** 
 ************************************************************] 
  
 [********************************************************************************************************** 
 **********************] 
  
 [**********************************************************************************************************’ 
 ************************************************] 
  
 [********************************************************************************************************** 
 **********************************************] 
  
 [********************************************************************************************************** 
 ***************************************************************************] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D- 9 

 SCHEDULE 8.3 – TRADEMARKS 
  
 PROMUNE-E5 
  

													
	 WGS File No.

	  	Country

	  	Registration No.

	  	 Filing
 Date

	  	 Date
 Granted

	  	Term

	  	Renewal Date

	 [***************]
	  	[********]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[********]	  	[*******]	  	[********]	  	 	  	[********]	  	[********]
	 [***************]
	  	[********]	  	[***************]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[*********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[**********]	  	[**************]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[**********]	  	[*******]	  	[********]	  	 	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[*******]	  	[********]	  	[********]	  	 	  	[********]
	 [***************]
	  	[*****]	  	[*********]	  	[********]	  	 	  	 	  	 
	 [***************]
	  	[*****]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*****]	  	 	  	 	  	 	  	 	  	 
	 [***************]
	  	[********]	  	[*********]	  	[********]	  	[********]	  	 	  	[********]
	 [***************]
	  	[*******]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*************]	  	[*********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*************]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[********]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*************]	  	[************]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******************]	  	[************]	  	 	  	[********]	  	 	  	[********]

  
 PROMUNE

  

													
	 WGS File No.

	  	Country

	  	Registration No.

	  	 Filing
 Date

	  	 Date
 Granted

	  	Term

	  	Renewal Date

	 [***************]
	  	[**********]	  	[************]	  	 	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[**********]	  	[********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[******]	  	 	  	[********]	  	 	  	 	  	 
	 [***************]
	  	[******]	  	 	  	[********]	  	 	  	 	  	 
	 [***************]
	  	[*****]	  	[**********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*****]	  	[**********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*************]	  	[********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*****************
*****************
******************
****************]	  	[**********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*********]	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[**********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[**********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[***********]	  	[********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[***********]	  	[********]	  	 	  	 	  	 
	 [***************]
	  	[***********]	  	[**************]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[***********]	  	[********]*	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[*******]	  	[********]	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[********]	  	 	  	[********]	  	[********]	  	[********]	  	[********]
	 [***************]
	  	[***********]	  	[************]	  	[********]	  	 	  	 	  	 
	 [***************]
	  	[***********]	  	 	  	[********]	  	 	  	 	  	 
	 [***************]
	  	[***********]	  	[**************]	  	[********]	  	 	  	 	  	 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D-10 

 SCHEDULE 9.3 
  
 PERMITTED DISCLOSURES 
  

	•	 	[*************************************************************************************************] 

  

	•	 	[************************************************************************************************** ****************] 

  

	•	 	[************************************************************************************************** **************************] 

  

	•	 	[********************************************] 

  

	•	 	[*******************************************************************] 

  

	•	 	[*********************************************************] 

  

	•	 	[***************************************************] 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D-11 

 SCHEDULE 10.1(a)(ii) 
  
 CHALLENGE TO COLEY PATENT 
  
 Patent Interference No. 105,171 
  
 USPTO - Before the Board of Patent Appeals and Interference 
  
 University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc. and
the United States of America, as represented by the Department of Health and Human Services. Junior Party, (Patent 6,207,646 B1) v. The Regents of the University of California, Senior Party (Application 09/265, 191) 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D-12 

 SCHEDULE 10.1(g)(i) 
  
 THIRD PARTY PATENT RIGHTS 
  
  
 [*******************************************************************************************] 
  
 [***************************************************************************************************** 
 **************************] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D-13 

 SCHEDULE 10.1 (j) 
  
 SUBSIDIARIES 
  
 COLEY’S wholly-owned subsidiary, Coley Pharmaceutical Group GmbH (“Coley GmbH”), is authorized to do business in Germany. 
  
 COLEY’S wholly-owned subsidiary, Coley Pharmaceutical Group, Ltd.
(“Coley Canada”) is authorized to do business in Canada. 
  
 COLEY’S wholly-owned subsidiary, Coley Pharmaceutical Group, Ltd. (“Coley Bermuda”) is authorized to do business in Bermuda. 
  
 COLEY’S wholly-owned subsidiary, Coley Securities Corporation (“Coley Securities Corp.”) is authorized to do business in Massachusetts.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 D-14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]